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ABSTRACT 
It has been hypothesized that the ubiquitously expressed Phase II drug metabolizing 
enzyme human arylamine N-acetyltransferase 1 (NAT1) has a role in cell biology other 
than the metabolism of xenobiotics.  The identification of p-aminobenzoylglutamate 
(pABG) as an endogenous substrate for NAT1 led to speculation that the enzyme might be 
involved in folate regulation.  NAT1 is overexpressed in human luminal breast cancers and 
is a proposed biomarker for estrogen receptor positive breast cancers in women as well as 
luminal M2 breast cancers in men.  Moreover, NAT1 has been shown to support human 
cancer cell growth, survival and invasion both in vitro and in vivo.  Overall, the aim of this 
work was to identify possible endogenous roles for NAT1 that might explain its wide tissue 
expression. 
Initially, mouse Nat2 (homologue to human NAT1) was considered, and the levels of 
pABG and 5-methyltetrahydrofolate, the predominant circulating folate, were measured in 
wild-type and Nat2-deleted (Nat2-/-) mice.  Both metabolites were unaltered in Nat2-/- 
mice suggesting the enzyme did not regulate either of these folate products in vivo under 
normal conditions.  Therefore, the effect of human NAT1 on pABG and 5-
methyltetrahydrofolate in the human colon adenocarcinoma cell line, HT-29, was 
investigated to determine if NAT1 regulated folate in cancer cells.  As with the mouse 
study, pABG and 5-methyltetrahydrofolate were unaltered when NAT1 was knocked down 
in these cells.  Overall, these results suggests that NAT1 is not essential for the regulation 
of 5-methyltetrahydrofolate nor is the acetylation of pABG physiologically relevant in these 
models.  
Metabolomic analysis following human NAT1 inhibition was also carried out.  Firstly, 
changes in the S-adenosylmethionine (SAM) cycle was also investigated because 5-
methyltetrahydrofolate provides the methyl group to the SAM cycle necessary for 
methylation reactions of DNA, proteins and lipids.  Secondly, differences in amino acids 
present in cell culture medium were investigated following human NAT1 knocked down.  
SAM cycle homeostasis was maintained in HT-29 cells independent of human NAT1 
activity.  Furthermore, there were very few changes in SAM cycle components in Nat2-/- 
tissues compared to wild-type.  This suggests that NAT1 was not involved in regulating 
methylation reactions.  However, changes in alanine and homocysteine concentrations in 
cell culture medium between control and human NAT1 knock-down cells were identified.   
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Homocysteine levels in the medium initially increased with time for both control and knock-
down cells.  However, by day 3 in culture, levels began to decrease in the knocked-down 
cells whereas they continued to increase in the controls.  This correlated with the depletion 
of methionine from the medium suggesting the knocked down cells required homocysteine 
whereas the control cells did not.  The methionine salvage pathway is a multi-enzyme 
multi-reaction process that recycles methylthioadenosine (MTA), a by-product of 
polyamine synthesis, back to methionine.  This pathway is important for supplying 
methionine when other sources are exhausted.   
Cancer cells were grown in medium deficient of methionine but containing MTA as an 
assay for a functional methionine salvage pathway.  In HT-29 cells, human NAT1 
knockdown resulted in an inability to convert MTA to methionine.  This was due to a loss in 
the enzyme methylthioribose isomerase 1 (MRI1), which is involved in the salvage 
pathway.  To confirm these results, NAT1 and MRI1 were individually and collectively 
knocked down in HeLa cells.  When either enzyme was knocked down, growth in MTA 
was sustained, albeit at a lower rate than in complete medium.  By contrast, simultaneous 
knock down of both enzymes completely inhibited growth in medium deficient of 
methionine but containing MTA.  Furthermore, ectopically expressed human NAT1 in HT-
29 cells supported the methionine salvage pathway when MRI1 was knocked down.  LC-
MS/MS was used to characterise the isomerase reaction and there is evidence to suggest 
that human NAT1 is capable of performing this reaction.  However, under the in vitro 
conditions used, this reaction was very inefficient and at times remained undetected.  
Further work is required to characterise the role of human NAT1 as a methylthioribose 
isomerase.  Overall, this shows that human NAT1 has a novel role in the methionine 
salvage pathway and suggests a redundancy between NAT1 and MRI1. 
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INTRODUCTION 
Arylamine N-acetyltransferases (NATs) (EC 2.3.1.5) are a family of enzymes that catalyse 
the transfer of an acetyl group to a nitrogen or oxygen atom of primary arylamines, their N-
hydroxylated metabolites, heterocyclic amines, and arylhydrazines.  NATs were first 
identified in the liver in the 1960s as a result of investigating heritable differences in the 
inactivation of the anti-tuberculosis drug isoniazid, which was causing progressive damage 
to the nervous system [1-4].  NATs have long been considered Phase II drug metabolising 
enzymes.   
NATs have been identified in prokaryotes and eukaryotes. Historically, NAT proteins have 
been studied in human [5], rabbit [3, 6], mouse [7], hamster [8], chicken [9], and pigeon 
[10] based on the acetylation activity.  Salmonella typhimurim NAT [11] was identified by 
amino acid sequence homology with higher organisms as well as by confirmation of 
acetyltransferase activity and multiple bacterial strains with NATs have been characterised 
by Deloménie et al. [12].  Bioinformatics has been used to identify putative NAT genes by 
searching genomic databases for a reference NAT sequence [13, 14].  For bacteria, the 
NAT1 protein from Salmonella typhimurium LT2 was used as the reference sequence.  
The deduced NAT1 protein for Halogeometricum borinquense, strain DSM 11551, was 
used for archaea searches.  NAT1 protein of Gibberella moniliformis (Fusarium 
verticillioides) was used for fungal NATs.  Salmonella typhimurium NAT1 and  Gibberella 
moniliformis NAT1 were also used as reference sequences for protist and plant queries.  
Available eukaryotic genomic sequences for mammals, birds, fish, reptiles, insects, 
invertebrates, plants and Protista have been screened using the sequence of NAT1 
protein of Homo sapiens (Human) as the reference.   
Any recovered hits were inspected for features known to be characteristic of NAT proteins, 
including a partially conserved I/VPFENL amino acid sequence and a fully conserved Cys-
His-Asp catalytic triad [13, 14]. This supports the identification of the NAT gene by 
confirming potential catalytic function.    
A comprehensive catalogue of putative prokaryote and eukaryote NAT homologues was 
presented by Vagena et al. [13] and revised by Glenn et al. [14]. The Database for 
Arylamine N-acetyltransferase provides all known NAT sequences and can be accessed at 
http://nat.mbg.duth.gr/.  This database also provides NAT nomenclature and rules for 
naming NAT genes and alleles.  To summarise, over 1200 prokaryotic genomes were 
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interrogated for putative NAT genes and 274 bacterial NAT1 genes were identified from 
177 species. Sequences have been recovered from 62 fungi. NAT1 has been identified for 
one species of archaea and 9 protists.  Of the animal genomes, NAT1 homologues for 4 
invertabrates, 5 fishes, 1 lizard, 2 bird and 38 mammals were reported.  Full length NAT1 
open reading frames (ORFs) were identified in species representing all major mammalian 
taxa (monotremes, marsupials and eutherian [placental] mammals), including domestic 
(horse, cow, pig) and wild mammals (elephant, platypus, bat). This was in addition to the 
already reported sequences for Chinese and Syrian hamster. Currently, no NATs have 
been identified in plants and lower invertebrates (insects and worms). 
NAT1 has been identified for the domestic cat and wild felids by Trepanier et al. based on 
substrate specificity and immunoreactivity to specific NAT1 specific antibodies [15].  
Trepanier et al. also provides a comprehensive study of arylamine N-acetyltransferase in 
Canids [16].  Surprisingly, it was evident that the dog (both domestic and wild) is 
completely deficient in NAT activity.  No NAT protein was detected by immunoblot. This 
was due to complete lack of NAT genes in the canid genome demonstrated by Southern 
blot and PCR analysis of 25 domestic dogs and 8 wild canids.  Supporting this, no NAT 
genes were identified during the bioinformatics interrogation of the dog genomes.   
In humans, two functional isozymes have been characterised: NAT1 and NAT2 [5, 17].  
There is 87% sequence homology translating to 81% amino acid homology between the 
two isozymes. The genes for both NAT1 and NAT2 are located on human chromosome 8 
[17].  There are differences in substrate specificity between the two human NAT isoforms.  
NAT1 has a greater affinity for smaller arylamines compared to NAT2.  Several substrates 
for each enzyme are outlined in Table 1. 
Animal models exhibit fast and slow acetylator phenotypes, similar to those in the human 
NATs, and have been important in the investigation of NAT drug metabolism and 
polymorphisms.  Two functional NAT isozymes have been characterised for mouse [18], 
rabbit [19], rat [20] and hamster [21]: Nat1 and Nat2.  These isozymes demonstrate 
substrate specificity similar to human NATs. Studies have shown that mouse Nat1 
acetylates isoniazid, while mouse Nat2 acetylates pABA and pABG, and both acetylate 2-
AF [22, 23].  Human NAT1 possesses higher amino acid homology to Nat2 than Nat1 for 
these animal models with the exception of rat, which is the same for both isozymes. 
Specifically, 76% amino acid homology exists between human NAT1 and rabbit Nat2, 82% 
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with mouse Nat2, 82% with Syrian hamster Nat2, and 81% with rat Nat1/2 [24].  On that 
basis, mouse Nat2 is considered homologous to human NAT1.   
Table 1: Substrates for NAT1 and NAT2 
NAT1 NAT2 
p-aminobenzoic acid [25] sulfamethazine [25] 
p-aminosalicylic acid [25] procainamide [25] 
Sulphanilamide [25] hydralazine [26] 
p-aminobenzoylglutamate [27, 28] dapsone [26] 
benzidine [29] caffeine [26] 
 Isoniazid [26] 
2-aminofluorine (carcinogen) [25] 2-aminofluorine (carcinogen) [25] 
 
Human NAT1 is considered to be ubiquitously expressed while Human NAT2 is limited 
mainly to the liver and gastrointestinal tract. NAT2 mRNA expression is greatest in human 
liver and gastrointestinal tract but is also expressed at lower levels in other tissues [30]. 
NAT1 mRNA is expressed in all tissues studied, without noticeably increased expression 
in either the liver or gastrointestinal tract [31].  
Boukouvala et al. reviewed studies performed between 1965 and 2005 that provide NAT 
expression in human tissues [24]. Studies investigating human NAT1 and NAT2 activity 
simultaneously showed that NAT1 activity was present in liver, intestines, bladder, 
placenta, mammary tissue, skeletal muscle, and leukocytes; while NAT2 was present in 
liver, intestines, bladder (marginal activity), and placenta. Marginal NAT2 activity was 
reported in prostate and no study was reported to have measured NAT1 in prostate.  
Additionally, NAT1 activity has been measured in adrenals, kidney, lung and erythrocytes.   
It would be informative to have a comprehensive investigation of NAT1 (and NAT2) protein 
expression in a single study of human tissues.  A single study looking at a range of tissues 
would allow relative expression of the enzyme throughout the body to be identified and, in 
doing so, isolate tissues of interest that might have exaggerated or minimal NAT1 
expression or provide clues for an endogenous role.  
Animal models have been screened for Nat1 and Nat2 activity.  Both isozymes have been 
measured in liver, gut, pancreas, bladder, and prostate in mouse [32] and more 
23 
 
extensively in the Syrian hamster [33]. Results presented by Hein et al. suggest that, while 
Nat1 (homologous to NAT2) is detectable in extrahepatic tissues and is highest in the liver, 
it is at a markedly lower (> 100 fold) level to that of Nat2 in the Syrian hamster.  An 
extensive tissue screen of Nat2 activity was performed in mice by Chung et al. revealing 
that Nat2 was present (based on immunoblot) and catalytically active throughout the 
gastrointestinal tract in the liver, gallbladder, pancreas, bladder, brain, heart, kidney, lung, 
muscle, parotid and submaxillary glands, as well as lymph, thymus, spleen, red blood 
cells, white blood cells, bone marrow and skin [34].  Later studies [35, 36] also showed 
broad Nat2 protein expression by immunohistochemistry or enzyme activity measurements 
supporting Chung’s results with the additional finding that Nat2 is present in the hair follicle 
[36]. Taken together, these findings indicate that Nat2, homologue to NAT1, also appears 
to be ubiquitously expressed. 
Both human NAT1 and NAT2 have been implicated in cancer.  They have been shown to 
bioactivate aromatic and heterocyclic amines resulting in the formation of DNA adducts 
with the potential for genotoxicity [37].  NAT1 and NAT2 are polymorphic resulting in “fast” 
and “slow” acetylators.  These polymorphisms have been shown to alter risk of various 
cancers.  In the case of NAT1, polymorphisms alter risk to pancreatic cancer [38, 39], 
colon cancer [40, 41], non-Hodgkin lymphoma [42-44], prostate cancer [45, 46], and breast 
cancer [47].  It has also been shown that inconsistencies in the effects of polymorphisms 
can occur between studies of the same cancer type due to differences in the carcinogens 
assessed, methods of measuring genotypes/phenotypes, sample sizes, and the possible 
effects of unidentified genes and factors, as reviewed in detail by Hein et al. [48].  More 
recently, Butcher and Minchin provided a summary of 65 studies that investigate NAT1 
genotype and cancer risk in 16 cancer types [49] that clearly emphasise these 
inconsistencies.   
 
NAT1 Catalytic Activity and Stability 
The enzymatic mechanism of drug acetylation used by NATs is the ‘ping-pong Bi-Bi’ 
reaction and was first described using partially purified rabbit liver protein [3] and 
confirmed in human liver N-acetyltransferase (NAT) [4].  The coenzyme, acetyl coenzyme 
A (acetyl-CoA), interacts with the NAT enzyme whereby the acetyl group is transferred 
from the coenzyme to acetylate NAT and coenzyme A (CoA) is released. A substrate 
interacts with the acetylated enzyme whereby the acetyl group is transferred from the NAT 
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onto the substrate.  Subsequently, the acetylated substrate is released leaving the NAT 
enzyme in its original form.  Product inhibition patterns confirmed that the reaction is a two 
substrate, two product reaction where the first product (i.e. CoA) must be released before 
the second substrate can enter the reaction (Figure 1). 
A cysteine residue is essential for NAT function. Andres et al. incubated rabbit cytosolic 
liver NAT with iodoacetic acid which binds irreversibly to thiol groups [50]. As a result, 
there was a rapid, irreversible loss of enzyme activity with approximately 1:1 stoichiometry 
of enzyme to inhibitor.  Additionally, NAT preincubated with acetyl-CoA provided complete 
protection against iodoacetic acid-induced inactivation. Therefore, a single cysteine group 
was shown to be imperative for NAT activity and in particular, present in the active site for 
binding to the acetyl group from acetyl-CoA.  Blum et al. showed that three cysteine 
residues (Cys44, Cys68, Cys223) were conserved between rabbit NAT, human NAT1, 
human NAT2 and chicken NAT [17].  Site directed mutagenesis studies carried out on 
NAT2 identified that Cys68 → Gly68 mutation led to a complete loss of enzyme activity 
[51].  Proteins with Cys44 → Gly44 and Cys223 → Gly223 mutations remained 
catalytically active but the intrinsic stability was reduced.  However, the authors suggested 
that this might have resulted from glycine-mediated entropic destabilization and therefore, 
to confirm if Cys44 and Cys223 are important for protein stability, replacing the cysteine 
residue with a different non-polar amino acid of similar sized side chain (perhaps alanine) 
would be advantageous.  Given that these cysteine residues are conserved between 
NAT1 and NAT2 it can be surmised that Cys68 is responsible for the binding of the acetyl 
group in NAT1.  
A catalytic triad has been identified, similar to that in proteins of the cysteine protease 
family [52] for N-acetyltransferases.  The crystal structure of Salmonella typhimurium NAT 
revealed a Cys-His-Asp catalytic triad that is conserved between prokaryotic and 
eukaryotic NATs  [53].  In mammalian NATs, this corresponds to residues Cys68, already 
identified as essential for acetyl-CoA binding: His106 and Asp122.  The catalytic 
mechanism has been described for hamster Nat2 (homologous for human NAT1) [54, 55].  
Cys68 and His107 form a thiolate-imidazolium ion pair to allow rapid formation of a stable 
acetylated enzyme in preparation for substrate reaction.  Cys68 was confirmed to be the 
site of acetylation from acetyl-CoA. Upon acetylation of the thiolate, the imidazole is poised 
to facilitate proton transfer to the arylamine substrate. Two pathways for acetyl group 
transfer were proposed depending on the nucleophilic strength of the substrate. The 
overall reaction mechanism is illustrated in Figure 1.  Additionally, a conformational 
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change was proposed to involve Asp122.  Site directed mutagenesis of His107 to Gln or 
Asn and Asp122 to Ala or Asn, revealed that mutants were devoid of catalytic activity.  
Moreover, mutant enzymes were only detected in the insoluble fraction of the cell lysate.  If 
the presence of recombinant protein in the soluble fraction of the cell lysate is an indication 
of successful protein folding and presence of recombinant protein in the insoluble protein 
is an indication of incomplete protein folding then Cys68, His107 and Asp122 are essential 
to the structural integrity of NAT proteins as well as catalytic activity.  
Specific amino acid residues contribute to the differing substrate specificities and intrinsic 
stability between NAT1 and NAT2.  Chimeric NAT proteins containing large sections of 
NAT1 polypeptides in a NAT2 structure, and vice versa, were compared with wild-type 
NAT1 and NAT2 proteins for enzyme activity with p-aminosalicylic acid and 
sulfamethazine, NAT1 and NAT2 substrates, respectively [56].  The results indicated that, 
while the region encompassing the active site (aa47-111 containing Cys68) was necessary 
for NAT1 activity, it alone does not impart selectivity. Instead, a combination of the active 
site region and a central region (aa112-210) resulted in the highest affinity.  Residues 112-
210 also imparted the largest enzyme velocities: conversion of substrate to product 
(Vmax).  This central region is highly conserved between NAT1 and NAT2 with the 
exception of residues 125, 127, 129 and 149.  Goodfellow et al. used site directed 
mutagenesis to replace NAT1 residues Phe125, Arg127 and Tyr129 with the serine 
residues of NAT2 to determine which, if any, were responsible for NAT1 substrate 
selection [57].   Arg127 conveys the greatest change in affinity, Phe125 has a modest but 
significant role in determining affinity and Tyr129 did not alter affinity. Intrinsic stability, 
measured as the time (in hours) for NAT activity to diminish to 50% of the initial activity 
when incubated at 37°C, was reported for NAT1 and NAT2 in both of these studies.  The 
result was consistent between reports.  NAT1 stability was approximately 4 hours, while 
NAT2 stability was 10-fold higher, at approximately 40 hours.  The site directed 
mutagenesis data provided by Goodfellow et al. indicates that the mutant NAT1 proteins 
containing serine in place of Arg127 or Tyr129 have approximately 80% reduction in their 
intrinsic stability.  Furthermore, any mutant containing the Tyr129 → Ser129 mutation 
resulted in obvious reduction in NAT1-like protein detected by immunoblot which was 
attributed to a reduction in overall expression of the proteins.  These results suggest that 
Tyr129 might be important for efficient NAT1 expression; however, this has not been 
confirmed.   
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Figure 1: The molecular mechanism of arylamine acetylation by the catalytic triad of 
NAT1.  Image obtained from Minchin et al. [58].   
Acetyl-CoA enters the active site and the acetyl group is transferred to the thiol group of 
Cys68 and CoA is released.  The arylamine substrate enters the active site.  Depending 
on nucleophilic strength of the substrate, acetyl group transfer can occur via PATH A or 
PATH B [54, 55].  
 
 
PATH A: Nucleophilic 
attack of the thiol ester by 
weak nucleophilic 
substrates (pKa < 5.5) 
PATH B: Deprotonation of 
a tetrahedral intermediate 
by strong nucleophilic 
substrates (pKa ≥ 5.5) 
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In summary, the catalytic triad (Cys68-His107-Asp122) is essential for NAT protein 
catalytic activity and structural integrity.  The region encompassing Cys68 (aa47-111) and 
the central region (aa112-210) of the NAT1 amino acid sequence are important for NAT1 
substrate selectivity. Furthermore, specific NAT1 residues, Phe125, Arg127 and Tyr129, 
are of importance.  Arg127 and Phe125 impart substrate specificity while Arg127 and 
Tyr129 are important for maintaining NAT1 stability.  
 
NAT1 protein structure 
NAT1 and NAT2 are 290 amino acid proteins weighing 33 kDa and 31 kDa, respectively 
[17].  The high resolution crystal structures of human NAT1 (1.8 Å) and NAT2 (1.9 Å) were 
achieved in 2007 [59] (Figure 2).  The 3D structure of NAT1 is similar to NAT2 and 
resembles the previously obtained 3D structure of the prokaryotic orthologue Salmonella 
typhimurium [53].  Additionally, it supports the computationally predicted 3D structure of 
NAT1 by Rodrigues-Lima [52] .  The overall fold of NAT1 is made up of three domains plus 
an interdomain: 
• Domain I (Amino-terminal domain) - residues 1-83 - five α-helices and one short β-
strand between α2 and α3 (α1-α2-β1-α3-α4-α5)  
• Domain II - residues 85-192 - ten β-strands with two short helices (β2-β3-β4-β5-α6-
β6-β7-β8-β9-β10-α7-β11) - β-barrel formation 
• Interdomain - three α-helices (α8-α9-α10) 
• Domain III - four β-strands and one α-helix (β12-β13-β14-β15-α11) 
 
The interface between the second and third domains forms the catalytic pocket or active 
site [53] which is hydrophobic.  A catalytic loop has been identified, originating at Asp122 
through to Met131, forming part of the catalytic pocket [52].  Interestingly, the catalytic loop 
contains Arg127 and Phe125 previously shown to direct substrate selectivity.  The 
substrate binding pocket for NAT1 (162 Å3) is smaller than NAT2 (257 Å3) as a result of 
two key residues.  Specifically, Arg127 and Tyr129 have bulky side chains protruding into 
the active site of NAT1 while the serine residues of NAT2 do not.  Hence, NAT1 has the 
natural tendency to be selective for smaller arylamine substrates.  The hydrophobic 
environment of the active site is necessary for positioning the substrate in close proximity 
to the acetylated Cys68 and hydrogen bonding occurs between Arg127, His107, Ile106 
and the substrate in NAT1.  The phenol group of NAT1 residue, Phe125, presents pi-pi 
stacking interactions for the aromatic ring of NAT1 substrates [59].  
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The catalytic triad, consisting of Cys68, His107 and Asp122, is clustered in an α-helix and 
two β-strands and buried in the active site.  It is maintained by non-polar and polar 
interactions involving highly conserved residues.  Wu et al. [59] formed a crystal structure 
of human NAT2 in complex with CoA.  Bound CoA is bent and wraps around the surface of 
the protein such that the sulfhydryl group of CoA is positioned close to Cys68 and held in 
the cleft by Van der Waals/hydrophobic interactions with residues within the pocket.  
Therefore, the acetyl group in acetyl-CoA would be similarly positioned close to and for the 
direct acetylation of Cys68.    
In contrast to the prokaryotic NAT structure, both eukaryotic NATs have an additional 17 
residue insertion, the “mammalian-like insertion”, between residues 167-183 [59].  
Additionally, the C-terminal region of human NAT1 and NAT2 extends deep within the 
active site, near the catalytic triad, while the C-terminus of bacterial NATs is a defined α-
helix away from the active site.  The “mammalian-like insertion” acts as a lid to bury the C-
terminus within the folds of the protein and make several contacts with the second and 
third domain contributing to the overall stability of the protein.   
 
Figure 2: The NAT1 crystal structure. 
The catalytic loop forming part of the active site is indicated.  The C-terminus, buried deep 
in the protein folds is in close contact with the catalytic triad and the “mammalian-like 
insertion” forms a lid over the c-terminus and stabilises the protein structure.  Protein Data 
Base accession code: 2IJA. Amino-terminal domain – blue, Second domain – orange, 
Interdomain – yellow, Third domain – green.   
“mammalian-like insertion” 
N-terminus 
C-terminus 
Catalytic loop 
29 
 
The crystal structures for human NAT1 (Protein Data Bank code 2PQT and 2IJA) were 
used for homology modelling of known NAT1 single nucleotide polymorphisms (SNPs) to 
determine structure-function relationships [60].  Eight SNPs resulting in a change of amino 
acid were identified from the NAT1 allelic variants.  Of these, three resulted in altered 
NAT1 structure.  Specifically, the SNP 190C>T results in Arg64 → Trp64, 560G>A results 
in Arg187 → Gln187 and 752A>T results in Asp251 → Val251.  Arg64 is completely 
conserved in NATs and the change to Glu64 gave rise to the complete loss of recombinant 
NAT2 activity [46].  Arg64 forms salt bridges with Glu36 and by substituting Trp64 for 
Arg64 in the homology model.   
Walraven et al. showed that the SNP compromises the amino-terminal domain resulting in 
reduced protein stability.  This supported the conclusion that loss of NAT activity was not 
due to loss of acetylation capability but rather a decrease in structural integrity and 
resultant protein degradation for the protein containing SNP 190C>T [46].  Hein et al. 
described the significant reduction of recombinant NAT1*14 protein containing the 
560G>A SNP (Arg187 → Gln187) compared to wild-type.  The homology modelling 
revealed that Arg187 is involved in hydrogen bonding with Domain II, III and the C-
terminal, thereby shaping the active site and stabilising the conformation of the C-terminal 
and catalytic loop.  It makes sense then, that this SNP would lead to altered substrate 
binding and destabilize NAT1 protein, resulting in reduction in protein as shown previously 
[46].  Finally, Asp251 forms hydrogen bonds with the catalytic loop and β-sheet of Domain 
III, directly influencing the conformation of the active site and contributing to protein 
stability.  This corresponded to the observed reduction in thermostability and expression of 
recombinant NAT1*22 protein (containing SNP 752A>T) in which valine replaced 
asparate. 
 
NAT1 Genomic Structure and Organisation 
The human NAT1 gene is located on human chromosome 8p22 [61], spanning 
approximately 53 kb [58] and it contains an 870 bp intronless coding region [17]. There 
have been 28 allelic variations identified to date and NAT1*4 is considered the wildtype.  
For more information about human NAT1 alleles visit The Database for Arylamine N-
acetyltransferase http://nat.mbg.duth.gr/ .   
By comparing the genomic sequence in the region of human chromosome 8 to the 
expressed sequence tags (EST) reported on the human EST database at the NCBI 
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(GenBank database), eight non-coding exons upstream of the intronless NAT1 coding 
region (exon 9) and at least two alternative polyadenylation signals downstream of the 
NAT1 stop codon have been identified [62, 63].  Accordingly, various transcripts were 
predicted and, by using real time PCR, it was shown that transcript expression was tissue 
specific and alternative splicing occurs [62].   
Transcripts containing various combinations of exons in the upstream untranslated region 
have been reported to originate from one of two alternative promoter regions. Type I 
transcripts commence with exon 1 and originate from promoter NATa, located 51.5 kb 
upstream of the NAT1 coding region [63, 64].  Type II transcripts commence with exon 4 
originating from promoter NATb, located 11.8 kb upstream of the NAT1 coding region.  
NATb is a TATA-less Initiator type promoter containing an Sp1 box [63, 64], and several 
putative transcription factor binding sites [63].  Two Type I transcripts and four Type II 
transcripts have been identified (Figure 3). PCR was used to determine the expression of 
the transcripts in different human tissues and human cell lines. Type IIA is the most 
common transcript and was present in the largest number of tissues as well as in all cell 
lines tested.  It is made up of exons 4, 8 and 9 only. 
 
Figure 3: Genomic organisation of NAT1 genes. 
Two alternative promoters have been identified, NATa and NATb.  Type I transcripts 
originate from promoter NATa while Type II transcripts originate from promoter NATb.  The 
most prevalent NAT1 transcript is Type IIA indicated by an asterisk. Non coding exons – 
red, coding exon - blue. [65]. 
 
 
* 
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Regulation of NAT1 
So far in this discussion, human NAT1 has been described as a ubiquitously expressed 
enzyme responsible for acetylation of small arylamines; for the clearance of xenobiotics 
but also activation of carcinogens.  It is polymorphic and investigators have shown direct 
effects on enzyme activity as a result, with implications in cancer susceptibility.  Therefore, 
it is important to understand how this enzyme is regulated. Examination of the literature 
indicates that NAT1 is regulated both at the gene expression and protein level by 
endogenous processes which will be described in detail.   
Additionally, it is apparent that external influences affect NAT1.  For example, very recently 
NAT1 and nanoparticles have been investigated.  Carbon black nanoparticles, prevalent in 
industrial applications along with aromatic amine carcinogens, have been found to interact 
with NAT1, causing conformation changes in the enzyme structure with consequent loss of 
enzyme activity and impaired detoxification of carcinogens [66].  Additionally, metal oxide 
nanoparticles (TiO2, SiO2, and ZnO) common in cosmetics and sunscreens, inhibit NAT1 
activity in a concentration-dependent manner while self-assembling thermo-responsive 
polymeric nanoparticles resulted in a dose-dependent increase in NAT1 activity [67].    The 
heavy metals, cadmium and mercury, are present as environmental pollutants as well as in 
cigarette smoke.  They have been shown to inactivate NAT1 at biologically relevant 
concentrations by interacting with the reactive thiol group of the catalytic cysteine (Cys68) 
[68, 69].   
Cellular oxidants and UVB irradiation inactivate NAT1 protein 
Identification of the catalytic triad and conserved reactive cysteine residue in NATs led to a 
comparison of NAT1 with other catalytic triad containing enzymes such as factor XIII 
transglutaminase, cysteine proteases and protein phosphatases as well as glutathione S-
transferase and caspases that have an essential reactive cysteine residue.  In doing so it 
became apparent to researchers that the cysteine residue of these proteins is a target for 
oxidation by cellular oxidants resulting in inactivation of these enzymes.  Therefore, a 
range of studies were carried out to investigate the effects of cellular oxidants on the 
ubiquitously expressed NAT1.  In particular, peroxynitrite [70], hydrogen peroxide [71], s-
nitosothiols [72], and photooxidation by UVB radiation [73] have been assessed.   
Peroxynitrite irreversibly inactivates NAT1 via oxidation of the catalytic cysteine residue.  
Peroxynitrite (ONOOˉ) is a strong cellular oxidant formed spontaneously through collision 
of superoxide (O2●¯) and nitric oxide (NO).  It reacts with proteins, lipids and DNA and is 
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implicated in virtually all disease processes in humans [74].  Dairou et al. performed 
extensive work to characterise NAT1 inactivation by peroxynitrite [70, 75, 76].  NAT1 
incubated with increasing concentrations of peroxynitrite or SIN1 (3-
morpholinosydnonimine N-ethylcarbamide), a chemical agent used to mimic endogenous 
peroxynitrite generation, resulted in a dose-dependent reduction in NAT1 activity (without 
changing protein expression).  This was observed for recombinant NAT1 and endogenous 
NAT1 from human cell lines MCF-7, A549, 16HBE and HLEB3 as well as mouse Nat2 in 
mtCC1-2 Clara cells, C2C12 and I28 myotubules.   
Importantly, this inactivation of NAT1 was observed at physiologically relevant 
concentrations of peroxynitrite.  In order to determine whether peroxynitrite interacts with 
the sulfhydryl group of cysteine and not tyrosine residues, NAT1 inactivated by SIN1 
generated peroxynitrite was incubated in the presence of fluorescein-conjugated 
iodoacetamide.  Iodoacetamide binds specifically to the thiol moiety of cysteine residues.  
If peroxynitrite modified cysteine/s then iodoacetamide would not be able to bind and, 
hence, not be detected via the fluorescein conjugate.  This was in fact the case.  
Therefore, peroxynitrite interacts with cysteine residues of NAT1.  Peroxynitrite-mediated 
inactivated NAT1 was found to be irreversible as thiol reducing agents, DTT or GSH, did 
not recover catalytic activity when added to the inactivated NAT1.  However, the reducing 
agents provided partial protection when incubated with NAT1 in presence of SIN1.  This 
was only observed at high concentrations that may not be physiologically attainable.   
Additionally, kinetic analysis indicated that peroxynitrite reacts 50 times more rapidly with 
NAT1 than the intracellular reducing agent GSH.  This suggests that intracellular reducing 
agents might not be sufficient to protect NAT1 from peroxynitrite dependent inactivation.  
And finally, if the catalytic cysteine was the site modified by peroxynitrite then acetyl-CoA 
would be protective against oxidation as it acetylates this residue thereby impeding 
peroxynitrite interaction with the thiol.   Indeed, NAT1 activity was significantly higher when 
incubated with acetyl-CoA prior to the addition of SIN1 confirming that the catalytic 
cysteine was the site modified by peroxynitrite.  
Overall, these studies successfully identified the mechanism for peroxynitrite-mediated 
inactivation of NAT1.  Furthermore, evidence was provided to suggest that the cellular 
environment might not protect NAT1 from this form of modification. Therefore, 
peroxynitrite-mediated inactivation could have a significant effect on NAT1 metabolism of 
xenobiotics especially in disease states where intracellular peroxinitrite is elevated.    
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Using similar rationale, Atmane et al. investigated the effects of the reactive oxygen 
species, hydrogen peroxide (H2O2), on NAT1 [71].  NAT1 incubated with increasing 
concentrations of H2O2 resulted in a dose-dependent reduction in NAT1 activity and NAT1 
incubated with GOX (Glucose/Glucose Oxidase System) as a means of generating 
constant physiologically relevant levels of H2O2, over time resulted in a time-dependent 
decrease in NAT1 activity.  Again, inactivation of NAT1 was observed at physiologically 
relevant concentrations of H2O2.  A reduction in fluorescein-conjugated iodoacetamide was 
observed for inactivated NAT1 incubated with H2O2 in a dose-dependent manner and 
NAT1 activity was significantly protected in the presence of acetyl-CoA, confirming that 
H2O2-mediated inactivation of NAT1 occurs as a result of catalytic cysteine modification.   
In contrast to peroxynitrite, H2O2-mediated inactivation of NAT1 could be reversed by the 
thiol reducing agents, DTT and GSH.  Moreover, physiological concentrations of GSH 
provided 60% reversion of NAT1 activity indicating that the cellular reducing agents could 
have a protective effect against H2O2-mediated inactivation of NAT1.  Additionally, the 
work confirmed that H2O2 oxidises the catalytic cysteine to form sulfenic acids not 
disulphide bonds.   H2O2-mediated inactivation of NAT1 was observed for recombinant 
NAT1 [71] and endogenous NAT1 from human cell lines A549, 16HBE and HLEB3 as well 
as mouse Nat2 in mtCC1-2 Clara cells [73, 76].  Overall, these studies successfully 
identified the mechanism for H2O2-mediated inactivation of NAT1; H2O2 reversibly 
inactivates NAT1 by forming sulfenic acid on the catalytic cysteine residue thiol. 
Similarly, mechanisms of NAT1 inactivation have been identified for S-nitrosothiols and 
UVB irradiation.  Specifically, S-nitrosothiols induce reversible inactivation of NAT1 via 
modification of the catalytic cysteine thiol, likely due to the formation of a mixed disulphide 
bond [72], and UVB-dependent inactivation of NAT1 was caused by a reversible 
photooxidative process [73].  
Substrate dependent down regulation of NAT1 
Down regulation of human NAT1 in the presence of substrate p-aminobenzoic acid (pABA) 
was observed in a number of different cell lines and cultured peripheral blood mononuclear 
cells [77].  Substrates with a structure similar to pABA (p-aminophenol, ethyl-p-
aminobenzoate and p-aminosalicylic acid) also down-regulated human NAT1.  Kinetic 
studies showed a reduction in Vmax for both substrate and cofactor (acetyl-CoA) while the 
Km for both substrate and cofactor remained unaltered. This indicated that down 
regulation was due to a loss of active enzyme; not a reduction in the ability to interact with 
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either substrate or cofactor.  Further investigation determined that the reduction in activity 
was due to a reduction in protein and semi-quantitative PCR indicated the reduced protein 
levels were not due to a reduction in mRNA.   
A subsequent study of “slow” acetylator NAT1 (i.e. alleles that resulted in less active 
protein), showed that these NAT1 proteins were considerably less stable and bound less 
than 10% of acetyl-CoA compared to wild-type enzyme [78].  Additionally, a NAT1 mutant 
carrying a Tyr68 in place of Cys68 which did not bind acetyl-CoA also had reduced 
stability.  Hence, it was postulated that non-acetylated human NAT1 is unstable and 
susceptible to rapid degradation in the cell.   Polyubiquitination of the unstable human 
NAT1 proteins was shown by Western blotting confirming that the ubiquitin/26S 
proteasome pathway is involved in the protein degradation.   
A model for substrate-dependent down-regulation has been proposed (Figure 4).  In the 
absence of substrate, NAT1 accepts the acetyl group from acetyl-CoA with the potential to 
deplete cellular levels of acetyl-CoA.  In the presence of substrate, the acetyl group is 
removed from NAT1.  At high levels of substrate, the NAT1 equilibrium shifts toward the 
unacetylated form which is then targeted for degradation via the ubiquitin/26S proteasomal 
pathway to avoid excessive hydrolysis of acetyl-CoA in the cell which can be toxic. 
 
Figure 4: Substrate-dependent down
proteasome degradation.  Image taken from Butcher et al.
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synthesis is required prior to androgen induction suggesting that the androgen receptor 
could induce a secondary transcription factor to promote NAT1 gene expression. 
It was concluded that the NATb promoter was involved in this androgen induced NAT1 
gene expression as only Type II transcripts were detected.  A series of luciferase reporter 
constructs (pGL3) were cloned to incorporate progressively shorter fragments of NATb 
promoter to determine which region of the promoter was involved in androgen induction of 
NAT1.    Comparison of luciferase activity in cells transfected with the various constructs 
identified a 157 bp section of the NAT1b promoter responsible for the androgen up-
regulation of NAT1 between -902 and -745 bp upstream of exon 4.  As a secondary 
transcription factor appears to be involved, it is unsurprising that there is no androgen 
response element present in this region.   
A 12 bp palindrome forming part of a putative Heat Shock Element was identified which 
binds the transcription factors: Heat Shock Factors (HSF) 1 and 2 [81].  Indeed, it was 
confirmed that both HSF1 and 2 could interact with NATb promoter both in vitro and in 
vivo.  Additionally, HSF1 but not HSF2 induced NATb promoter and resulted in elevated 
human NAT1 activity.  Furthermore, it was shown that the presence of R1881 accentuated 
HSF1 induction of the NAT1 promoter and subsequent NAT1 activity.  Therefore, HSF1 
acting on the Heat Shock Element is essential to the androgen mediated up-regulation of 
human NAT1. 
Overall, a thorough investigation of androgen mediated up-regulation of human NAT1 has 
been carried out.  It has provided two important findings: NAT1 is regulated by HSF1 
interacting with a heat shock element on the promoter NATb; and HSF1 induction is up-
regulated by androgens. However, the specific mechanism/interaction between androgens 
and HSF1 was not identified.  HSFs are important regulators of gene expression especially 
in times of cellular stress; particularly from elevated temperature, heavy metals, oxidative 
stress, inflammation, infection, tissue wound and healing, cancer and neurodegenerative 
disease [82].  Therefore, it seems plausible that expression of NAT1 could be increased in 
response to cellular stress.   
It is interesting that some of these ‘stressors’ have been shown to inactivate NAT1 (i.e. 
oxidative stress and heavy metals).  Could activation of NAT1 gene expression 
compensate for the loss of NAT1 catalytic activity?  This highly intricate regulation might 
suggest that NAT1 is essential to the cell.   
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Little work has been done to investigate promoter NATa structure and regulation.  
Wakefield et al. conducted a study of NAT1 promoter use in human breast cancer cell 
lines and identified one cell line, ZR-75-1, that possessed transcripts arising from the  
NATa promoter in addition to NATb derived transcripts [83].  Interestingly, this cell line 
possessed elevated NAT1 protein levels and greater than 40x higher NAT1 activity 
compared to the other cell lines assessed.  Whether the elevation in NAT1 protein and 
activity resulted from promoter NATa transcription was not clear.  Additionally, human 
NAT1 transcripts arising from this promoter have been identified in pooled tissue samples 
(lung/spleen and colon/kidney/stomach) and nasopharynx [62, 63].  Consequently, it would 
be valid to investigate whether a correlation exists between NATa promoter use and NAT1 
activity and furthermore it would be useful to determine specific tissue expression of Type I 
transcripts and regulation of promoter NATa.   
 
Does NAT1 have an endogenous role? 
NAT1 is ubiquitously expressed and is evolutionarily conserved.  NAT1 activity has even 
been detected throughout development as early as the blastocyst, neural tube and in the 
placenta [84, 85].  Additionally, cellular stresses could trigger NAT1 gene expression 
through the activation of HSF1.  This suggests that NAT1 could have an intrinsic cellular 
function.   
Only one endogenous substrate has been identified for NAT1 to date.  That is the folate 
catabolite, p-aminobenzoylglutamate (pABG) [27, 28].  Folate catabolism (Figure 5) occurs 
as a result of cleavage of the C9-N10 bond of the polyglutamated folate in the cell to 
produce polyglutamated p-aminobenzoylglutamate (pABGpolyglu) and pterin derivatives   
[86, 87].  Removal of the polyglutamates from pABG is facilitated by gamma glutamyl 
hydrolase.  pABG is then N-acetylated by NAT1.  This modification has been proposed to 
support removal of the catabolite from the cell.  N-acetyl pABG is the main folate catabolite 
measurable in urine [86, 88, 89] and NAT1 appears to be the only enzyme responsible for 
the acetylation of pABG as N-acetyl pABG has not been detected in Nat2 knock-out mice 
[90].   It has been proposed throughout the literature that NAT1 may have an endogenous 
role in folate metabolism.   
Folate, a family of B9 vitamins, is an essential co-enzyme for DNA, RNA and protein 
synthesis, and methylation reactions [91]. Dietary folate has been linked to a number of 
human pathologies including neural tube defects [92], orofacial clefts [93], neurological 
disorders [94], gastrointestinal
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Folate contains a one-carbon moiety at the N5 position and serves as the methyl-donor to 
the S-adenosylmethionine (SAM) cycle through the conversion of homocysteine to 
methionine, by methionine synthase, resulting in the recovery of THF.   The SAM cycle 
plays an important role in maintaining cell structure and function [99, 100]. It is involved in 
polyamine synthesis, the transulfation pathway (antioxidant detoxification), recycling of 5-
methyl-THF in the folate pathway and methylation reactions of phospholipids, CH3 
accepting proteins and CpG sequences in DNA.  Furthermore, DNA methylation is an 
important mechanism of epigenetic gene regulation [101] and consequently, folate 
influences gene expression [102, 103].  
The impact of human NAT1 acetylation of pABG on the folate pathway and subsequently 
the SAM cycle is unknown.  If NAT1 regulates the folate pathway it could have far reaching 
effects on DNA, RNA and protein synthesis as well as methylation reactions and gene 
expression and in the prevention and treatment of the human pathologies listed above. 
Very recently, NAT1 was found to act as a folate-dependent acetyl-CoA hydrolase [104]. 
Laurieri et al. demonstrated that both human NAT1 and mouse Nat2 could catalyse the 
direct hydrolysis of acetyl-CoA in the presence of folic acid using high performance liquid 
chromatography (HPLC) and H1-NMR.  Moreover, this was shown to be a specific reaction 
performed by NAT1/Nat2 as Human NAT2, mouse Nat1, as well as bacterial homologues 
were unable to hydrolyse acetyl-CoA in the presence of folic acid.  HPLC analysis showed 
a reduction in acetyl-CoA and increase in CoA with no change in folic acid with time.  
Thus, folic acid is not a substrate and does not get acetylated.   
Furthermore, the catalytic reaction was analysed by H1-NMR in real time using 
recombinant mouse Nat2 revealing the disappearance of the acetyl CH3 from acetyl-CoA 
and the appearance of CH3 corresponding to acetate (AcOH) over time.  It was clear from 
the H1-NMR that folate did not change, acetyl-CoA decreased, and CoA increased which 
was consistent with the HPLC analysis. This confirmed that folate was not modified during 
the reaction and provided evidence to suggest that the acetyl group was released.  This 
reaction would require a water molecule to be present within the active site and while in 
silico docking studies suggested that folate binding in the active site could induce 
conformational changes to allow for the water molecule to be present in the active site, 
Laurieri et al. conceded that a crystal structure with bound folate would be required to 
clarify this mechanism.   
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This study provides an alternative role for human NAT1 that also involves folate.  
Throughout these in vitro experiments, recombinant NAT proteins were examined and 150 
µM folic acid was routinely used as the cofactor which is considerably higher than the 
physiological folate concentration.  Intracellular folate concentrations have been measured 
in the low micromolar range (approximately 1-10 µM) [105, 106].  It is important to 
determine if this hydrolysis reaction is possible under physiological conditions using cell 
lysates.  Folic acid is the synthesised supplement of folate which is reduced and 
polyglutamated once in the cell.  As mentioned earlier, 5-mTHF is the predominant form of 
naturally occurring folate.  Additionally, polyglutamated folates form the active coenzyme 
species with high affinity binding to many folate dependent enzymes and binding proteins 
[107]. Therefore, determining whether 5-mTHF and polyglutamated folate forms are also 
involved in the hydrolysis of acetyl-CoA would be valuable.  Perhaps the polyglutamates 
are more efficient cofactors.  It would also be interesting to perform in silico docking of 
these compounds in the NAT1 active site to see if the polyglutamates wrap around the 
surface of the protein like CoA has been shown to do. 
 
NAT1 and Cancer 
While NAT1 has the ability to bioactivate carcinogenic compounds and has been 
associated with an increased risk of various cancers, studies are now showing that NAT1 
may have a more intimate role in cancer.  Many microarray studies have shown that NAT1 
has heightened gene expression in estrogen receptor (ER) positive breast cancer tumours 
[108-112].  A study of overexpression of human NAT1 in the normal HB4α l breast 
epithelium cell line showed that HB4α/NAT1 cells proliferated more rapidly than 
HB4α/vector control cells (by two-fold over 96 hours).  Even with a reduction of serum, 
HB4α/NAT1 cells continued to proliferate.  When treated with the apoptotic agent 
etoposide, HB4α/NAT1 had a marked reduction in cell death compared to the control cells 
[113].  Importantly, NAT1 appears to be performing a protective role and supporting 
proliferation. 
In cancer cell lines, a reduction in NAT1 has been shown to have a marked effect on cell 
proliferation and invasion.   Inhibition of recombinant human NAT1 protein and human 
NAT1 from intact MDA-MB-231 breast cancer cells by a novel inhibitor, Rhod-o-hp, is 
concentration dependent and results in a reduction in NAT1 activity [114].  NAT1 inhibition 
correlated with a decrease in cell proliferation whereby an increased number of cells 
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paused in the G2/M phase of the cell cycle.  A reduction in NAT1 activity also resulted in a 
decreased ability of the MDA-MB-231 cells to grow in soft agar which is an in vitro marker 
for anchorage independent growth. Additionally, MDA-MB-231 cells treated with the NAT1 
inhibitor exhibited a dose dependent decrease in cell invasion using an invasion assay.   
These results were supported by RNAi mediated knock-down of human NAT1 in MDA-
MD-231 cells which led to a 50% decrease in cell invasiveness.  The MDA-MB-231 cell 
line is ER negative.  While a strong correlation exists between NAT1 and the ER in breast 
cells, NAT1 is not an estrogen responsive gene.  Further investigation is required to 
determine whether there is another gene/s that might act on NAT1 expression present in 
ER positive breast cancer cells.   
An 85% reduction in human NAT1 activity was achieved in RNAi mediated NAT1 knock-
down of colon adenocarcinoma cell line HT29 compared to the control cell line (scrambled 
RNA) which again resulted in a decrease in cell proliferation and a reduction of cell growth 
in soft agar [115].  Tiang et al. observed marked changes in cell morphology between the 
knock-down and control cells. In particular, knock-down cells grew as monolayers while 
control cells grew as multilayers at high density.  Together, these results suggested that 
cell-cell contact inhibition is altered between the knock-down and control cells.   
E-cadherin is integral to intercellular adhesion in epithelial cells and suppresses invasion 
[116] and is a mediator of contact inhibition to regulate cell growth and division [117].  The 
reduction of E-cadherin leads to increased invasion and metastasis of cancer [117-119] .  
Knock-down of NAT1 in HT29 cells results in an increase in E-cadherin mRNA and protein 
expression.  Therefore, contact inhibition would increase and intercellular adhesion would 
be maintained.  Indeed, the change in phenotype observed in the study is suggestive of 
this occurring for the HT29 NAT1 knock-down cells.   This is also observed in RNAi 
mediated NAT1 knock-down in the prostate cell line 22Rv1.  Upregulation of E-cadherin 
was independent of the transcription repressors Snail, Slug and Twist suggesting that 
another mechanism is involved in regulating gene expression with respect to changes in 
NAT1 activity.  
There is strong evidence showing that human NAT1 contributes to cancer cell proliferation, 
invasion and metastasis. It is uncertain by what biochemical mechanism NAT1 supports 
these functions, although there is some evidence to suggest that epigenetic gene 
regulation may be involved.  Furthermore, a full understanding of the regulation of NAT1 
gene expression might indicate when NAT1 becomes involved in the cancer progression 
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or predict potentially affected cell/tissue types when cell/tissue specific regulators are 
involved. 
 
Summary 
Human NAT1 is one of two human N-acetyltransferase enzymes responsible for the 
acetylation of arylamine and hydrazine drugs and carcinogens.  It is ubiquitously 
expressed and present during development.  NAT1 is the only enzyme to biotransform the 
folate catabolite, pABG, so that it can be excreted.  There is evidence to suggest that 
NAT1 might regulate folate levels in the cell.  Folate is critical to cell survival and, in fact, 
antifolate compounds are used as chemotherapeutic agents for cancer treatment.  Human 
NAT1 knock-down has shown that NAT1 is important in cancer invasion and metastasis. 
There is evidence of increased expression of genes in the absence of NAT1 but not as a 
result of transcription regulators, suggesting epigenetic mechanisms of gene regulation.   
The endogenous role and mechanism of action of human NAT1 has not been fully 
elucidated.  The impact of NAT1 acetylation of pABG on the folate pathway and 
subsequently the SAM cycle is unknown.  The answers to these questions could implicate 
NAT1 in cellular metabolism. This is important regarding foetal development to further the 
understanding of neural tube defects and orofacial clefts. It will also be significant 
regarding normal cell function and cancer development and progression.  Novel inhibitors 
of human NAT1 may be agents for anticancer therapies. 
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Project Aims 
To investigate changes resulting from the silencing of NAT1 at a biochemical level in order 
to identify an endogenous role for NAT1 
AIM 1:  Determine whether intracellular pABG and N-acetyl pABG concentrations are 
altered when NAT1/Nat2 are silenced/deleted 
AIM 2:  Determine whether intracellular 5-mTHF and SAM cycle compounds 
concentrations are altered when NAT1/Nat2 are silenced/deleted 
AIM 3:   Analyse the metabolic profile of tumour cells with NAT1 knock-down 
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CHAPTER 2: METABOLOMIC ANALYSIS OF NAT2 KNOCKOUT 
MICE 
Introduction 
Human NAT1 and the mouse homologue, Nat2, have substrate specificity for the folate 
catabolite, p-aminobenzoyl glutamate (pABG).   Folate catabolism results in the formation 
of pABG that can then be N-acetylated by NAT1 presumably to support removal of the 
catabolite from the cell [27, 28] (Figure 5).  N-acetyl pABG is the main folate catabolite in 
urine [86, 88, 89].  It is important to note that NAT1 appears to be the only enzyme 
responsible for the acetylation of pABG.  Wakefield et al. measured levels of N-acetyl 
pABG in urine from Nat2+/+ (wild-type) and Nat2-/- (Nat2 gene knock-out) transgenic mice 
and found that N-acetyl pABG was not present in knock-out mice [90]. pABG may also be 
detected in urine but it has been suggested that this is a result of non-specific extracellular 
degradation of folate in the bladder or circulation [87].  By virtue of its unique role in 
acetylating the folate catabolite, pABG, NAT1 is viewed as having a potential role in 
regulating folate. 
Folate is important for foetal development.  Increased folate and folic acid supplements in 
the diet prior to and during pregnancy has been shown to reduce the risk of neural tube 
defects [120] such as spina bifida and anencephaly [92] as well as orofacial clefts [93].  
The protective mechanism has not been fully elucidated.  Excretion of the folate catabolite, 
N-acetyl pABG in women at  2nd and 3rd trimesters of pregnancy is significantly greater 
than non-pregnant women and women at the 1st trimester of pregnancy [89]. Increasing 
NAT1 activity in the placenta throughout pregnancy has been measured, providing an 
explanation for the increase in urinary N-acetyl pABG which occurs during pregnancy [84].  
Upton et al. confirmed that NAT1 was responsible for N-acetylation of pABG in the 
placenta [85].   Expression of the NAT1 gene has been measured in human embryos as 
early as the blastocyst stage [84] prior to neuralation.  This is the point in development 
most receptive to folate protection and Payton et. al. suggest that NAT1/Nat2 may have an 
important role in folate protection against neural tube defects [35]. Indeed, Cornish et. al. 
state that preliminary results indicate upregulation of Nat2 expression in the mouse neural 
tube from embryonic day 8.5 [121] and this was later reported by Wakefield et. al. [122].  
Deletion of Nat2 in some mouse strains increases the incidence of several phenotypes 
attributable to altered folate effects.  The incidence of neural tube defects resulting from 
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Nat2 knockout was investigated in the C57BL/6 mouse strain [90] and the results are 
interesting because the strain is not prone to neural tube defects [123].  One of 64 Nat2-/- 
embryos had a neural tube defect and 4 of 28 Nat2 +/- offspring generated from Nat2+/+ 
and  Nat2 -/- parents were observed to have neural tube defects [90]. Another Nat2 
knockout study [124], in the A/J mouse strain not susceptible to congenital ocular defects 
[125] showed that the Nat2 is expressed within the developing eye in embryos and the 
presence of the Nat2 null allele in one or both parents could result in ocular defects [124].  
Together, this suggests that the presence of NAT1/Nat2 has a role coinciding with folate 
protection.   
Genotyping of NAT1 single nucleotide polymorphisms in 374 families with at least one 
child suffering from spina bifida was used to assess the effect of NAT1 activity on spina 
bifida occurrence.  Spina bifida is a common neural tube defect resulting from failed fusion 
in the spinal region of the neural tube.  A loss or reduction of NAT1 activity was associated 
with a reduced risk of spina bifida [126].  Jensen et al. provided two possible explanations 
for this; NAT1 regulates folate levels whereby a decrease in NAT1 allows folate levels to 
remain sufficient for development, or activation of potential teratogens is reduced in the 
absence of NAT1.  In 2010, folate levels in red blood cells from transgenic mice containing 
the Nat2*1 (wild-type) or Nat2*2 (reduced Nat2 activity) alleles were investigated.  Folate 
levels in wild-type mice were diminished compared to mice with the reduced activity allele 
[127].  Additionally, a similar effect was observed in human erythrocyte cytosols where 
there was an inverse correlation between intracellular folate levels with NAT1 activity 
[128].  This is consistent with Jensen’s suggestion that NAT1 regulates folate levels.   
A large-scale epidemiological study, in which Californian infants were genotyped for two 
NAT1 polymorphisms, NAT1 1095C>A and NAT1 1088T>A, was carried out to determine 
whether NAT1 altered the risk of orofacial clefts with or without periconceptional 
multivitamin intake (containing folic acid) [129].  Odds ratios for isolated cleft lip 
with/without cleft palate were calculated based on comparison with the homozygous wild-
type genotype.  The authors state that there was a “slightly increased risk” of cleft lip 
with/without cleft palate in infants homozygous for the variant alleles of both NAT1 1088 
and 1095.  Furthermore, the authors also “found suggestive evidence” linking NAT1 1095 
genotype with maternal multivitamin use, whereby there was a two-fold increase in risk of 
orofacial clefts in infants who were homozygous for the variant allele and whose mothers 
did not take periconceptional multivitamins.  Unfortunately, while it was stated that the 
multivitamin contained folic acid, there was no way to determine if the results reported 
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were due specifically to folate intake and NAT1 polymorphisms or if it was related to one or 
combination of other vitamins present in the supplement.  This report presents tenuous 
links between NAT1 and folate by virtue of NAT1s role in folate catabolism and the 
presence of folate in the multivitamin. 
There is now reasonably strong evidence to suggest that NAT1 is actively involved in the 
folate pathway through epidemiological studies and measurement of the folate catabolite 
in urine.  However, there appears to be two contradictory stands on the mode in which 
NAT1 is involved.  Firstly, the presence of NAT1 and increased expression during 
development, when folate protection is necessary, would suggest that NAT1 has a role 
coinciding with folate protection.  Is this because NAT1 is essential to clearing the folate 
catabolite? Does pABG have an adverse effect of the cell?  Conversely, studies have 
shown an inverse correlation between NAT1 activity and folate levels suggesting that the 
presence of NAT1 regulates intracellular folate.  To date, no study has shown a direct 
relationship between NAT1 and folate within the cell.  It is necessary to determine whether 
the presence or absence of NAT1 results in a difference in the levels of folate-pathway 
metabolites.  This could lead to isolation of a folate function affected by NAT1 and provide 
insight into an endogenous role. It is reasonable to consider that an increase in NAT1 
activity causes a decrease in folate in the cell resulting in a reduction of metabolites 
leading to other cellular processes. For example, a decrease in folate in the form of 5-
methyl-THF may consequently lead to a decrease in functionality of the SAM cycle 
resulting in a reduction in methylation reactions (Figure 6).  Therefore, the effect of Nat2 
knockout on folate tissue and blood levels, as well as the SAM cycle has been 
investigated.  Specifically, tissue levels of 5-mTHF and the folate catabolites, pABG and N-
acetyl pABG were compared between wild-type and Nat2-/- C57BL/6 mice. Additionally, 
components of the SAM cycle were also investigated in tissues from these animals.  
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Figure 6: Biochemical pathways for the interaction of folate metabolism and the S-
adenosylmethionine cycle.   Dietary folate is metabolized to 5-methyltetrahydrofolate (5-
mTHF), which is used by methionine synthase for the conversion of homocysteine to 
methionine. Methionine can also be synthesized from betaine, especially in liver tissue. 
Catabolism of the folates produces p-aminobenzoylglutamate (pABG) and pterin (not 
shown). Murine Nat2 (and human NAT1) acetylates pABG to N-acetyl pABG, which is a 
major folate metabolite found in the urine. 
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Methods 
Animal Tissues 
Congenic mice colonies were maintained and tissues collected by Kim Sugamori and 
Debbie Brenneman, and supplied by Professor Denis Grant, Department of Pharmacology 
& Toxicology, University of Toronto.  Tissues and blood samples were shipped on dry ice 
to the University of Queensland and stored at -80°C until analysed. 
Sample Preparation 
Approximately 50 mg of liver, kidney, brain, heart or lung tissue was sonicated in 0.5 mL of 
ice cold water before centrifugation at 100,000 x g for 30 min at 4°C.  Approximately 0.1 
mL of whole blood in a final volume of 0.5 ml ice cold water was sonicated before 
centrifugation at 16,000 x g for 10 min at 4°C. 
Liquid phase extraction of the tissue/blood supernatant was carried out by adding 0.425 
mL of methanol and 0.525 mL of chloroform to 0.4 mL of supernatant and 10 µL internal 
standard (p-aminohippuric acid). The aqueous phase was collected, reduced to near 
dryness under vacuum centrifugation and resuspended in 30 µL 2% methanol/0.1% formic 
acid for immediate analysis by LC-MS/MS.  Standard curves were constructed and used to 
calculate the concentration of each metabolite in the samples.  Standard compounds were 
commercially available with the exception of the polyglutamated pABG (E2-E5) which were 
synthesised by Dr Richard Clark, School of Biomedical Sciences, University of 
Queensland.  
High Pressure Liquid Chromatography – Mass Spectrometry 
The LC-MS/MS system consisted of an Agilent 1200 Series LC system with an Agilent 
1260 Series column oven (Agilent Technologies, Palo Alto, CA, USA) coupled with an API 
3200 triple quadrupole mass spectrometer with electron ion source (ABSciex, Foster City, 
CA, USA).  HPLC separation of analytes was performed on a Poroshell 120 SB-C18 
column (150 mm x 2.1 mm, 2.7 µm particle size, Agilent Technologies) with gradient 
elution comprised of 0.1% formic acid in water (eluent A) and 0.1% formic acid in methanol 
(eluent B).  Two gradients were used; one to separate pABG, polyglutamated forms of 
pABG and N-acetyl pABG (Gradient 1) and the other to separate SAM cycle components 
(Gradient 2).  The flow rate for both gradients was 0.15 mL/min.  The column was 
maintained at a constant temperature of 37°C while the autosampler tray temperature was 
maintained at 4°C.   
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The detection of the analytes by mass spectrometry was carried out using positive 
electrospray ionization and multiple reaction monitoring mode.  Three precursor-to-product 
transitions for each compound were measured.   
Quantification of Tissue Nat2 mRNA 
Total RNA was extracted from approximately 20 mg of liver and kidney tissue from male 
and female wild-type mice using an RNeasy mini kit (Qiagen, Chadstone, VIC, Australia) 
and cDNA was synthesized using Superscript III reverse transcriptase (Invitrogen, 
Mulgrave, VIC, Australia) and oligo(dT)15 primer (Promega, Alexandria, NSW, Australia) as 
per the manufacturer’s instructions. Quantitative PCR used specific primers for Nat2 
(sense 5’-gcacaacacagtcctgactttcc-3’, antisense 5’-aagtccagtttgctcctggtgc-3’) or β-actin 
(sense 5’-cctaaggccaaccgtgaaaag-3’, antisense 5’-tcttcatggtgctaggagcca-3’) and Sensimix 
SYBR kit (Bioline, Alexandria, NSW, Australia) and was performed using an iCycler PCR 
machine (Bio-Rad, Gladesville, NSW, Australia). PCR protocol consisted of 95oC for 10 
min followed by 40 cycles of 95 oC for 10 s, 58 oC (Nat2) or 52 oC (β-actin) for 15 s, 72 oC 
for 20 s. Melt curves also were performed to show PCR specificity. No PCR product was 
detected for Nat2 using cDNA from male Nat2-/- liver tissue. Results were normalized to β-
actin and expressed relative to male samples using the ∆∆CT method. 
Statistical Analysis 
Student’s t-test or 1-way ANOVA was used to compare metabolite concentrations in the 
different tissues (GraphPad Prism, Version 5.03). Significance was assumed at p < 0.05. 
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Results 
PART A: Method Development 
LC-MS/MS characterisation of 5-mTHF, pABG, pABG polyglutamates, N-acetyl pABG 
and SAM cycle compounds 
LC-MS/MS was used to analyse 5-mTHF, pABG, pABG polyglutamates (pABAE2-E5), N-
acetyl pABG and SAM cycle compound levels in tissue and blood samples from wild-type 
and Nat2 knock-out mice.   
An internal standard is required to correct for any loss of analyte during sample processing 
and preparation.  Para-aminohippuric acid (pAH) was identified as a suitable internal 
standard (IS) as it is not an endogenous compound and it has similar structure and 
aqueous solubility to pABG.  pAH had comparable sensitivity to pABG and good resolution 
under the HPLC conditions set for pABG analysis.  5-mTHF, SAM, SAH, Hcy and 
methionine were also soluble in aqueous solutions, making pAH a suitable internal 
standard for SAM cycle analysis. 
The detection of the analytes by mass spectrometry was carried out using positive 
electrospray ionization and multiple reaction monitoring (MRM) mode.  Positive 
electrospray ionisation was selected based on the presence of the amine moiety in 
compounds being analysed.  The ion source parameters were optimized for all analytes 
(Table 2).  Manual tuning of all analytes and the internal standard was performed to 
optimise the following electron spray mass spectrometry conditions and three precursor-to-
product transitions for each compound were identified (Table 3): 
• declustering potential 
• entrance potential 
• collision cell entrance potential 
• product ions 
• collision energy for each product ion 
• collision cell exit potential for each product ion 
Theoretical fragmentation of the analytes was performed using ChemBioDraw Ultra 
V14.0.0.117 (Cambridge Soft Corporation, Perkin Elmer Inc.) to confirm product ions 
selected during manual tuning were from the parent compound.  Fragment structures are 
provided in Table 3. 
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HPLC separation of analytes was performed with gradient elution composed of 0.1% 
formic acid in water (eluent A) and 0.1% formic acid in methanol (eluent B).  Each analyte 
was injected onto the LC-MS over an increasing range of solvent (eluent B) to identify 
approximate hydrophobicity and retention. Two gradients were then created, one to 
separate pABG, pABAE2-E5 and N-acetyl pABG (Gradient 1) and the other to separate 
SAM cycle components (Gradient 2).  Due to pressure limitations of the HPLC system, the 
flow rate was only 0.15 ml/min and the re-equilibration stage of the gradients needed to be 
prolonged.  Specifically, the HPLC pump maximal pressure (5600 psi) was significantly 
lower than the column maximal pressure (13000 psi) and the flow rate and re-equilibration 
required to accommodate the pressure rises during the mixing of water and methanol was 
chosen accordingly.  Each gradient was optimised so that a balance between analysis 
time and separation of analytes was achieved (Figure 7).   Specifically, Gradient 1 started 
at 2% B (98% A) increasing to 70% B over 20 min followed by an increase to 98% B over 
2 min with column flushing at 98% B for 1 min before returning to 0% B.  Gradient 2 
started at 0% B (100% A) increasing to 20% B over 2 min followed by an increase to 98% 
B over 3 min with column flushing at 98% B for 2 min before returning to 0% B. 
The final retention times were confirmed based on appearance of all three characteristic 
product ions occurring at the same retention time and are provided in Table 4.  Examples 
of chromatograms showing separation of analytes are provided in Figure 8. 
 
Table 2: Optimised source conditions for detection of analytes by MS 
Source conditions 
Curtain Gas  30 
IonSpray Voltage (V) 5500 
IonSpray Source Temperature (°C) 500 
Ion Source Gas 1 (Nebuliser)  50 
Ion Source Gas 2 (Turbo)  50 
Interface Heater (°C) 100 
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Table 3: Optimised MRM conditions for analytes and structures of parent and product ions  
Compound (precursor) 
pABG 
  
 
pAH 
 
 
N-acetyl pABG 
 
 
5-mTHF 
Precursor m/z 267.3 195.2 309.4 460.4 
Declustering Potential 22.8 12 25 30 
Entrance Potential 4.2 4.8 4.8 7 
Collision Cell Entrance Potential 16 13.5 18 23 
Product Ion m/z 120.1 92.1 65 120.1 92.1 65 162.1 120.1 92 313.3 194.2 180.2 
Collision Energy 22 55 71 18 41 57 23 45 65 28 45 22 
Collision Cell Exit Potential 2.2 3.3 9 2.1 2.1 3.6 3.5 3.3 3.8 7 5 3.5 
Fragmentation: Product ions 
          
 
          
Structure fragmentation was performed using ChemBioDraw Ultra V14.0.0.117. Cambridge Soft Corporation. Perkin Elmer Inc. 
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O
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Table 3: Optimised MRM conditions for analytes and structures of parent and
Compound (precursor) 
s-adenosylmethionine
Precursor m/z 399.2 
Declustering Potential 26 
Entrance Potenial 4.5 
Collision Cell Entrance Potential 26 
Product Ion m/z 250 136.1 
Collision Energy 24 38 
Collision Cell Exit Potenial 4 3 
Fragmentation: Product ions 
  
  
 Structure fragmentation was performed using ChemBioDraw Ultra V14.0.0.117. Cambridge Soft Corporation. Perkin Elmer Inc.
 
 
 product ions (continued)
  s-adenosylhomocysteine  methionine  
 
385.1 150.2 
26 25 
4.5 5.5 
26 10 
96.9 136 118.9 87.9 74.1 61 
46 29 80 67 27 35 
3 2.9 4.9 3.9 8 8 
    
  
    
 
  
(+ H
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homocysteine 
136.2 
24 
4.5 
11 
56.1 90 73 56.1 
28 18 28 29 
8 2 2.2 7 
  
  
  
 
2
O) 
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Table 3: Optimised MRM conditions for analytes and structures of parent and product ions (continued) 
Compound (precursor) 
pABA-E2 
 
pABA-E3 
 
pABA-E4 pABA-E5 
Precursor m/z 396.4 525.5 654.6 783.6 
Declustering Potential 19 30 40 40 
Entrance Potenial 4.3 5 6 7.5 
Collision Cell Entrance Potential 25 24 31 45 
Product Ion m/z 120.1 92.2 249.2 120.1 84 249.2 336.8 120.1 581.3 249.1 120.1 259.2 
Collision Energy 43 75 18 55 65 21 60 60 40 42.5 68 48 
Collision Cell Exit Potenial 2.9 3.5 7 3.5 3.5 6 4 4 10 3.5 4 4 
Fragmentation: Product ions 
  
  
    
  
              
Structure fragmentation was performed using ChemBioDraw Ultra V14.0.0.117. Cambridge Soft Corporation. Perkin Elmer Inc. 
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Figure 7:  Gradient 1 (top) was used for analysis of pABG, N-acetyl pABG and pABG 
polyglutamates (top) and Gradient 2 (bottom) SAM cycle components including 5-
mTHF.  Eluent A is 0.1% formic acid in H2O.  Eluent B is 0.1% formic acid in methanol. 
 
Table 4: Expected retention times for 5-mTHF, pABG, pABG polyglutamates and 
SAM cycle components 
Analyte RT (min) Gradient 
pABG 12.9 1 
N-acetyl pABG 18.4 1 
pABA-E2 14.1 1 
pABA-E3 15.3 1 
pABA-E4 16.7 1 
pABA-E5 17.9 1 
5-methyltetrahydrofolate 10.4 2 
S-adenosylmethionine 2.3 2 
S-adenosylhomocysteine 8.1 2 
Methionine 3.7 2 
Homocysteine 2.8 2 
pAH (internal standard) 9.5 1 
pAH (internal standard) 9.5 2 
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Figure 8: Representative chromatograms of pABG, polyglutamated pABG (pABAE2-
E5) and N-acetyl pABG (top) and SAM cycle compounds including 5-mTHF (bottom).  
The internal standard, pAH, is included in both. 
 
Validation of Sample Processing Method  
Two methods for sample preparation were considered based on availability within the lab.  
Solid phase extraction using the Waters Sep-Pak C18 reversed-phase cartridge was 
assessed for recovery of pABG, N-acetyl pABG and pAH initially.  While pABG and N-
acetyl pABG had acceptable recovery, only 40% of pAH could be recovered making this 
method unsuitable.  Liquid phase extraction consisting of water, methanol and chloroform 
was subsequently considered and preliminary recovery of pABG, N-acetyl pABG, pAH, 
SAM and SAH was 100% making this the preferred sample processing method (Figure 9). 
Standard curves were prepared for pABG, pABAE2-E5 and N-acetyl pABG ranging from 
0.06 to 8 pmol, and for SAM, SAH, Hcy and methionine ranging from 6 – 800 pmol based 
on expected quantities in tissue samples.   Recovery of analytes using the liquid phase 
extraction method was investigated to determine how suitable the entire process was 
pAH 
pABG 
pABAE2 
pABAE3 
pABAE5 
pABAE4 
N-acetyl pABG 
SAM 
Hcy 
Met SAH 
5-mTHF 
pAH 
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(Table 5).  Specifically, the standard curve concentrations for SAM, SAH, Hcy, Met (range 
800 – 6 pmol injected on column) and pABG, N-acetyl pABG and pABAE2-E5 (range 8 – 
0.06 pmol injected on column) were prepared in a final volume of 400 µL. The standard 
curves were processed as described for sample processing.  Additionally,  replicate 
samples containing fresh standards, with appropriate dilutions such that SAM, SAH, Hcy 
and Met final concentrations range 800 – 6 pmol injected on column and pABG, N-acetyl 
pABG and pABAE2-E5 final concentrations range 8 – 0.06 pmol injected on column were 
also prepared.  Both sets of standards were analysed by LC-MS/MS as described and the 
area under the curve (AUC) for processed and freshly prepared standards for each 
concentration were compared to determine recovery.  Standard curves were generated by 
relating the AUC of the analyte to that of the internal standard.  The linear regression 
coefficient, R2, is reported for analyte standard curves (Table 5) and an R2 greater than 
0.95 was considered acceptable.  
 
Figure 9: Preliminary investigation of liquid phase sample processing. Standard 
compounds were diluted to 0.01 mg/mL in water and subjected to liquid phase extraction 
and 5 µL injected onto LC-MS.  Additionally, standards were firstly diluted to 0.01 mg/mL 
the further diluted in water to mimic liquid phase extraction and 5 µL injected onto LC-MS.  
AUC for standards processed by liquid phase extraction were normalised to AUC of 
unprocessed standards (% unprocessed compounds).  Results are mean ± SEM, n = 3. 
 
Reproducibility of standard curves was investigated (Table 6).  A selection of 
concentrations across the standard curve range were prepared in triplicate and processed 
as described above.  The mean, standard deviation and coefficient of variance for each 
compound was calculated. Recovery of Hcy decreased with decreasing concentrations of 
the standard.  However, reproducibility of the Hcy standard curve at the lowest 
concentration was deemed satisfactory with a CV of 11.9%.  This indicated that the 
processing of standards and samples concurrently would be consistent.  
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Table 5:  Recovery of analytes processed by liquid phase extraction 
Recovery: Processed as % of Fresh AUC 
pmol SAM SAH Hcy Met  pmol pABG 
N-acetyl 
pABG pABAE2 pABAE3 pABAE4 pABAE5 
800 112% 98% 91% 99%  8 100% 103% 93% 131% 88% 138% 
400 118% 102% 71% 46%  4 107% 97% 94% 80% 146% 109% 
200 129% 98% 71% 74%  2 111% 124% 167% 159% 101% 92% 
100 163% 107% 58% 79%  1 85% 128% 70% 112% 102% 106% 
50 145% 90% 47% 90%  0.5 109% 113% 125% 106% 77% 71% 
25 137% 83% 20% 54%  0.25 96% 121% 92% 90% 76% 84% 
12.5 194% 83% 4% 76%  0.125 73% 107% 42% 60% 141% ND 
6.25 199% 82% 7% 71%  0.062 150% 107% 67% 70% 208% ND 
Linear regression coefficient, R2 
Fresh 0.9949 0.9927 0.9926 0.9894  Fresh 0.9941 0.9867 0.9808 0.9412 0.9938 0.9948 
Processed 0.9936 0.9860 0.9997 0.9576  Processed 0.9974 0.9954 0.9992 0.9942 0.9733 0.9743 
 ND- not detected pABAE2-E5 = polyglutamated pABG
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Therefore, analysis of Hcy from samples processed in this manner was considered 
acceptable.  The recovery of the remaining SAM cycle components was satisfactory.   
The limit of detection (LOD) for analytes was determined by the lowest concentration 
measured during the reproducibility experiment that resulted in CV < 20%.  The LOD for 
SAM, Hcy and Met was 6.25 pmol while the LOD for SAM was 12.5 pmol.  The LOD for 
pABG and N-acetyl pABG was 0.06 pmol.  When preparing the pABG, N-acetyl pABG, 
and pABAE2-E5 standards, all compounds were included in the one preparation (for each 
concentration) containing IS.  This is also the case for SAM cycle compounds.  Therefore, 
by comparing AUC/IS AUC of each compound, it was possible to relate sensitivity of 
detection for all analytes.  Using the reproducibility of standards  data provided in Table 6, 
it was evident that pABG is approximately 4x more sensitive than N-acetyl pABG or 
pABAE3, approximately 10 times more sensitive than pABAE4, approximately 45 times 
more sensitive than pABAE2 and 100 times more sensitive than pABAE5.  It is clear from 
these data that the standard curves for the polyglutamates was not reproducible.  From the 
reproducibility data, the LOD for pABAE2-E5 were 1 pmol for pABAE2 and pABAE4, and 8 
pmol for pABAE3 and pABAE5.  As the LC-MS/MS method using Gradient 1 contains the 
multiple reaction monitoring conditions for detecting pABAE2-E5, these analytes could be 
monitored for all samples analysed.  However, no intracellular concentrations were 
determined because of the lack of a valid standard curve. 
In order to avoid interference with other assays, reducing agents were not routinely added 
for the extraction of 5-mTHF.  Consequently, initial studies were performed to determine 
whether their omission affected recovery and/or stability.  Mouse liver homogenates 
prepared in either 20 mM ammonium acetate buffer (pH 7.4) containing 1% ascorbate and 
0.1% 2-mercaptoethanol or water, were spiked with 2.4 nmol 5-mTHF and pABG, and 
extracted as described above (Figure 10). The spike concentration equated to 400 pmol 
injected on column and fell on the standard curve.  5-mTHF and pABG levels were then 
determined by LC-MS/MS and compared to extraction in water.  There were no differences 
in the measured amounts of either 5-mTHF or pABG between the different extraction 
procedures.  Additionally, there was no significant elevation of pABG levels suggesting 
that degradation of 5-mTHF to pABG does not occur during sample processing.  
Therefore, pABG measured in the tissues was not due to degradation of intracellular 5-
mTHF during processing of samples. 
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Table 6: Reproducibility of analytes across the standard curve concentration range 
  
AUC/IS AUC   AUC/IS AUC 
  
SAM SAH Hcy Met 
  
pABG pABAE2 pABAE3 pABAE4 pABAE5 N-acetyl pABG 
800 
pmol 
Mean 56.94 164.16 104.92 57.90 
8 
pmol 
Mean 20.15 0.45 4.83 1.73 0.19 4.91 
SD 3.26 6.22 3.42 4.01 SD 2.57 0.04 0.60 0.16 0.01 0.20 
%CV 5.7% 3.8% 3.3% 6.9% %CV 13% 9% 12% 9% 7% 4% 
100 
pmol 
Mean 5.30 24.39 11.92 8.35 
1 
pmol 
Mean 2.76 0.06 0.60 0.20 0.02 0.65 
SD 0.09 2.39 0.85 0.20 SD 0.45 0.00 0.13 0.03 0.01 0.07 
%CV 1.7% 9.8% 7.1% 2.4% %CV 16% 7% 22% 15% 48% 11% 
12.5 
pmol 
Mean 0.72 
Not measured 0.125 pmol 
Mean 0.34 0.00 0.04 0.01 0.00 0.10 
SD 0.05 SD 0.03 0.00 0.01 0.00 0.00 0.01 
%CV 7.3% %CV 9% 31% 29% 27% 19% 14% 
6.25 
pmol 
Mean 0.24 1.15 0.05 0.58 
0.06 
pmol 
Mean 0.20 0.01 0.03 0.01 0.00 0.07 
SD 0.08 0.09 0.01 0.04 SD 0.03 0.00 0.01 0.00 0.00 0.01 
%CV 32.5% 8.1% 11.9% 6.7% %CV 17% 47% 27% 12% 92% 13% 
IS = Internal Standard pABAE2-E5 = polyglutamated pABG 
 
 
 
 
Figure 10: Recovery of 5-mTHF and pABG in spiked mouse tissue.  
Liver tissue homogenised in 20 mM ammonium acetate buffer (pH 7.4) 
containing 1% ascorbate and 0.1% 2-mercaptoethanol (buffer) or water 
was spiked with 2.4 nmol 5-mTHF and pABG. Samples were processed 
by liquid phase extraction and 5-mTHF and pABG were measured. 
Results are mean ± SEM, n = 3, and spiked sample measurements are 
expressed as % expected concentration.   
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PART B: 5-mTHF and SAM cycle in mouse tissues and effects of Nat2 
deletion Transcription from Witham, K.L., et al., 5-Methyl-Tetrahydrofolate and the S-
Adenosylmethionine Cycle in C57BL/6J Mouse Tissues: Gender Differences and Effects of 
Arylamine N-Acetyltransferase-1 Deletion. PLoS ONE, 2013. 8(10): p. e77923.[130] 
Tissue Levels of 5-mTHF, Hcy and Methionine in C57BL/6J Mice 
5-mTHF is the predominant folate species in both humans and rodents [131-133].  It is 
utilized in the conversion of Hcy to methionine, which is a precursor for the synthesis of 
SAM.  Consequently, 5-mTHF is essential for maintenance of the SAM cycle and one-
carbon metabolism (Figure 6).  Several components of the SAM cycle have demonstrated 
gender differences.  For example, female A/J and C57BL/6J mice have approximately 
50% higher circulating Hcy than male mice [134]. Similarly, female rats exhibited higher 
hepatic glycine N-methyltransferase, an enzyme that regulates SAM levels, compared to 
male animals [135]. 
The concentrations of the SAM precursors, 5-mTHF, methionine and Hcy, were measured 
in tissues from male and female wild-type C57BL/6J mice.  The level of all 3 metabolites 
was highest in the liver and kidney compared to other tissues examined (Figure 11).  In the 
liver from female animals, 5-mTHF, Hcy and methionine levels were 50 to 100% higher 
than in male livers (Figure 11).  Similarly, both Hcy and methionine levels were higher in 
female kidney.  No gender-based differences were seen in brain, heart, lung tissue or 
blood.  These results show that the precursors for SAM biosynthesis are elevated in the 
liver of female mice compared to male mice. 
Tissue Levels of SAM and SAH in Wild-type Mice 
Consistent with the elevated levels of 5-mTHF, Hcy and methionine, SAM concentrations 
were significantly higher in female livers compared to males (Figure 12). This was 
accompanied by a decrease in SAH, which suggests methylation turnover may be lower in 
female liver tissue.  Surprisingly, SAM concentrations in the female kidney were only 25% 
of that seen in the male kidney.  Again, no differences were seen in other tissues 
examined. 
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Figure 11: Tissue concentrations of 5-mTHF (A), Hcy (B) and methionine (C) in 
C57BL/6J mice. The open bars are male tissue samples while the closed bars are female 
tissue samples. Results are mean ± SEM, n = 3. Asterisk indicates significant difference 
compared to respective male concentrations (p < 0.05). 
 
A
 
 B
  
Figure 12: Tissue concentrations of SAM (A) and SAH (B) in C57BL/6J mice. The 
open bars are male tissue samples while the closed bars are female tissue samples. 
Results are mean ± SEM, n = 3. Asterisk indicates significant difference compared to 
respective male concentrations (p < 0.05). 
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Hepatic and Renal Levels of Folate Catabolites in Wild-type Mice 
Both pABG and N-acetyl pABG were detected in liver and kidney tissue from wild-type 
C57BL/6J mice (Figure 13). Hepatic concentrations for both metabolites were considerably 
higher than those found in the kidney.  In the liver, female mice had higher pABG 
concentrations than male mice, whereas the opposite was seen for N-acetyl pABG.  This 
suggested that Nat2 may be more highly expressed in the male mouse liver resulting in a 
larger extent of pABG acetylation.  In the absence of a specific murine Nat2 antibody, 
qPCR was performed on mRNA extracted from liver tissue to detect any gender 
differences in expression.  Male animals exhibited a significantly higher Nat2 mRNA level 
(approximately 5-fold) compared to female animals, indicative of a higher level of gene 
expression.  In the kidney, there was a slight but significant decrease in Nat2 mRNA in 
female compared to male mice.  The amount of the polyglutamated forms of pABG were 
below the limit of detection in both tissues examined (data not shown). 
A B C
 
Figure 13: Liver and kidney concentrations of pABG (A) and N-acetyl pABG (B) in 
C57BL/6J mice. (C) Relative NAT1 mRNA levels determined by qPCR. The open bars 
are male tissue samples while the closed bars are female tissue samples. Results are 
mean ± SEM, n = 3. Asterisk indicates significant difference compared to respective male 
concentrations (p < 0.05). 
 
Effect of Nat2 Deficiency on 5-mTHF, Hcy and Methionine Tissue Levels 
In Nat2-/- mice, there was a significant increase in the concentration of 5-mTHF in the liver 
of male animals but not in female animals, compared to wild-type animals (Figure 14A).  
No other differences in 5-mTHF, Hcy or methionine were seen (Figure 14).  In the brain 
tissue of female animals, Hcy and methionine levels were elevated approximately 50% but 
this was not statistically significant (one-way ANOVA, p > 0.05). 
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Figure 14: Tissue concentrations of 5-mTHF (A), Hcy (B) and methionine (C) in Nat2-
/- C57BL/6J mice. Results are mean ± SEM, n = 3, and are expressed as percentage of 
wild-type concentrations. Asterisk indicates significant difference compared to respective 
wild-type concentrations (p < 0.05). 
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Effect of Nat2 Deficiency on SAM and SAH Tissue Levels 
The concentration of SAM in the blood of male Nat2-/- mice was more than twice that seen 
in wild-type mice (Figure 15).  There was also a significant increase in SAH in the lung of 
male Nat2-/- animals.  By contrast, there were no significant changes in the concentration 
of either SAM or SAH in the tissues from female Nat2-/- mice compared to wild-type. 
 
A
 
 
B
  
Figure 15: Tissue concentrations of SAM (A) and SAH (B) in Nat2-/- C57BL/6J mice. 
Results are mean ± SEM, n = 3, and are expressed as percentage of wild-type 
concentrations. Asterisk indicates significant difference compared to respective wild-type 
concentrations (p < 0.05).  BD = below detection. 
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Effect of Nat2 Deficiency on Hepatic and Renal Levels of Folate Catabolites 
In Nat2-/- mice, N-acetyl pABG was undetectable in both the liver and kidney samples. 
This is consistent with previous reports [90] and confirms the essential role of Nat2 in the 
acetylation of pABG in vivo.  Surprisingly, the concentration of pABG in liver and kidney 
were similar in Nat2-/- mice compared to wild-type mice (Figure 16). This was true for both 
male and female animals.  These results suggest that Nat2 activity is required for the 
acetylation of pABG but it is not essential for regulating pABG tissue concentrations, at 
least in the liver and kidney of C57BL/6J mice. 
 
Figure 16: Liver and kidney concentrations of pABG in male and female Nat2-/- 
C57BL/6J mice. Results are mean ± SEM, n = 3, and are expressed as percentage of 
wild-type concentrations.  
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Discussion 
Transcription from Witham, K.L., et al., 5-Methyl-Tetrahydrofolate and the S-
Adenosylmethionine Cycle in C57BL/6J Mouse Tissues: Gender Differences and Effects of 
Arylamine N-Acetyltransferase-1 Deletion. PLoS ONE, 2013. 8(10): p. e77923.[130] 
In the present study, tissue concentrations of the folate precursor to the SAM cycle, 5-
mTHF, along with methionine, SAM, SAH and Hcy were evaluated in C57BL/6J mice.  
These metabolites regulate methylation reactions, including epigenetic control of gene 
expression, by controlling the levels of SAM in the cell.  There is evidence that the folate-
SAM cycle pathway varies with gender [134, 136].  In the liver of female mice, 5-mTHF, 
methionine, SAM and Hcy were significantly elevated compared to male liver tissue.  
Recently, Chew et al. showed that betaine was utilized to a greater extent in methionine 
synthesis (Fig. 6) in the female BALB/c mouse liver compared to that in male liver [137], 
which could explain the elevated SAM cycle metabolites in the female liver.   Since female 
mice also show higher DNA methyltransferase activity in the liver [138], the results suggest 
that female mouse liver may have a higher methylation capacity compared to male 
animals. In the kidneys, 5-mTHF, methionine and Hcy were significantly higher in females, 
but unexpectedly, SAM levels were only 25% of that in male tissue.  The physiological 
reason for this difference is currently unknown.  There were no differences in any of these 
metabolites in brain, heart or lung tissue.  
Folates are metabolized along a number of pathways.  A major catabolic pathway is the 
formation of pABG following cleavage of the C9-N10 bond.  pABG is readily acetylated by 
Nat2 to form N-acetyl pABG, which is then excreted in the urine.  Previous studies with 
Nat2 null mice showed no evidence of N-acetyl pABG formation in the absence of Nat2, 
indicating its essential role in pABG acetylation [90].  An absence of N-acetyl pABG 
following Nat2 gene deletion was also observed.  However, somewhat surprisingly, there 
was no change in pABG concentrations in either liver or kidney tissue from male or female 
animals.  These results indicate that pABG levels are not directly regulated by Nat2 activity 
in vivo and suggest that acetylation is of little or no consequence in pABG homeostasis.  
The deletion of Nat2 in C57BL/6J mice produced few changes in the folate-SAM pathway.  
A notable exception was a significant increase in hepatic 5-mTHF, which was only seen in 
the male animals.  Following gene knockout, the male liver 5-mTHF levels increased to 
that seen in wild-type female mice.  Interestingly, female liver tissue expressed much lower 
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levels of Nat2 compared to males.  Taken together, these results suggest there is an 
inverse relationship between hepatic 5-mTHF and Nat2 activity.   
In summary, the current study has demonstrated gender differences in the folate-SAM 
cycle in murine liver and kidney tissue.  Deletion of Nat2 selectively affected 5-mTHF in 
male liver tissue but had no effect on the concentrations of its putative endogenous 
substrate pABG.  It should be noted that the tissues used in the present study were 
harvested from animals raised under normal conditions where no phenotypic differences 
between the strains is evident.  More pronounced changes in folates and the SAM cycle 
may be evident under folate deficiency or following other stresses that alter the folate-SAM 
cycle pathway. 
 
  
69 
CHAPTER 3: METABOLIC ANALYSIS OF HT-29 CANCER CELL 
LINES 
Introduction 
NAT1 is commonly viewed as having a role in folate metabolism because its endogenous 
substrate, pABG, is a folate catabolite.  If NAT1 has an effect on folate metabolism, it is 
possible that the SAM cycle might be affected, as 5-mTHF, the main naturally occurring 
form of folate, provides the methyl group to the SAM cycle.  The previous study sought to 
determine if mouse Nat2 (homologous to human NAT1) was essential for regulating pABG 
and consequently 5-mTHF, while simultaneously investigating whether Nat2 altered the 
SAM cycle in Nat2 knock-out and wild-type mice.  Surprisingly, the levels of pABG in 
knock-out and wild-type tissues did not differ overall, nor were there any great changes in 
5-mTHF or the SAM cycle.  Therefore, it is apparent that Nat2 was not essential for 
regulating pABG levels and there was no evidence to support NAT1 regulation of folate or 
the SAM cycle.  
Nat2 knock-out mice have been reported to be largely aphenotypical compared to wild-
type suggesting that NAT1 might not be required under normal developmental or growth 
conditions [49].  However, NAT1 has been shown to support cancer cell survival and 
growth [113-115].  In one study of particular interest, investigators found that NAT1 knock-
down in the human colon adenocarcinoma cell line, HT-29, resulted in altered cell growth 
and morphology, reduced anchorage-independent growth in soft agar (an in vitro test for 
metastatic potential) as well as an increase in cell-cell contact growth inhibition [115].  
Moreover, E-cadherin, an important protein in cell adhesion, was up-regulated with the 
loss of NAT1.  This was due to increased E-cadherin mRNA expression.  The change in 
transcription could not be attributed to altered levels of E-cadherin transcriptional 
repressors (Snail, Slug and Twist). Consequently, Tiang et al. suggested that epigenetic 
regulation might be involved.  The investigators also showed that up-regulation of E-
cadherin following NAT1 knock-down was not restricted to the one cell line as it was also 
observed in the prostate cancer cell line, 22Rv1.   
Methylation of CpG sequences in DNA is an important mechanism of epigenetic gene 
regulation [101].  DNA methylation regulates gene expression by inhibiting the binding of 
transcription factors at the promoter region of genes or enables binding of specific 
transcription repressors resulting in the recruitment of histone deacetylases to silence 
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gene expression.  This is performed by DNA methyltransferase enzymes (DNMTs) that 
catalyse the transfer of methyl groups from SAM to cytosine residues of CpG sequences.  
Changes in the SAM cycle alter DNA methylation and therefore, it is important to 
understand SAM cycle homeostasis.  Finkelstein has reviewed the SAM cycle in depth 
[139-141] and a schematic summary is provided in Figure 17.  Very simply, SAM is 
produced intracellularly by methionine adenosyltransferases (MAT) using the essential 
amino acid methionine, and ATP.  SAM production may be regulated by MAT, which is 
inhibited by SAM at high levels.  SAM can be decarboxylated and becomes a substrate for 
polyamine synthesis or donates its methyl group to methyltransferase enzymes for DNA, 
protein and phospholipid methylation producing S-adenosylhomocysteine (SAH).  
Removal of SAH is essential as it is a potent competitive inhibitor of methyltransferases 
that use SAM as the substrate.  S-adenosylhomocysteine hydrolase catalyzes the 
hydrolysis of SAH to Hcy and adenosine, as well as catalyzes the formation of SAH from 
Hcy and adenosine.  The reaction equilibrium favours SAH formation.  Therefore, the 
removal of Hcy is essential for SAH hydrolysis and the continuation of the SAM cycle.  In 
some tissues, Hcy may be removed from the SAM cycle by entering the trans-sulfuration 
pathway for production of cysteine and its derivatives.  Ubiquitously, Hcy may be bound to 
proteins and exported from the cell (especially when adenosine is limited) or remethylated 
to produce methionine by methionine synthase (or betaine-homocysteine 
methyltransferase in the liver) to preserve SAM cycle homeostasis.       
Studies have shown that increased SAM levels resulted in increased DNA methylation and 
changes in gene expression [142-144].  Elevated SAH competitively inhibits DNA 
methyltransferases by competing with SAM and has been shown to decrease DNA 
methylation [145, 146].  In addition, elevated Hcy leads to elevated SAH and resultant 
DNA hypomethylation [147]. 
A recent study showed that changes in the SAM cycle components methionine and Hcy 
resulted in altered DNA methylation leading to changes in cancer cell growth and survival 
[148].  Promoter DNA methylation patterns of human gastric carcinoma cell line MKN74 
cultured for 3 days under normal conditions (RPMI 1640 medium containing 100 µM 
methionine) or in methionine deficient medium (methionine free RPMI 1640 medium 
supplemented with 100 µM Hcy) were investigated [148].  The promoters of five genes 
were assessed and changes in DNA methylation was observed for all.  Of particular 
interest was CDH1, the gene for E-cadherin.  Under normal culture conditions (RPMI 1640 
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Figure 17: The SAM Cycle. 
S-adenosylmethionine donates the methyl group to a range of methyltransferase enzymes 
involved in DNA, protein and phospholipid methylation and S-adenosylhomocysteine is 
produced.  Additionally, it may be decarboxylated and enter the polyamine synthesis 
pathway.  S-adenosylhomocysteine hydrolase catalyzes the reversible conversion of S-
adenosylhomocysteine to homocysteine and adenosine depending on the presence of 
homocysteine (and adenosine).  Homocysteine is methylated by methionine synthase in 
the presence of 5-mTHF (or by betaine homocysteine methyltransferase in the presence of 
betaine) to produce methionine.  Alternatively, it may enter the trans-sulfation pathway.  S-
adenosylhomocysteine and homocysteine can also be excreted from the cell.  Methionine 
can be taken up by the cell and methionine adenosytransferase catalyses the ATP 
dependent conversion of methionine to S-adenosylmethionine completing the SAM cycle.  
MS, Methionine Synthase; SAHH, S-adenosylhomocysteine Hydrolase; MAT, Methionine 
Adenosyltransferase; BHMT, Betaine-Homocysteine Methyltransferase. 
 
 
medium containing 100 µM methionine), the DNA methylation profile was as follows; 
13.9% hypermethylated, 86.03% intermediately methylated and 0.07% unmethylated 
according to the investigators real-time qPCR methodology.  However, when methionine 
was deficient and replaced with Hcy, the DNA methylation profile was 100% unmethylated.  
This translated into significantly increased CDH1 mRNA expression in MKN75 as well as 
the other gastric cancer cell lines assessed (MKN45 and KOTOIII).  Moreover, methionine 
deprivation reduced cellular adhesion, migration and invasion in vitro.  This was shown to 
be physiologically relevant as tumour growth resulting from MKN74 cells grafted into 
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NOD/SCID mice was significantly reduced when mice were fed a methionine free diet 
supplemented with Hcy.  This work provides strong evidence to indicate that altered SAM 
cycle alters DNA methylation which leads to changes in cancer growth and survival.  
Additionally, it provides specific results to show that epigenetic regulation of E-cadherin is 
influenced by components of the SAM cycle. 
Given that NAT1 induced changes in cancer cell growth and survival have been reported,  
possibly mediated by altered E-cadherin protein expression, and that E-cadherin DNA 
methylation and expression is influenced by changes in SAM cycle components, it stands 
to reason that NAT1 might alter the SAM cycle to induce the changes in E-cadherin 
observed previously.   
In this chapter, a metabolomics-based approach was adopted to investigate the effect of 
NAT1 knock-down in the HT-29 cancer cell line.  Metabolomics is the measurement of 
products of metabolism and changes in these products, in response to biological stimuli or 
genetic manipulation.  These changes can reflect altered cellular metabolism and provide 
insights into the biochemical processes involved.  In this case, components of the SAM 
cycle as well as the methyl donor, 5-mTHF have been measured along with the folate 
catabolites, pABG and N-acetyl pABG to determine if NAT1 alters these pathways in a 
cancer model.  Examination of the amino acids in HT-29 when NAT1 was knocked down 
was also undertaken with the view of identifying biochemical pathway/s in which NAT1 
may be involved.  
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Methods 
Cell lines  
Human colon adenocarcinoma cell line, HT-29 (ATCC HTB-38), stably expressing shRNA 
targeting NAT1 mRNA (NAT1 KD) or scrambled shRNA (control) were previously 
generated [115].  Cell lines were routinely cultured in RPMI 1640 supplemented with 10% 
fetal bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and 0.3 mg/mL 
G418 (to maintain selection) and maintained at 37°C in a humidified atmosphere of 5% 
CO2 in air.  The exception to this was the amino acid analysis in which 5% FBS was used 
instead of 10% FBS.  
NAT1 activity assay 
Cells were washed with PBS, resuspended in ice cold reaction buffer (20 mM Tris, pH 7.4, 
1 mM EDTA, and 1 mM DTT) and lysed by sonication at 4°C (Branson sonifier B250; duty 
cycle 100%, output = 4; 2 x 5 sec bursts with 30 sec on ice between bursts). Cell lysates 
were then centrifuged at 16,000g, 4°C for 10 min.   Supernatant protein concentrations 
were determined using the Bradford method [149] and the supernatant assayed for NAT1 
activity by high performance liquid chromatography as previously described [77].   
Culture conditions for metabolomics analysis by LC-MS/MS 
HT-29 NAT1 KD and control cell lines were seeded at 2 x 106 cells per 10 cm plate in 10 
mL complete medium (10% FBS).  At 72 hours, a sample of the medium was collected and 
the cells were washed with PBS, detached from the plate by trypsin and both medium and 
cells were subjected to sample processing for metabolite analysis by LC-MS/MS.   
Additionally, HT-29 NAT1 KD and control cell lines were seeded at 2 x 106 cells per 10 cm 
plate in 10 mL complete medium (10% FBS) over a time course.  Medium samples (100 
µL) were collected daily and stored at -20°C for analysis.  
Culture conditions for metabolomics analysis of amino acids 
HT-29 NAT1 KD and control cell lines were seeded at 2 x 106 cells per 10 cm plate in 10 
mL complete medium (5% FBS) over a time course.  Medium samples (100 µL) were 
collected daily and stored at -20°C for analysis.  
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Processing cell line samples for LC-MS/MS 
Trypsinised cells were pelleted by centrifugation. The pellets were washed twice with PBS 
and lysed by sonication in 400 µL ice cold water (as described in NAT1 activity assay).  
Cell lysates were centrifuged at 16000 g, 4°C for 10 min and the supernatant was kept for 
processing.  Ice cold water (300 µL) was added to the 100 µL medium samples. 
Liquid phase extraction of the cell lysates and medium was carried out by adding 0.425 mL 
of methanol and 0.525 mL of chloroform to 0.4 mL of supernatant and 10 µL internal 
standard (p-aminohippuric acid). The aqueous phase was collected, reduced to near 
dryness under vacuum centrifugation and resuspended in 30 µL 2% methanol/0.1% formic 
acid for immediate analysis by LC-MS/MS.  Standard curves were constructed and used to 
calculate the concentration of each metabolite in the samples. 
High Pressure Liquid Chromatography – Mass Spectrometry 
The LC-MS/MS system consisted of an Agilent 1200 Series LC system with an Agilent 
1260 Series column oven (Agilent Technologies, Palo Alto, CA, USA) coupled with an API 
3200 triple quadrupole mass spectrometer with electron ion source (ABSciex, Foster City, 
CA, USA).  HPLC separation of analytes was performed on a Poroshell 120 SB-C18 
column (150mm×2.1mm, 2.7 µm particle size, Agilent Technologies) with gradient elution 
comprised of 0.1% formic acid in water (eluent A) and 0.1% formic acid in methanol 
(eluent B). Two gradients were utilized, one to separate pABG, polyglutamated forms of 
pABG and N-acetyl pABG (Gradient 1) and the other to separate SAM cycle components 
(Gradient 2).  The flow rate for both gradients was 0.15 mL/min.  The column was 
maintained at a constant temperature of 37°C while the autosampler tray temperature was 
maintained at 4°C.   
The detection of the analytes by mass spectrometry was carried out using positive 
electrospray ionization and multiple reaction monitoring mode.  This method is outlined in 
detail in Chapter 3.  Further to this, the analytes putrescine and N-acetyl spermidine were 
incorporated into Gradient 2.  Manual tuning of these analytes was performed to optimise 
the following electron spray mass spectrometry conditions and two precursor-to-product 
transitions for each compound were identified (Table 7).  Retention times were identified 
(Table 8). 
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Table 7: Optimised MRM conditions for polyamines and structures of parent and 
product ions 
Compound (precursor) 
Putrescine 
 
 
 
N-acetyl spermidine 
 
 
H
N
H2N
H
N
O  
Precursor m/z 89.0 188.3 
Declustering Potential 22 21 
Entrance Potential 1.9 3.2 
Collision Cell Entrance Potential 12 12 
Product Ion m/z 72.1 55.1 100.1 72.1 
Collision Energy 16 28 23 30 
Collision Cell Exit Potential 10 7 1.5 10 
Fragmentation: Product ions 
   
 
 
  
Structure fragmentation was performed using ChemBioDraw Ultra V14.0.0.117. Cambridge Soft Corporation. 
Perkin Elmer Inc. 
 
Table 8: Expected retention times for putrescine and N-acetyl spermidine 
Analyte RT (min) Gradient 
Putrescine 1.9 2 
N-acetyl spermidine 2.7 2 
pAH (reference) 9.5 2 
 
 
Processing medium samples for amino acid analysis  
Medium samples and amino acid standards were processed using the Phenomonex 
“Phree” Phospholipid Removal Plates as per the manufacturer’s instruction.  Specifically, 
300 µL acetonitrile/1% formic acid was added per well of the 96 well plate followed by 100 
µL medium sample/standard plus 10 µL internal standard (Norvaline).  The plate was 
vortexed vigorously for 2 minutes and vacuum filtration was used to remove protein and 
phospholipids from the samples.  The filtered sample was collected and reduced to 30 µL 
by vacuum centrifugation.  Standard curves (0.02 – 2 nmol injected on column) were 
constructed and used to calculate the concentration of each amino acid in the samples. 
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Amino acid derivatization and analysis by HPLC 
Amino acid derivatization and analysis by HPLC was performed using the amino acid 
analysis method developed by Agilent Technologies, Inc.  The HPLC system consisted of 
an Agilent 1100 Series system with an Agilent 1260 Series column oven (Agilent 
Technologies, Palo Alto, CA, USA).  HPLC separation of analytes was performed on a 
ZORBAX Eclipse Plus C18 column (250mm×4.6mm, 5 µm particle size, Agilent 
Technologies) with gradient elution comprised of 10 mM Na2PO4 : 10 mM Na2B4O7 pH 8.2 
: 5 mM NaN3 (eluent A) and acetonitrile:methanol:water (45:45:10, v:v:v) (eluent B). The 
flow rate was 1.5 mL/min.  The column was maintained at a constant temperature of 40°C.  
The gradient is shown in Figure 18.   
 
Time (min) %B 
0  2 
0.84  2 
33.4  57 
33.5  100 
39.3  100 
39.4  2 
40  end 
 
 
Figure 18: Traditional high resolution method gradient, 5 µm 250mm×4.6mm. 
(Transcribed from Agilent Technologies Inc. Amino Acid Methods using Agilent ZORBAX 
Eclipse Plus C18 Columns Application Note) 
 
Ortho phthalaldehyde (OPA) derivatization of primary amino acids was automated and 
programmed into the HPLC method.  It took place immediately prior to sample injection 
(Figure 19).  The diode array detector (DAD) signal was set to 338 nm, 10 nm bandwidth.  
This method was capable of detecting 20 of the 23 amino acids.  Detection of proline, 
hydroxyproline and sarcosine required fluorenylmethoxy chloroformate (FMOC) 
derivatization and therefore not analysed.   
An internal standard was required to correct for any loss of analyte during sample 
processing/preparation or variation during the auto-sampler derivatization.  Norvaline, an 
isomer of the amino acid, valine, was used as the internal standard.  
0
20
40
60
80
100
0 10 20 30 40
%
 E
lu
e
n
t
Time (min)
Gradient 
%A
%B
77 
Individual preparations of 1 mM amino acids were prepared and analysed to determine the 
specific retention times of each amino acid.  The order of eluted amino acids matched data 
provided in Agilent Technologies’ method (Figure 20).     
 
1. Draw 2.5 µL from borate vial (0.4 M Boric acid, pH 10.2). 
2. Draw 1.0 µL from sample vial. 
3. Mix 3.5 µL in air default speed 5 times. 
4. Wait 0.2 min. 
5. Draw 0.5 µL from OPA vial (Agilent p/n 5061-3335). 
6. Mix 4.0 µL in air, 10 times default speed. 
7. Draw 32 µL from injection diluent vial 
8. Mix 20 µL in air default speed 8 times. 
9. Inject. 
10. Wait 0.1 min. 
11. Valve bypass. 
Figure 19: Automatic liquid sampler (ALS), with injection program  
(Transcribed from Agilent Technologies Inc. Amino Acid Methods using Agilent ZORBAX 
Eclipse Plus C18 Columns Application Note) 
 
 
Figure 20: Chromatogram of amino acid standards show the order of elution using 
4.6 x 250 mm, Agilent ZORBAX Eclipse Plus C18, 5 µm columns. (Taken from Agilent 
Technologies Inc. Amino Acid Methods using Agilent ZORBAX Eclipse Plus C18 Columns 
Application Note). 
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Results 
The HT-29 human colon cancer cell lines stably expressing shRNA targeting NAT1 mRNA 
(NAT1 KD) or scrambled shRNA (control) were previously generated [115].  NAT1 activity 
was determined pre and post metabolomic analysis to ensure that NAT1 knock-down was 
maintained throughout the investigation (Figure 21).  NAT1 remained ≥ 80% knocked 
down throughout this study. 
 
A
 
B
 
Figure 21: NAT1 activity in HT-29 control and NAT1 KD cells.  Cell lysates were 
prepared and NAT1 activity was determined using saturating concentrations of pABA as 
substrate (440 µM) and acetyl Co-A (1.1 mM) as cofactor. (A) NAT1 activity of the HT-29 
cell lines measured at the beginning of the study.  (B) NAT1 activity of the HT-29 cell lines 
measured after the study was complete.  Mean ± SEM; n=3. Student’s t-test * = p<0.05. 
 
Effect of NAT knock-down on 5-mTHF, pABG and N-acetyl pABG 
HT-29 cells were grown in complete medium for 72 hours, cell lysates and the medium 
were processed by methanol/chloroform extraction and LC-MS/MS was used to analyse 
the intracellular levels of pABG, N-acetyl pABG and 5-mTHF in both cell lines as well as 
the levels in the medium (Figure 22).  When NAT1 was knocked down, there was no 
difference in intracellular pABG. The levels of N-acetyl pABG neared the limit of detection 
with high variability in the HT-29 control samples.  It was below detection for the NAT1 KD.  
There was no significant difference in 5-mTHF between the two HT-29 cell lines.   
 
Concurrently, in the absence of cells, complete medium was also incubated for 72 hours.  
pABG and N-acetyl pABG were detected in complete medium at 51 pmol/mL and 21 
pmol/mL respectively.  It was apparent that both the HT-29 control and NAT1 KD had 
significantly more pABG and N-acetyl pABG in the medium compared to the medium only 
and the concentrations of both compounds was much greater in the medium than 
  
79 
intracellularly.  HT-29 control and NAT1 KD contributed an additional 30 pmol/mL pABG 
and 20 pmol/mL N-acetyl pABG (approximately) to the medium, with no difference 
observed between the cell lines.  The results indicate that the HT-29 NAT1 KD and control 
cells excreted both N-acetyl pABG and pABG.  5-mTHF was not detected in the medium 
samples.  This folate may not be excreted into the medium under these experimental 
conditions or it is possible that it was undetected due to binding with albumin or folate 
binding proteins present in the FBS and lost during the sample processing. 
 
A
 
B
  
Figure 22: Metabolomic analysis of 5-mTHF, pABG and N-acetyl pABG in HT-29 
control and NAT1 KD samples.  2 x 106 cells seeded on 10 cm plates were incubated in 
10 mL complete medium for 72 hrs. In parallel, 10 mL complete medium was incubated in 
10 cm plates.  (A) Endogenous pABG, N-acetyl pABG and 5-mTHF measured in HT-29 
control and NAT1 KD cell lysates.  (B)  pABG and N-acetyl pABG measured in medium 
from HT-29 control and NAT1 KD cell culture and complete medium. Mean ± SEM; n=5. 
One-way ANOVA (Tukey’s multiple comparisons test) * = p<0.05 comparison with medium 
only. 
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Effect of NAT1 knock-down on the intracellular SAM cycle  
Metabolomic analysis of the SAM cycle compounds in HT-29 control and NAT1 KD cell 
lysates was performed concurrently with the analysis of 5-mTHF and the folate catabolites.  
No difference in SAM, Hcy or methionine was determined between control and NAT1 KD 
cell lysates (Figure 23), although, t-test analysis of methionine neared significance 
(p=0.0513).  The intracellular concentration of SAM in HT-29 measured in this study was 
similar to that reported for the human liver cancer cell line, HuH7 [144].  The intracellular 
SAH concentrations were not determined as they were below limit of detection.   
 
Figure 23: Metabolomic analysis of the SAM cycle compounds in HT-29 control and 
NAT1 KD samples.  2 x 106 cells seeded on 10 cm plates in 10 mL complete medium for 
72 hrs.  Endogenous SAM, homocysteine and methionine measured in HT-29 control and 
NAT1 KD cell lysates.  Mean ± SEM; n=5.  
 
Effect of NAT1 knock-down on the SAM cycle - Metabolomic analysis of HT-29 
control and NAT1 KD cell culture medium over time 
As an essential amino acid, methionine is not produced de novo.  It is required by cells 
from an external source, which for cultured cells is the medium.  To maintain SAM cycle 
homeostasis, Hcy and/or SAH may be excreted by the cell.  The previous result (Figure 
22) indicated that NAT1 did not have any effect on the SAM cycle.  However, analysis of 
the SAM cycle compounds in the cell culture medium was performed to determine if NAT1 
had any effect on excretion or uptake of SAM cycle compounds.   
HT-29 control and NAT1 KD cells were grown in complete medium and a sample of the 
medium was collected daily for processing and analysis by LC-MS/MS over 5 days.  In 
parallel, complete medium was incubated in 10 cm plates for the time course confirming 
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that changes in compound concentrations in the sampled medium arose from the cells and 
was not a result of degradation in the medium. SAM, SAH, Hcy and methionine were 
measured.  SAH and SAM were below the level of quantitation while methionine and Hcy 
were measured throughout the time course (Figure 24).  Overall, there was no difference 
in the change in medium methionine between HT-29 control and NAT1 KD samples (Two-
way ANOVA).  The concentration of methionine decreased in the medium with time and 
was essentially depleted on day 3.  Conversely, the change in medium Hcy measured was 
significantly different between cell lines.  Hcy increased in the medium over the first 3 days 
with no difference between control and NAT1 KD.  The concentration of Hcy continued to 
increase in HT-29 control medium, while it decreased in medium from the NAT1 KD cells 
from day 3.  These results indicated that HT-29 cell take up all methionine from RPMI1640 
medium by 3 days under these culturing conditions.  HT-29 cells release Hcy throughout 
the experiment while HT-29 NAT1 KD cells release Hcy over the first 3 days and then take 
up Hcy from the medium.  Interestingly, the point at which methionine was depleted 
coincided with the shift from release to uptake of Hcy when NAT1 is deficient.  
Taken together, SAM homeostasis for HT-29 is maintained when NAT1 is knocked down, 
as indicated by the unchanged concentration of intracellular SAM for both the NAT1 KD 
and control cell lines.  However, differences observed in medium from the NAT1 KD and 
control cell culture suggest that the means of maintaining SAM cycle homeostasis differ in 
HT-29 control and NAT1 KD cells.   
 
Figure 24: Metabolomic analysis of SAM cycle compounds in medium from HT-29 
NAT1 KD and control cells cultured over time.  2 x 106 cells were seeded on 10 cm 
plates in 10 mL complete medium.  Medium was sampled daily for analysis. Methionine 
and homocysteine levels for control () and NAT1 KD (). Means ±SEM; n=3. Two-way 
ANOVA * = p<0.05 
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Because SAM can be decarboxylated and become a substrate for polyamine synthesis, 
putrescine and N-acetyl spermidine, the major polyamines exported from the cells [150], 
were also measured during the analysis of HT-29 control and NAT1 KD cell culture 
medium.  Figure 25 provides a schematic summary of the polyamine synthesis pathway. 
 
 
Figure 25: The Polyamine Synthesis Pathway. 
SAM is decarboxylated and donates the aminopropyl group to spermidine and spermine 
synthases.  Ornithine is decarboxylated to form putrescine which becomes the substrate 
for spermidine synthase.  Spermidine is formed by the transfer of the aminopropyl group to 
putrescine, and spermine is formed by the transfer of an additional aminopropyl group to 
spermidine.  SSAT catalyzes the N1-acetylation of spermine and spermidine using acetyl-
CoA as the cofactor.  APAO catalyzes the FAD-dependent conversion of N-acetyl 
spermine to spermidine and N-acetyl spermidine to putrescine.  N-acetyl spermidine and 
putrescine may be exported from the cell to regulate intracellular polyamine 
concentrations.   
SAMDC, S-adenosylmethionine decarboxylase; ODC, ornithine decarboxylase; APAO, 
acetylpolyamine oxidase; SSAT, Spermidine/Spermine N1-acetyltransferase; SMO, 
spermine oxidase.   
Adapted from references [150, 151] 
 
The concentrations of the polyamines present in the medium are shown in Figure 26.  
Putrescine increased and plateaued from day 2 with no significant difference between 
control and NAT1 KD (two-way ANOVA).  The concentration of N-acetyl spermidine in the 
medium samples increased with time. There was a slight but significant elevation in N-
acetyl spermidine levels in the medium from HT-29 control compared to NAT1 KD cells 
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from day 4.   Furthermore, the concentration of N-acetyl spermidine was approximately 10 
fold higher than putescine by day 4.  These results indicate that putrescine and N-acetyl 
spermidine are released from HT-29 cells and that less putrescine is excreted compared to 
N-acetyl spermidine. This is in agreement with results previously reported for HT-29.  Pegg 
et al. reported that HT-29 contained little APAO resulting in elevated N-acetyl spermidine 
release compared to putrescine  [152, 153].   
 
Figure 26: Metabolomic analysis of polyamines in medium from HT-29 NAT1 KD and 
control cells cultured over time.  2 x 106 cells were seeded on 10 cm plates in 10 mL 
complete medium.  Medium was sampled daily for analysis.  Polyamine levels for control 
() and NAT1 KD (). Means ±SEM; n=3. Two-way ANOVA * = p<0.05 
 
Following the time course experiment, the cells were trypsinised and cell lysates were 
prepared.  The total amount of protein was determined for each plate of cells (Figure 27).  
There was an apparent decrease in total protein from NAT1 KD cells grown in 10 cm 
plates at the end of the time course, compared to the controls, although this did not reach 
significance (Student’s t-test p=0.0519).   
 
Figure 27: Total protein in cell lysates from HT-29 control and NAT1 KD cells 
cultured for 6 days.  Means ±SEM; n=3.   
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Quantitation of amino acids - Metabolomic analysis of HT-29 control and NAT1 KD 
cell culture medium over time 
Both essential and non-essential amino acids are necessary for protein synthesis, or to be 
metabolised to provide amino groups and carbon skeletons for biosynthetic pathways.  
Medium provides the nutrients necessary for growth in cell culture.  By measuring changes 
in amino acid levels in medium, amino acid flux can provide an insight into biochemical 
processes occurring within the cells.   
HT-29 control and NAT1 KD cells were grown in complete medium and a sample of the 
medium was collected daily for processing and analysis by HPLC.  In parallel, complete 
medium was incubated in 10 cm plates for the time course confirming that changes in 
amino acids in the sampled medium was derived from the cells, not a result of degradation 
in the medium.  Amino acid concentrations are reported (Figure 28) and time 0 reflected 
the ‘complete medium only’ time course measurements.  Furthermore, these were in line 
with the concentrations published for the formulation for RPMI1640 (Invitrogen).   All amino 
acids measured in medium from HT-29 cell culture decreased with time, with the exception 
of alanine and glutamic acid.  Valine, methionine, phenylalanine, serine, threonine, 
cysteine and glutamine were effectively depleted from the medium by day 3.  This result 
for methionine is consistent with that previously observed during the SAM cycle analysis 
(Figure 24).  Near depletion of glycine, leucine and isoleucine was observed at the end of 
the time course (day 4).   Lysine, arginine and histidine appear to plateau suggesting 
cellular requirements for these essential amino acids was minimal by the end of the time 
course.  Glutamine was the most concentrated amino acid in the medium (as indicated by 
Time 0) nearing an order of magnitude higher than that the next most concentrated amino 
acids (isoleucine/leucine).  As it was depleted, this suggests that glutamine was 
extensively used by the HT-29 cells.    
There were few differences in amino acid flux between HT-29 control and NAT1 KD with 
the exception of glutamate and alanine, both of which increased in the medium with time.  
There was only a slight, albeit significant, difference in the elevation of glutamate between 
the cell lines.  HT-29 NAT1 KD cells released marginally more glutamate compared to 
control (two-way ANOVA p<0.05).  More obvious was the difference in alanine.  From day 
2, the NAT1 KD medium had significantly higher concentrations of alanine compared to 
the control (two-way ANOVA p<0.05) suggesting that NAT1 suppressed alanine 
production and/or export. 
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Figure 28: Metabolomic analysis of amino acids in medium from HT-29 NAT1 KD 
and control cells cultured over time.  2 x 106 cells were seeded on 10 cm plates in 10 
mL complete medium.  Medium was sampled daily for analysis.  Amino acid levels for 
control () and NAT1 KD (). Means ±SEM; n=3. Two-way ANOVA * = p<0.05 
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Discussion 
Following on from the study of Nat2 deficiency in the C57BL/6J Nat2 -/- mouse model, 
NAT1 knock-down in the human colon carcinoma cell line, HT-29, was investigated.  
Evidence has been reported previously to suggest that epigenetic regulation is involved in 
the phenotypic changes observed when NAT1 is reduced in HT-29 .  The SAM cycle is 
important in methylation reactions including DNA methylation, a form of epigenetic 
regulation.  Therefore, in the present study, the SAM cycle, 5-mTHF (the methyl donor to 
the SAM cycle) and the catabolites, pABG and N-acetyl pABG were examined, both 
intracellularly and in culture medium.  Furthermore, SAM can be decarboxylated and enter 
the polyamine synthesis pathway.  Therefore, the exported polyamines, putrescine and N-
acetyl spermidine, were analysed in parallel with the SAM cycle compounds in the medium 
from cultured HT-29 control and NAT1 KD cells. 
As was the case for Nat2 knock-out in mice, NAT1 knock-down did not alter 5-mTHF or 
pABG levels in the HT-29 cells.  The intracellular concentration of pABG in the control cells 
was markedly higher than the acetylated NAT1 product, N-acetyl pABG suggesting that 
NAT1 is not efficiently metabolising pABG.  Surprisingly, pABG was released into the 
medium by control cells indicating that acetylation by NAT1 is not required for the 
excretion of this folate catabolite.   N-acetyl pABG was released into medium by NAT1 KD 
indicating that either residual NAT1 present in the cell line (13-20% of control) was 
sufficient to acetylate pABG or another enzyme is capable of acetylating pABG.  These 
results provide further evidence to suggest that NAT1 is not essential for the regulation of 
intracellular 5-mTHF or pABG. 
NAT1 knock-down in HT-29 did not alter the SAM cycle.  SAM homeostasis is regulated by 
the flux of Hcy, SAH and methionine, which can provide an insight into the mechanisms by 
which homeostasis is maintained.   For instance, the removal of Hcy from the SAM cycle 
ensures that SAH, the by-product of methylation reactions, is hydrolysed.  This reduces 
the detrimental effects that SAH can cause as a result of competitively inhibiting 
methyltransferases.  Conversely, Hcy can be converted to methionine, or methionine may 
be taken up, to support the production of SAM.  Therefore, investigation of the medium 
was undertaken to determine if changes in SAM cycle compounds occurred extracellularly.  
Methionine was taken up by both control and NAT1 KD cell lines at the same rate and was 
depleted from the medium by day 3 of culturing.  Meanwhile, Hcy was released into the 
medium until day 3 by both cell lines and at the point in which the source of methionine 
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was depleted, the HT-29 control cells continued to release Hcy while the NAT1 KD take up 
Hcy.  Therefore, the results suggest that when NAT1 is deficient, HT-29 cells uptake Hcy 
to produce methionine and maintain SAM homeostasis and growth.  Conversely, HT-29 
cells containing NAT1 did not require Hcy to supplement cellular methionine even though 
growth was similar to the NAT1 KD cells.  Methionine is an essential amino acid required 
for cell survival.  Thus, this provides an interesting question; how could the HT-29 control 
cells maintain cellular methionine if they are no longer obtaining it from an external source, 
nor are they converting Hcy into the amino acid?  Methionine may be salvaged from 
methylthioadenosine (MTA), a by-product of polyamine synthesis, via the methionine 
salvage pathway.  Consequently, the results presented in this study suggest that NAT1 
may be involved in the methionine salvage pathway.   
NAT1 deletion had a slight effect on the release of polyamine, N-acetyl spermidine, from 
HT-29 cells.  However, it was not determined if this was a reflection on intracellular 
polyamine levels, a result of altering SSAT (the enzyme responsible for acetylating 
spermidine), altering the mode of N-acetyl spermidine export, or some other factor.  If 
NAT1 promotes the methionine salvage pathway, MTA would be metabolised to produce 
intracellular methionine. It is possible that, when NAT1 is absent, MTA levels become 
elevated.  This could be important as MTA is an inhibitor of enzymes involved in polyamine 
synthesis; spermine synthase and to a lesser extent, spermidine synthase and ornithine 
decarboxylase [154].  Therefore, the altered levels of N-acetyl spermidine observed in the 
medium may be a reflection of MTA inhibition of polyamine synthesis when NAT1 was 
knocked down.  Further studies are required to confirm this proposal. 
Amino acid analysis of the medium suggests that a change in alanine metabolism 
occurred when NAT1 was deficient.  Alanine aminotransferase transfers the α-amino 
group from glutamate to pyruvate, producing alanine.  Conversely, alanine may be 
transaminated to produce pyruvate. Two molecules of pyruvate are generated from the 
breakdown of one glucose molecule during glycolysis and pyruvate provides the carbon 
backbone for the biosynthesis of glucose (gluconeogenesis).  Additionally, oxidative 
decarboxylation of pyruvate produces acetyl-CoA for the citric acid cycle.  Hence, alanine 
has close links to major cellular processes; glycolysis, gluconeogenesis and the citric acid 
cycle [155].  Elevated alanine in medium from NAT1 KD cells was observed in this study.  
Therefore, it is possible that NAT1 alters alanine export or supports cellular alanine 
sequestration.  NAT1 may be involved in regulating the conversion of alanine to pyruvate 
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(and vice versa), or alternatively, it might support the conversion of pyruvate to lactate or 
acetyl-CoA instead of alanine, resulting in a reduction in intracellular alanine for export into 
the medium.  However, further studies are required to identify the molecular mechanism 
that leads to the increased excretion of alanine when NAT1 is limited.    
Overall, metabolomic analysis of medium derived from HT-29 cells has provided the 
means to identify target biochemical processes in which NAT1 appears to be involved, 
namely, the methionine salvage pathway and alanine metabolism via glycolysis, 
gluconeogenesis or the citric acid cycle.  The role of NAT1 in the methionine salvage 
pathway requires investigation as different enzymes of this pathway have moonlighting 
roles in cancer biology as either tumour suppressors or oncogenes [156, 157].  Further to 
this, tumour cells have increased glycolytic activity, with increased glucose uptake and 
lactate production, even when high concentrations of oxygen are present (Warburg Effect) 
and altered citric acid cycle provides precursors for lipid, protein and nucleic acid synthesis 
essential for proliferating cells [158, 159].  Therefore, it is important to determine if NAT1 
plays a role in these pathways to better understand the implications this enzyme is likely to 
have on cancer biology. 
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CHAPTER 4: EFFECT OF NAT1 ON THE METHIONINE 
SALVAGE PATHWAY - NAT1 MAY COMPENSATE FOR 
METHYLTHIORIBOSE ISOMERASE 1 
Introduction 
Methionine is an essential amino acid.  It is necessary for protein synthesis and is involved 
in the SAM cycle.  It is essential for the formation of SAM for transmethylation reactions 
and regeneration of tetrahydrofolate.  Methionine is also important for cystathione, 
cysteine and glutathionine formation through the trans-sulfuration pathway as well as 
choline metabolism via homocysteine remethylation, which branch off the SAM cycle.  It is 
obtained from the diet but may also be acquired intracellularly via the methionine salvage 
pathway, which recycles the by-product of polyamine synthesis, methylthioadenosine 
(MTA).     
The methionine salvage pathway is present in all types of organisms with some variations 
in reactions/enzymes involved.  In eukaryotes, six enzymatically catalysed reactions are 
required to convert MTA to methionine (Figure 29) [160]. 
1. Methylthioadenosine phosphorylase (MTAP) catalyses the phosphorolytic cleavage of 
MTA using inorganic phosphate to produce adenine and methylthioribose 1-phosphate 
(MTR-1P) .  Adenine is important for cellular purine synthesis, cellular respiration and 
protein synthesis. 
2. Methylthioribose 1-phosphate isomerase (MRI1) converts the ribose moiety to a 
ribulose moiety producing methylthioribulose 1-phosphate (MTRu-1P) . 
3. MTRu-1P dehydratase (or Apaf-1 interacting protein (APIP) [161]) produces dioxo-
methylthiopentane 1-phosphate (DMTP-1P) releasing a water molecule. 
4. ENOPH 1 (enolase/phosphatase) releases the phosphate group and produces an aci-
reductone compound, dihydroxy-oxomethiopentene. 
5. Aci-reductone dioxygenase 1 (ADI1) requires O2 to produce methylthio-oxobutanoic 
acid (MTOB) and formate. 
6. A transaminase reaction (multiple enzymes capable of performing this step) transfers 
the amine moiety from glutamine (or asparagine) to MTOB producing methionine. 
Interestingly, most methionine salvage enzymes have also been identified as moonlighting 
proteins implicated in other major cellular processes.  MTAP is a tumour suppressor gene 
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involved in regulating intracellular polyamine levels [156] as well as inhibiting cellular 
processing that leads to cellular migration and adhesion [162].  MRI1, also known as MRDI 
(Mediator of RhoA Dependent Invasion) is involved in cell motility and invasion in response 
to constitutive RhoA activation [157].  APIP inhibits caspase-9 activation and Apaf-1-
mediated apoptosis [163] as well as caspase-1 mediated proinflammatory cell death 
(pyroptosis) [164].  Finally, ADI1 regulates MT1-MMP-dependent cell migration and 
invasion by binding to the cytoplasmic tail of membrane type 1 – matrix metalloproteinase 
[165].  In addition, it modulates mRNA splicing [166].  
The potential for NAT1 to have a role in the methionine salvage pathway was identified by 
metabolomics in the previous chapter.  Therefore, the aim of this chapter was to determine 
whether NAT1 altered the function of the methionine salvage pathway and if so, identify 
what step of the pathway was affected.      
 
Figure 29: The Methionine Salvage Pathway in Eukaryotes.  Methionine (Met) may be 
obtained from external sources or recycled within the cell via the methionine salvage 
pathway.  S-adenosylmethionine (SAM) may be decarboxylated to form a substrate 
(dcSAM) for polyamine synthesis.  The byproduct of polyamine synthesis, 
methylthioadenosine (MTA) is the substrate for the 6 reaction pathway that is the 
methionine salvage pathway.  The human enzymes responsible for these reactions have 
been identified: 1. Methylthioadenosine phosphorylase (MTAP) 2. Methylthioribose 1-
Phosphate isomerase (MRI1) 3. Apaf-1 interacting protein (APIP) (or MTRu-1P 
dehydratase) 4. ENOPH 1 (enolase/phosphatase) 5. Aci-reductone dioxygenase 1 (ADI1) 
6. transaminase reaction (multiple enzymes capable of performing this step). 
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Methods 
Parent cell lines and culture conditions 
The human cancer cell lines used in this chapter are listed below. Routinely, cell lines 
were cultured in RPMI 1640 supplemented with 5% fetal bovine serum (FBS), 100 U/mL 
penicillin and 100 µg/mL streptomycin, unless stated otherwise.  Cell line specific medium 
variations are listed in the table below. Cells were maintained at 37°C in a humidified 
atmosphere of 5% CO2 in air.   
Cell Line Disease ATCC Code Medium variations 
HT-29 Colon adenocarcinoma HTB-38  
SW620 Colorectal adenocarcinoma CCL-227  
CaCo-2 Colon adenocarcinoma HTB-37  
PANC-1 Pancreas epithelioid carcinoma CRL-1469 DMEM not RPMI 1640 
HepG2 Hepatocellular carcinoma HB-8065  
T-24 Bladder carcinoma HTB-4  
MDA-MB-231 Breast adenocarcinoma HTB-26  
MBA-MB-436 Breast adenocarcinoma HTB-130  
BT-549 Breast ductal carcinoma HTB-122 10% FBS + 0.23 IU/100 mL insulin 
T-47D Breast ductal carcinoma HTB-133 + 0.20 IU/100 mL insulin 
MCF-7 Breast adenocarcinoma HTB-22  
SK-OV-3 Ovary adenocarcinoma HTB-77  
HeLa Cervix adenocarcinoma CCL-2  
PC-3 Prostate adenocarcinoma CRL-1435 DMEM not RPMI 1640 
22Rv1 Prostate carcinoma CRL-2505  
SK-N-MC Neuroepithelioma HTB-10 Advanced MEM, 10% FBS 
IMR32 Neuroblastoma CCL-127 10% fetal bovine serum 
SH-SY-5Y Neuroblastoma CRL-2266 Advanced DMEM/F12, 10% FBS 
 
Stable NAT1 knockdown cell lines and culture conditions 
HT-29 cell lines stably expressing shRNA targeting NAT1 mRNA (NAT1 KD) or scrambled 
shRNA (control) previously generated [115] were cultured in RPMI 1640 supplemented 
with 5% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 0.3 mg/mL G418 to 
preserve selection.  NAT1 stably knocked down by the shRNA lentivirus system in the 
human breast cancer cell lines, MDA-MB-231, MDA-MB-436 and BT549, were previously 
generated by Tiang et al. [114] and cultured as described above. 
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Ectopic expression of genes of interest 
Cells were seeded in a 6 well plate at a density of 1x106 cells per well or in a 12 well plate 
at a density of 4x105 cells per well.  When cell density reached 80-90% confluence, 4 µg or 
2 µg plasmid DNA (6 or 12 well plate, respectively), was transfected into the cells using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruction. 
Transient gene knockdown with siRNA 
Cells were seeded in a 6 well plate at a density of 2-2.5x105 cells per well.  When cell 
density reached 40-60% confluence, 20 nM siRNA (Origene) was transfected into the cells 
using Lipofectamine RNAiMax (Invitrogen) in accordance with the manufacturer’s 
instructions.   
NAT1 siRNA (SR300003C) – CCAUAGGAGAUUCAAUUAUAAGGAC 
MRI1 siRNA (SR313419A) – GCAAGGAGAUCAUUAUUGAAGAGCG  
Generation of HT-29 NAT1 Knock-In cell lines 
To generate HT-29 NAT1 KD/control + NAT1 cells, HT-29 NAT1 KD (shRNA #3.2) and 
control (#4) cell lines were seeded in 24 well plates at a density to 2x105 cells per well in 
triplicate.  When cell density reached 80-90% confluence, 0.5 µg linearized pcDNA3.1-EV 
or pcDNA3.1-NAT1 plasmid DNA was co-transfected with 0.1 µg pTK-Hyg plasmid DNA 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruction.  Stable 
cell lines were selected with 1 mg/mL hygromycin.  Each well was trypsinised and colonies 
were combined.  These cell lines were not clonal.  NAT1 activity was determined for each 
cell line to confirm successful NAT1 knock-in.  Stable cell lines were cultured in RPMI 
1640 supplemented with 5% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 
mg/mL G418 plus 0.3 mg/mL hygromycin to maintain selection.   
RNA extraction and reverse transcription  
Cell lines were seeded in a 6 well plate at a density of 1x106 cells per well overnight.  Cells 
were washed with PBS and RNA extraction was performed using RNeasy Mini Kit 
(Qiagen) as per the manufacturer’s instructions. RNA was resuspended in ultrapure 
RNAse-free water.  SuperScript II® Reverse Transcriptase (Invitrogen) was used to 
synthesise complementary DNA using Oligo(dT) 15 primer (Promega) as outlined by the 
manufacturer’s instructions. 
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Oligonucleotide primers  
MTAP 
Forward  5’ – GATCGAATTCcATGGCCTCTGGCAC – 3’  EcoRI 
Reverse  5’ – GATCGGATCCTTAATGTCTTGG – 3’  BamHI 
APIP 
Forward  5’ – GATCAAGCTTATGTCTGGCTGTG – 3’  HindIII 
Reverse  5’ – GATCGGATCCTTAGACAATTCC – 3’  BamHI 
ENOPH1 
Forward  5’ – GATCAAGCTTATGGTCGTGCTTTCG – 3’ HindIII 
Reverse  5’ – GATCGGATCCCTAGGTTGAGGAAG – 3’ BamHI  
Primers were designed for the insertion of MTAP, APIP and ENOPH1 coding sequence 
into p3XFLAG-CMV-7.1.  The forward and reverse primers each included a different 
restriction recognition sequence (underlined) that was compatible with the receiving 
plasmid while not present in the coding sequence of the gene.  Where necessary, an 
additional base was included following the recognition sequence to ensure that the coding 
sequence was in frame (lowercase). 
MRI1  
Forward  5’ – GGACCCCTAGCTCCCTCTGAGTTGCGCTGG – 3’  
Reverse  5’ – GGAAGGCCCTGTCTGAGCTCCCTGCACTAGG – 3’ 
Primers were designed for the sequencing of MRI1 from mRNA in mammalian cell lines. 
Forward and reverse PCR primers were designed to encapsulate the coding region of 
MRI1 (GenBank® Accession: NM_001031727.2).    The forward primer was selected from 
the sequence upstream of the start codon, and the reverse primer downstream of the stop 
codon. 
Oligonucleotides were purchased from GeneWorks Pty Ltd, Adelaide, SA, Australia. 
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Generation of Flag-protein constructs 
Untagged cDNA clones containing the complete coding sequence for MTAP, APIP, or 
ENOPH1 cloned in pCMV-XL5 were purchased from Origene.  Plasmid DNA supplied in 
lyophilised form was reconstituted with UltraPure H2O as per the manufacturer’ 
instructions.   
MRI1 cDNA cloned into pCMV-HA plasmid for expression in mammalian cells was kindly 
supplied by Professor Natalie Ahn, Department of Chemistry and Biochemistry, University 
of Colorado Boulder, on paper.  UltraPure H2O was used to resuspend plasmid DNA.   
The coding sequence for each gene was released from the expression vector and inserted 
into p3XFLAG-CMV-7.1 at complimentary restriction sites as described below.   
Flag-MRI1 construct cloned in p3XFLAG-CMV-7.1 was generated by Dr Neville Butcher, 
Molecular & Cellular Pharmacology Laboratory, School of Biomedical Sciences, University 
of Queensland.  UltraPure H2O was used to resuspend plasmid DNA. 
Transformation of DH5α™ E. coli cells 
Amplification of the plasmid DNA was performed by transforming DH5α™ E. coli cells by 
exponential decay electroporation.  Specifically, 1 µL plasmid DNA was added to 50 µL 
freshly thawed DH5α cells and incubated on ice for 5 minutes.  The cells were subjected to 
electroporation (GenePulsar XCell™ (Bio-Rad) at 200 Ohms, 25 uF, 1.8 kV, exponential 
decay) in a 1 mm cuvette and 600 µL SOC medium was added to the cells immediately 
afterwards.  The cells were then left to recover at 37°C for 45 minutes.  DH5α cells were 
grown on Luria-Bertani (LB) plates under antibiotic selection overnight at 37°C.  Resistant 
colonies were chosen and expanded overnight at 37°C in LB medium while maintaining 
antibiotic selection.  The plasmids from the resistant DH5α colonies were harvested with 
PureLink™ HiPure Plasmid DNA Purification Kits (Invitrogen) according to the manufacturer’s 
instructions.  Additionally, glycerol stocks of DH5α containing the plasmid were prepared and 
stored at -80°C. 
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PCR amplification of MTAP, APIP and ENOPH1 coding sequences 
Polymerase chain reaction was used to amplify the full length coding sequence of MTAP, 
APIP and ENOPH1 from the pCMV-XL5 plasmid.  Reactions (50 µL) were performed using 
2 units VentR® DNA polymerase (New England Biolabs Inc., Ipswich, MA, USA) in 
ThermoPol® Reaction Buffer (final concentrations: 20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 
mM KCl, 2 mM MgSO4, 0.1% Triton® X-100,  pH 8.8 at 25°C). PCR reactions contained 
0.2 mM dNTPs, 0.25 µM forward and reverse primers and approximately 200 ng template 
DNA (pCMV-XL5-MTAP, APIP or ENOPH1).   
PCR reactions were initiated with a 5 minute 95°C hot start followed by a three step cycle: 
step 1 was denaturation of DNA at 95°C for 15 seconds, step 2 was annealing of primers 
at 47°C for 15 seconds, and step 3 was elongation of DNA at 72°C for 90 seconds.  
Cycling was repeated for a total of 36 cycles before holding at 4°C.  Thermocycling was 
carried out using a Perkin Elmer Cetus DNA Thermal Cycler.   
Restriction Digests 
Double restriction digestions were carried out on p3XFLAG-CMV-7.1 and MTAP, APIP and 
ENOPH1 PCR products.  High Fidelity (HF®) restriction endonucleases, EcoRI, BamHI 
and HindIII, were purchased from New England Biolabs.  Double digestions were carried 
out with 5 µg plasmid DNA or the entire purified PCR product (approximately 0.5-1 µg 
DNA), in a final volume of 30 µL with CutSmart™ Buffer (final concentrations: 20 mM Tris-
acetate, 10 mM Magnesium acetate, 50 mM Potassium acetate, 100 µg/ml BSA, pH 7.9 at 
25°C).   
Single restriction digestions were carried out on pcDNA3.1-NAT1 and pcDNA3.1 plasmids.  
The restriction endonuclease, Sca1 was also purchased from New England Biolabs.  
Digests were carried out with 5 µg plasmid DNA, in a final volume of 30 µL with NEB 
Buffer #3 (final concentrations: 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2 , 1 mM DTT, 
pH 7.9 at 25°C).   
Digests were incubated at 37°C for 1 hour with enzyme heat inactivation at 80°C for 20 
minutes to stop the reaction.  Digests were electrophoresed to confirm linearization of the 
plasmid.  
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Ligation Reactions 
The digested PCR-amplified inserts were ligated into the respective p3XFLAG-CMV-7.1 
fragments using T4 DNA ligase (New England Biolabs Inc.) under the conditions specified 
by the manufacturer.  The plasmid and insert DNA was combined in a 1:1 molar ratio 
(plasmid:insert DNA), specifically, 100 ng plasmid DNA (~5 kb) to 20 ng insert DNA (~1 
kb).  The 10 µL ligation reaction was carried out in T4 DNA Ligase Reaction Buffer (final 
concentrations: 50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 10mM DTT, pH 7.5 at 25°C), 
incubated at 4°C overnight followed by enzyme heat inactivation at 70°C for 10 minutes.  
Two negative control reactions were carried out concurrently in the same ligation 
experiment, the “no insert control” and the “uncut control”.  The “no insert control” 
contained the plasmid DNA and T4 DNA ligase to show auto ligation of the plasmid ends.  
The “no insert control” contained the plasmid DNA only to show plasmid DNA that was 
unsuccessfully digested by the restriction enzymes and therefore remained circular.   All 
ligation reactions were transformed into DH5α™ E. coli. 
Agarose Gel Electrophoresis 
Agarose (1%) was dissolved in TAE buffer (400 mM Tris, 200 mM sodium acetate, 10 mM 
EDTA, pH 7.2). HydraGreen™ Safe DNA Dye, 20 000x (ACTGene Inc., Piscataway, NJ, 
USA) was diluted in the agarose solution once it had cooled to approximately 50°C for a 
final 1x concentration and gels were cast. HydraGreen™ Safe DNA Dye is present for 
detection of nucleic acids in agarose gels.  DNA samples in DNA loading buffer (final 
concentrations: 5% (v/v) glycerol, 0.05% (w/v) bromophenol blue, 40 mM Tris, 20 mM 
sodium acetate, 1 mM EDTA, pH 7.2) were electrophoresed for 1 hour at 100 volts.  The 1 
Kb Plus DNA Ladder (Invitrogen™, Life Technologies Australia Pty Ltd, Mulgrave, VIC, 
AUS) was run simultaneously on all agarose gels. 
DNA bands were visualised under UV light using Bio-Rad Gel Doc™ and Quality One 1D 
Analysis Software (Bio-Rad Labs Inc., Hercules, CA, USA). 
Gel extraction and Purification of DNA 
DNA bands were isolated according to their expected molecular weight and were excised 
from the agarose gels.  Excised bands, PCR products and digest products were purified 
using the NucleoSpin Extract II Kit (MACHEREY-NAGEL GmbH & Co. KG, Germany).  
Purification was performed as outlined by the manufacturer. The DNA concentration was 
then determined for each purified product by UV spectroscopy. 
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Determination of DNA purity and concentration 
DNA purity and concentration was analysed using the NanoDrop™ Spectrophotometer 
ND-1000 (and software V3.8.0) (ThermoFisher Scientific Inc. Wilmington, DE, USA).  The 
absorbance at 260 nm and 280 nm was measured, and the ratio of A260/A280 was 
determined.  The absorbance at 260 nm is used to calculate the DNA concentration 
(based on a 50 µg/mL solution of double stranded DNA having an absorbance of 1 at 
260nm).  The ratio of A260/A280 is used to determine DNA purity with a ratio between 1.8 
and 2.0 considered acceptable. 
Sequencing 
BigDyeTerminator (BDT) reactions are performed and samples cleaned according to the 
Australian Genome Research Facility protocol. Sequencing was performed by capillary 
separation by the Australian Genome Research Facility, Level 5 Gehrmann Laboratories, 
University of Queensland, Research Road, St Lucia QLD 4072.   
NAT1 activity assay 
Cells were washed with PBS, resuspended in ice cold reaction buffer (20 mM Tris, pH 7.4, 
1 mM EDTA, and 1 mM DTT) and lysed by sonication at 4°C (Branson sonifier B250; duty 
cycle 100%, output = 4; 2 x 5 sec bursts with 30 sec on ice between bursts). Cell lysates 
were then centrifuged at 16,000g, 4°C for 10 min.   Supernatant protein concentrations 
were determined using the Bradford method [149] and the supernatant assayed for NAT1 
activity by high performance liquid chromatography as previously described [77].   
Cell proliferation assay 
Cells were seeded in 96-well plates at a density of 10000 cells/well in a final volume of 150 
µL of methionine free RPMI 1640 supplemented with 5% FBS, 100 U/mL penicillin and 100 
µg/mL streptomycin, and 208 µM L-cystine only (with 0.3 mg/mL G418 or 0.23 IU/100 mL 
insulin if required for the cell line), or with the addition of 100 µM methionine, 
homocysteine, 5’-methylthioadenosine, or methylthio-2-oxobutanoate.  Cell proliferation 
was measured using the CellTiter96H AQueous  One Solution Cell Proliferation Assay kit 
(Promega, Madison, WI, USA) as per the manufacturer’s instructions, 4 hours after the 
cells were seeded (Time 0) and over the following 7-8 days.  The conversion of the 
tetrazolium salt, MTS, to formazan was measured at 490 nm with a micro-plate reader 
(BMG LabTech POLARstar Omega V1.02). 
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Western blot analysis 
Denatured protein samples were obtained by lysing cells directly into 1 x SDS-reducing 
buffer or firstly lysing in modified-RIPA buffer containing protease inhibitors then diluting 
with 5 x SDS-reducing buffer, followed by heating at 95°C for 5 minutes.  Typically, 10 µg 
protein samples were electrophoresed on 12% polyacrylamide gels (200 V, 50 minutes), 
transferred to nitrocellulose membranes (350 mA, 1 hour) and membrane blocked with 5% 
skim milk powder in PBS-T for 1 hour at room temperature before incubating with the 
primary antibody  overnight  at 4°C.  Membranes were washed with PBS-T and incubated 
with the secondary antibody-horseradish peroxidase conjugate for 1 hour at room 
temperature.  After further washing with PBS-T, protein levels were detected using the 
enhanced chemiluminescence HRP substrate, Western Lightning Plus ECL (PerkinElmer, 
Waltham, MA, USA).  
 Target Dilution Diluent Source Manufacturer 
Pr
im
a
ry
 
 
An
tib
o
di
e
s 
MTAP 1:1000 PBS-T Rabbit Cell Signaling Technology, Danvers, MA, USA 
MRI1 (Transcript 
Variant 1, GenBank® 
Accession: 
NM_001031727) 
1:1000 PBS-T Mouse OriGene Technologies Inc, Rockville, MD, USA 
Flag M2 Monoclonal 
Antibody – Peroxidase 
Conjugate 
1:5000 PBS-T 
Murine 
cell 
culture 
Sigma, St Louis MO, USA 
α-Tubulin (DM1A) 1:2000 PBS-T Mouse Cell Signaling Technology Inc, Danvers, MA, USA 
Se
co
n
da
ry
 
An
tib
o
di
e
s Anti-Rabbit IgG 1:30000 PBS-T (Goat) 
Jackson ImmunoResearch 
Laboratories Inc. West Grove, 
PA, USA 
Anti-Mouse IgG 1:30000 PBS-T (Goat) 
Jackson ImmunoResearch 
Laboratories Inc. West Grove, 
PA, USA 
 
Immunoprecipitation 
Hela cells were seeded in a 6 well plate at a density of 1x106 cells per well overnight.  
Plasmid DNA (pFLAG-MTAP, pFLAG-MRI1 or pFLAG-NAT1) at 4 µg, was transfected into 
the cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruction.  
After 48 hours incubation, cells were washed in ice-cold PBS, scraped into 0.8 mL lysis 
buffer (50 mM Tris HCl, 100 mM NaCl, 1 mM EDTA, pH 7.4, 1% Triton X-100, 0.5 mM 
PMSF, 2 µg/mL leupeptin, and 2 µg/ml pepstatin A) and lysed on ice for 20 min.  Lysates 
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were then centrifuged at 4°C for 10 min at 14,000g.  The supernatants were added to 75 
µL Anti-Flag M2 Affinity Beads (Sigma) and incubated at 4°C for 2 hours on a rotating 
wheel.  Flag-tagged proteins bound to the affinity beads were collected by centrifugation 
and washed three times in TBS (50 mM Tris HCl, 100 mM NaCl, 1 mM EDTA, pH 7.4).   
MTAP reaction 
Flag-MTAP beads were incubated with 50 nmol 5’-methylthioadenosine in 100 mM 
ammonium acetate / 100 mM phosphoric acid pH 7.4 (such that the reaction contained 9.5 
µmol inorganic phosphate) in a final volume of 100 µL.  The reactions were incubated on a 
rotating wheel at 37°C for 1-2 hours.  To stop the reaction, the beads were separated from 
the supernatant by centrifugation.  MTA consumption and adenine production were 
measured by HPLC.  Supernatant (5 µL) was diluted in 45 µL H2O for sample injection.  
The analytes were detected by UV absorbance at 260nm using isocratic mobile phase 
12% acetonitrile/1% glacial acetic acid/5 mM sodium heptanosulfate, flow rate of 1 mL/min 
on a LiChrospher® 60 RP-select B column (LiChroCART® 250 mm x 4 mm cartridge, 5 
µm particle size, C-8 properties, Merck Millipore, Merck KGaA, Germany).  MTR-1P was 
measured by LC-MS/MS.  Supernatant (5 µL) was injected directly onto the column (see 
LC-MS/MS below). 
Isomerase reaction 
Flag-MRI1 or Flag-NAT1 beads were incubated in 100 µL Flag-MTAP reaction supernatant 
for 1-2 hours on a rotating wheel at 37°C.  To stop the reaction, the beads were separated 
from the supernatant by centrifugation.  MTR-1P and MTRu-1P were measured by LC-
MS/MS.  Supernatant (5 µL) was injected directly onto the column (see LC-MS/MS below). 
LC-MS/MS 
The LC-MS/MS system consisted of  Agilent 1200 Series LC system with additional Agilent 
1260 Series column oven (Agilent Technologies, Palo Alto, CA, USA) coupled with API 
3200 triple quadrupole mass spectrometer with electron ion source (ABSciex, Foster City, 
CA, USA).  The system was operated using Analyst software, Version 1.5.1 (ABSciex, 
Foster City, CA, USA).   
HPLC separation of analytes was performed on a Poroshell 120 SB-C18 column 
(150mm×2.1mm, 2.7 µm particle size, Agilent Technologies). The flow rate for mobile 
phase was 0.15 mL/min.  The column was maintained at a constant temperature of 40°C 
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while the autosampler tray temperature was maintained at 4°C.  Sample (5 µL) was 
injected onto the column. 
The detection of analytes by mass spectrometry was carried out using negative 
electrospray ionization and Multiple Reaction Mode for MTR-1P and MTRu-1P.   When 
gradient elution, composing of 0.1% formic acid in water (eluent A) and 0.1% formic acid in 
Acetonitrile (eluent B) was performed, the gradient started at 2% B (98% A) increasing to 
70% B over 20 min followed by an increase to 98% B over 2 min with column flushing at 
98% B for 1 min before returning to 0% B.  The column was equilibrated at 2% B for a total 
run time of 45 min.  The ion source parameters were optimised for this elution method.  
The ionspray voltage was set at -4500V and the ionspray source temperature was 500°C. 
The interface heater was set at 100°C.  The curtain gas, ion source gas 1 (nebulizer gas) 
and ion source gas 2 (turbo gas) were set to 30, 50 and 50 psi, respectively.   The 
optimised declustering potential (-65 V), entrance potential (-10 V), and collision cell 
entrance potential (-25 V) were used.  When isocratic elution, composing of 100 mM 
ammonium acetate pH 7.4, was performed, the total run time was 8 min.  The ion source 
parameters were optimised for this elution method.  The ionspray voltage was set at -
4500V and the ionspray source temperature was 600 °C. The interface heater was set at 
100°C.  The curtain gas, ion source gas 1 (nebulizer gas) and ion source gas 2 (turbo gas) 
were set to 30, 60 and 60 psi, respectively.  The optimised declustering potential (-42 V), 
entrance potential (-10 V), and collision cell entrance potential (-15 V) were used.   
The precursor-to-product transitions for each compound were determined.  The collision 
energy (CE) and cell exit potentials (CXP) were optimised. 
For transition m/z 259.0 → 241.0, the CE was -5 V and the CXP was -5 V.  For transition 
m/z 259.0 → 168.8, the CE was -10 V and the CXP was -6 V.  For transition m/z 259.0 → 
96.9, the CE was -22 V and the CXP was -2 V. 
Statistical Analysis 
Growth curves were analysed using two-way ANOVA to compare the effects of both time 
and medium condition of cell proliferation.  One-way ANOVA was used to compare 
multiple conditions within a single experiment.  Significance was assumed at p < 0.05.  
Linear regression analysis was used to verify the linearity of the standard curves.  
(GraphPad Prism, Version 6.0).   
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Results 
Methionine dependent growth of human cancer cell lines 
To determine how different cancer cells acquire methionine for growth, cells were cultured 
under different medium conditions over time.  Specifically, using complete medium 
(RPMI1640 containing 100 µM methionine), cells obtain this essential amino acid from the 
extracellular environment.  Supplementing methionine with equimolar concentrations of 
homocysteine promotes the use of the SAM cycle. Replacing methionine with MTA (100 
µM) requires the cells to use the entire methionine salvage pathway for the reformation of 
methionine whereas using MTOB (100 µM) engages the aminotransferases necessary for 
the conversion of the penultimate substrate of the pathway to methionine. 
Seven human cancer cell lines were investigated over 7-8 days; three breast, two colon 
and two reproductive cell lines (Figure 30).  Methionine supported growth in all cell lines 
and with the exception of MDA-MB-436 cells, maximal growth was reached at 3-4 days in 
the presence of methionine.  All cell lines, except BT-549, were unable to grow in the 
absence of methionine.  There was no significant difference in growth in the presence or 
absence of methionine (two-way ANOVA) for BT-549 cells.  Supplementing methionine 
with MTOB supported cell growth to the same extent as methionine.  With the exception of 
BT-549 cells, replacing methionine with Hcy supported cell growth although not at the 
same rate as methionine, although CaCo-2 reached maximal growth under this medium 
condition within the time course.  Maximal growth for BT-549 was observed at day 5 when 
methionine was replaced with Hcy.  This was unlike the other cell lines examined and 
suggests a difference in the expression or activity of the SAM cycle enzyme, methionine 
synthase, in this cell line.  However, review of the literature provided no data to support or 
exclude this suggestion.  Further investigation into the altered growth of BT-549 cells 
cultured in the presence of Hcy when methionine is absent is warranted. 
MTA is the initial substrate for the methionine salvage pathway.  Culturing the cell lines in 
the absence of methionine with the addition of MTA (- methionine + MTA medium) forces 
the cells to use this salvage pathway to obtain methionine essential for growth.  MDA-MB-
436, HT-29, CaCo-2, HeLa and SK-OV-3 all grow in - methionine + MTA medium 
indicating that the methionine salvage pathway is functional.  MTA did not support growth 
to the same degree as culturing under normal methionine conditions.  The cell line MDA-
MB-231 is deficient in the methionine salvage pathway due to a homozygous gene 
deletion for MTAP, the first enzyme of the pathway [167].  As expected, MDA-MB-231 did 
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not grow in - methionine + MTA medium.  These results show that culturing cells in - 
methionine + MTA medium can be used to identify cell lines with a functional methionine 
salvage pathway. 
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Figure 30: Methionine dependent growth for human cancer cell lines. Cells (10000) 
seeded on a 96 well plate were grown in differing medium conditions. (A) Breast cell lines 
(B) Colon cell lines (C) Reproductive cell lines.  + Methionine, - Methionine, - 
Methionine + Hcy, - Methionine + MTA, - Methionine + MTOB. Means ±SEM; n=4 
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Effect of NAT1 on the methionine salvage pathway in human cancer cell lines 
The effect of NAT1 on the methionine salvage pathway was investigated in three cell lines 
stably transfected with shRNA to knock-down NAT1; HT-29 (also used in Chapter 3),  
MDA-MB-436 and BT-549 cell lines.  A scrambled shRNA was used as a control (control 
line). Additionally, transient NAT1 knock-down using siRNA (or scrambled siRNA for 
controls) was performed in the HeLa and CaCo-2 cell lines.  Cells were then cultured in - 
methionine + MTA medium over time. 
NAT1 gene silencing was confirmed by measuring NAT1 activity for the knock down cell 
lines at the beginning of the time course (Figure 31).  NAT1 was 87% knocked-down in 
HT-29, 74% in MDA-MB-436, 50% in BT-549, 90% in HeLa, and 94% knocked-down in 
CaCo-2. 
There was a significant difference between the HT-29 NAT1 KD and control cells when 
grown in - methionine + MTA medium (two-way ANOVA p<0.0001) (Figure 32).  The HT-
29 NAT1 KD cell line was unable to grow in this medium condition indicating that the 
methionine salvage pathway was not functional.  There was a slight but significant 
reduction in growth for the BT-549 cells when NAT1 was knocked down (two-way ANOVA 
p<0.001).  There was no difference in growth for MDA-MB-436, HeLa or CaCo-2 cell lines 
indicating that NAT1 had no effect on the methionine salvage pathway in these cells 
(Figure 32). 
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Figure 31: NAT1 knock-down in cell lines used for methionine salvage pathway 
investigation. Cell lysates were prepared and NAT1 activity was determined using 
saturating concentrations of pABA as substrate (440 µM) and acetyl Co-A (1.1 mM) as 
cofactor. (A) NAT1 activity for each cell line (control).  (B) NAT1 activity of knockdown cell 
lines expressed as % of the control cell line.  Means ±SEM; n=3. 
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Figure 32: Effect of NAT1 KD on methionine salvage pathway for human cell lines. 
Cells (10000) seeded on a 96 well plate were grown in in – Methionine + MTA medium. 
(A)Cell lines stably transfected with NAT1 shRNA () or scrambled shRNA (control) (). 
(B)Cell lines transiently transfected with NAT1 siRNA () or scrambled siRNA ().  Means 
±SEM; n=4. Two-Way ANOVA * = p<0.05 
 
To determine if the effect of NAT1 silencing on the methionine salvage pathway was due 
to an off-target effect, three additional experiments were performed to eliminate this 
possibility.  Firstly, different shRNA sequences were examined.  Secondly, different clones 
originating from the same shRNA sequence were examined.  And thirdly, attempts were 
made to reverse the phenotype by re-introducing NAT1 into cells expressing shRNA.  
The sequences for the NAT1 shRNA used to produce the stable NAT1 KD cell lines and 
scrambled shRNA are shown in Figure 33A.  There is 100% complementarity between 
both NAT1 shRNA #1 siRNA, NAT1 shRNA #3 siRNA and the NAT1 mRNA sequence.  
Moreover, there was only 33% complementarity between the scrambled siRNA and NAT1 
mRNA sequences. 
When NAT1 was knocked down using different shRNA sequences, the HT-29 cells were 
unable to grow in - methionine + MTA medium as seen for HT-29 NAT1 KD shRNA #3.2 
and shRNA #1.8 (Figure 33B).  Using different shRNA sequences to induce the NAT1 
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knock-down growth phenotype indicated that non-specific RNAi mediated gene knock-
down was unlikely.   
Different HT-29 NAT1 knock down clones originating from the same shRNA sequence and 
transfection, were unable to grow in - methionine + MTA medium as seen for HT-29 NAT1 
KD shRNA #3.2 and shRNA #3.8 (Figure 33B).  This indicating that the phenotype 
observed when NAT1 was knocked down in HT-29 cells was not peculiar to the clone 
routinely investigated in this study (HT-29 NAT1 KD shRNA #3.2) and again suggests that 
off-target gene silencing arising from differential shRNA insertions into the genome was 
unlikely.  Two independent control clones were also assessed and the results showed that 
both cell lines were able to grow in - methionine + MTA medium.  
Finally, attempts were made to reverse the phenotype by reintroducing NAT1.  The stable 
HT-29 NAT1 KD cell line (shRNA #3.2) was transiently transfected with the p3XFLAG- 
NAT1-CMV-7.1 construct.  Both electroporation and lipofectamine methods were 
attempted but each resulted in poor transfection efficiency (approximately 7% of the cells 
expressed the eGFP transfection marker by FACS).  Western blotting was performed and 
the Flag epitope was undetected.   Attempts were made to create a stable knock-in HT-29 
NAT1 KD cell line constitutively expressing untagged NAT1 using the pcDNA3.1-NAT1 
construct.  This would have had the additional benefit of avoiding any issues that might 
arise from tag interference with the NAT1 protein.  Again, this proved unsuccessful.  
Following cloning and selection (with hygromycin), NAT1 activity was not elevated 
compared to the HT-29 NAT1 KD containing the empty pcDNA3.1 vector.  These results 
suggest that the shRNA stably transfected into these cells was sufficient to knock down 
any mRNA produced from the re-introduced NAT1 plasmid. 
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A   
Suresilencing NAT1 shRNA #1 
GAAGCCTCGAACATTTTTTTATCTTCCTGTCAATCTTCAATTGTTCGAGGCTTCT 
Suresilencing NAT1 shRNA #3 
GATCAGAAGGGAACAGTACATTCTTCCTGTCAAATGTACTGTTCCCTTCTGATCT 
Suresilencing scramble shRNA (control)  
GGAATCTCATTCGATGCATACCTTCCTGTCAGTATGCATCGAATGAGATTCCCT 
 
B
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Figure 33: Growth for HT-29 stable shRNA clones using the methionine salvage 
pathway. Cells (10000) seeded on a 96 well plate were grown in differing medium 
conditions. (A) Sequences determined for shRNA used to produce HT-29 NAT1 KD and 
control stable cell lines.  Bold nucleotides – siRNA sequence, Red nucleotides – hairpin. 
(B) NAT1 KD shRNA #3.2, 3.8 and 1.8, and (C) Scramble control #4 and #2.  + 
Methionine, - Methionine, - Methionine + MTA. Means ±SEM; n=4. (D) NAT1 activity 
of knockdown cell lines expressed as % of the control cell line (#4).  Means ±SEM; n=3.  
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Ectopic expression of a methionine salvage pathway enzyme supported HT-29 cell 
growth in - methionine + MTA medium when NAT1 was knocked down 
Artificial overexpression of a gene/s is commonly used as an investigative tool to assist in 
the determination of function of a gene/protein of interest, particularly where the gene is 
absent or not functional.  This is known as ectopic expression.  In order to identify where in 
the methionine salvage pathway NAT1 may participate, each human enzyme involved in 
the pathway was ectopically expressed in the HT-29 NAT1 KD cell line to rescue the 
phenotype.  Flag-tagged constructs were generated for each of the pathway enzymes and 
individually transfected into the HT-29 NAT1 KD cells.  Empty vector control transfections 
were performed concurrently.  Cell growth after 5 days was then determined in - 
methionine + MTA medium.  Additionally, the HT-29 control cell line was used as a positive 
control and NAT1 KD cells were used as a negative control (Figure 34).  Ectopic 
expression of the enzymes was confirmed by immunoblot detection of the Flag epitope 
(Figure 34B).  Of the methionine salvage pathway enzymes transfected into HT-29 NAT1 
KD cells (Figure 34B), only MRI1 supported growth in the - methionine + MTA medium 
(one-way ANOVA p<0.05).  This suggests that NAT1 has a role in line with the second 
step of the pathway (see Figure 29).  
A
 
B
 
Figure 34: Ectopic expression of methionine salvage pathway enzymes in HT-29 
NAT1 KD cells in - methionine + MTA medium.  (A) HT-29 NAT1 KD cell were 
transfected with Flag-7.1 empty vector (EV) or Flag-enzyme.  HT-29 control and NAT1 KD 
cells (10000) seeded on a 96 well plate 5 days post transfection were grown - methionine 
+ MTA.  Means ±SEM; n=8; One-way ANOVA (Tukey’s multiple comparisons test) * = 
p<0.05 compared to HT-29 NAT1 KD + EV.  (B) Expression of Flag-tagged proteins by 
Western blot analysis HT-29 NAT1 KD cells (60000) seeded on a 24 well plate for 5 days 
post transfection with Flag-7.1 empty vector or Flag-enzyme grown in - methionine + MTA.  
Immunoblotting was performed with anti-Flag M2 Monoclonal Antibody–Peroxidase 
Conjugate and tubulin was probed with anti-tubulin (DM1A) antibody as loading control. 
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Growth of HeLa following NAT1 and MRI1 knockdown 
The results presented in the previous section showed that replacing NAT1 with MRI1 in 
the HT-29 NAT1 KD cell line supported cell growth via the methionine salvage pathway.  
Therefore, it should be possible to recapitulate the phenotype observed in the HT-29 cells 
in an independent cell line using the double knock-down of NAT1 in concert with MRI1.  
Data in Figure 30 showed that the HeLa cell line has a functional methionine salvage 
pathway and consequently HeLa cells were used for this investigation.   
siRNA mediated gene silencing of NAT1 and MRI1 (with scrambled siRNA used as the 
control) was performed in HeLa cells cultured in - methionine + MTA medium for 7 days. 
To ensure NAT1 and MRI1 expression was knocked down for the entire time course, 20 
nM siRNA was used for each gene per transfection.  A total of 40 nM was used, with 
scambled siRNA added where necessary.  Cells were collected for NAT1 activity and 
MRI1 Western blot analysis to confirm gene knock-down was maintained throughout the 
experiment (Figure 35).   
Consistent with previous results (Figure 30C), HeLa cells were sensitive to methionine 
deficiency and growth in - methionine + MTA medium confirmed a functional methionine 
salvage pathway (Scr Control) (Figure 35C).  HeLa cells transfected with scramble siRNA 
or NAT1 siRNA grew in - methionine + MTA medium.  MRI1 KD reduced growth in this 
medium (two-way ANOVA p<0.05) but this did not inhibit the pathway altogether.  The 
simultaneous knock-down of MRI1 and NAT1 in the HeLa cells abolished the methionine 
salvage pathway as there was no difference between the double knock-down grown in - 
methionine + MTA compared to - methionine with the exception of Day 3 (two-way ANOVA 
Sidak’s multiple comparison test p<0.05).  These results confirmed that NAT1 has a role in 
the methionine salvage pathway by affecting the step catalyzed by MRI1.  
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Figure 35: Growth via the methionine salvage pathway was altered in HeLa cells 
when NAT1 and MRI1 were knocked-down.  HeLa cells transfected with 20 nM NAT1 (+ 
20 nM scr), 20 nM MRI1 (+ 20 nM scr), 20 nM NAT1 + 20 nM MRI1 siRNA or 40 nM 
scrambled siRNA were cultured in – methionine + MTA medium 48 hrs after transfection.  
Cells (10000) were seeded per well of 96 well plate for both growth and cell lysates.  (A) 
MRI1 protein levels were detected by Western blot.  Immunoblotting was performed with 
anti-MRI1 antibody and tubulin was probed with anti-tubulin (DM1A) antibody as the 
loading control. (B) NAT1 activity was determined using saturating concentrations of pABA 
as substrate (440 µM) and acetyl Co-A (1.1 mM) as cofactor.   scrambled siRNA,  
MRI1 KD,  NAT1 KD,  NAT1/MRI1 KD. Mean ±SD; n=2. (C) Growth curves for each 
transfection.  + Methionine, - Methionine, - Methionine + MTA. Means ±SEM; n=4.  
Two-way ANOVA (Sidak’s multiple comparisons test) * = p<0.05. 
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Is NAT1 a methylthioribulose 1-Phosphate isomerase? 
MRI1 is an isomerase responsible for the conversion of methylthioribose 1-Phosphate 
(MTR-1P) to methylthioribulose 1-Phosphate (MTRu-1P).  Based on the results in the 
previous section, it was hypothesised that NAT1 may also catalyse this reaction. 
In order to address this hypothesis, the following approach was employed (Figure 36).  
Flag-MTAP, Flag-MRI1 and Flag-NAT1 were ectopically expressed separately in HeLa 
cells.  Cell lysates were prepared and flag-proteins were isolated using Anti-Flag M2 
Affinity Beads.  Flag-protein bound beads were used in reactions and centrifugation 
performed to separate the supernatant for analysis.  Flag-MTAP was used to synthesise 
adenine and MTR-1P from MTA.  Adenine and MTR-1P are produced in a 1:1 
stoichiometric ratio.  Therefore, the production of adenine, measured by HPLC, confirmed 
MTR-1P synthesis and MTR-1P was characterised by LC-MS/MS.  Flag-MRI1 was used to 
convert MTR-1P to MTRu-1P.  Fragmentation of the ribose differed from the ribulose 
moieties.  Therefore, MTRu-1P synthesis could be confirmed and the compound 
characterised by LC-MS/MS.  Flag-NAT1 was then incubated in the presence of MTR-1P 
and the production of MTRu-1P was assessed.  Affinity beads (without bound proteins) 
were processed in parallel throughout the investigation. 
 
 
Figure 36: Schematic approach to NAT1 isomerase function assessment. 
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Flag-MTAP was incubated with MTA and inorganic phosphate to synthesise adenine and 
MTR-1P (Figure 37).  Initially, standards for both MTA and adenine were analysed by 
HPLC (A260nm) to identify their respective retention times (Figure 37A).  Standard curves 
were produced for both, and reaction conditions were determined (Figure 37B/C).  A 
maximum of 75% conversion of MTA to adenine was achieved by 60 minutes incubation 
with Flag-MTAP.  The presence of DTT did not enhance the reaction.  The reduction in 
MTA and increase in adenine was monitored over time (Figure 37D).  The presence of 
adenine confirmed the synthesis of MTR-1P and the reaction supernatant was then 
analysed by mass spectrometry to characterise MTR-1P.  
Tandem mass spectrometry (MS/MS) was used to characterise both MTR-1P and MTRu-
1P (Figure 38).  This involved (very generally) ionising or introducing a charge to the 
sample molecules at the ion source. In this case, electrospray ionization was used.  The 
ions then enter the mass spectrometer and were separated according to the mass-to-
charge (m/z) ratio at the first mass analyser (MS1).  Selected m/z ratios (precursor ions) 
were transferred to the dissociation chamber where the ions were “excited” energetically 
and ion collision was induced, resulting in fragmentation of the precursor ion into product 
ions.  Fragments were separated in the second mass analyser (MS2) according to m/z 
ratio.  The MS2 passed selected m/z ratio fragments to the ion detector.  
Negative electrospray ionisation MS/MS was used for the characterisation and subsequent 
analysis of MTR-1P (and MTRu-1P).  The molecular weight of MTR-1P is 260.2.  The 
phosphate group of MTR-1P (and MTRu-1P) (Figure 39) is deprotonated to form a 
negative charge.  Therefore, it was expected that the mass-to-charge ratio (m/z) would be 
259.0.  The scan of m/z ratios at MS1 was performed and a peak for m/z 259.0 was 
detected for the supernatant from Flag-MTAP beads while no peak was evident in the 
beads only reaction (Figure 40).  Hence, the m/z 259.0 corresponded to MTR-1P and 
could be further characterised.  By sequentially increasing the collision energy, the 
fragmentation pattern for MTR-1P was identified (Figure 41).  Fragmentation of MTR-1P 
results in the formation of the following product ions: m/z 241.0, 139.0, 96.9, 78.9 and 
63.0.   
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Figure 37: Monitoring the reduction in MTA and subsequent presence of adenine by 
HPLC confirms the synthesis of MTR-1P by MTAP.  (A) HPLC chromatograms for 
MTA and adenine standards. 2.5 nmol standard injected onto HPLC column.  Signal at 
A260nm.  Retention times 12.7 minutes and 5.6 minutes, MTA and adenine respectively. 
MTAP reaction using Flag-MTAP.  (B) Representative standard curve for MTA () and 
adenine (). (C) Conversion of MTA () to adenine () overtime in the presence of Flag-
MTAP in the presence (open) or absence (closed) of DTT. (D) HPLC chromatographs of 
adenine and MTA to monitor MTAP reaction. 5 µL from reaction (50 nmol MTA in 100 
µL reaction) was injected on column. Top: Time 0 Flag-MTAP reaction at 0 min. Middle: 
Flag-MTAP reaction at 120 min (75% MTA converted to adenine). Bottom: Beads only at 
120 min (MTA does not degrade under reaction conditions). 
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Figure 38: Schematic for MS/MS. 
Taken from reference [168]. 
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Figure 39: Chemical structure MTR-1P and MTRu-1P. 
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Figure 40: Q1 scan spectra of Flag-MTAP reaction supernatant, generated in 
negative-ionization mode.  Beads incubated with MTA and inorganic phosphate for 90 
min at 37°C.  Adenine detection by HPLC confirmed MTR-1P production in presence of 
Flag-MTAP only. (A) Beads only reaction (B) Flag-MTAP reaction.  m/z 259.0 indicated by 
arrow corresponds to MTR-1P. MS paramaters:  Q1 Scan 200 – 300 m/z, curtain gas, 30 
U; IonSpray voltage, -4500 V; source temp., 400°C; Ion Source Gas 1, 40 U; Ion Source 
Gas 2, 40 U; declustering potential, -45.0 V and entrance potential, -10.0 V. 
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MTRu-1P, the product of MTR-1P isomerization by MRI1, also has a molecular weight of 
260.2 and expected m/z ratio of 259.0.  Therefore, a scan at MS1 would not distinguish 
between the two compounds.  However, the fragmentation pattern for MTRu-1P was 
expected to differ due to the structural differences between the two molecules (ribose v 
ribulose) (Figure 39).  The products of the Flag-MTAP reactions (containing MTR-1P) were 
incubated in the presence of Flag-MRI1 beads for 1 hour and the fragmentation pattern for 
the precursor ion m/z 259.0 was analysed (Figure 42).  The product ions identified were 
m/z 241, 168.9, 138.9, 96.9, 78.9 and 63.0.  The appearance of m/z 168.9 confirmed that 
the supernatant analysed post incubation with Flag-MRI1 differed from the supernatant 
analysed from the Flag-MTAP reactions (or beads only).  Therefore, the product ion m/z 
168.9 was used to distinguish between MTR-1P and MTRu-1P. 
Coupling tandem mass spectrometry with HPLC (LC-MS/MS) provided the added benefit 
of characterising the two compounds based on their retention time.  Again, due to the 
structural differences between the ribose and ribulose moieties, it was expected that their 
hydrophobicity and consequent retention times would differ.  Initially, a gradient mobile 
phase approach, using H2O/0.1% formic acid and acetonitrile/0.1% formic acid, was 
performed for HPLC analyte separation.  The transitions m/z 259.0 → 241.0 and m/z 259.0 
→ 168.8 were monitored by MS/MS (Figure 43).  One peak was present for the Flag-
MTAP reaction supernatant (MTR-1P) in the presence of beads only, m/z 259.0 → 241.0, 
confirming that fragmentation of m/z 259.0 to 241.0 was characteristic of MTR-1P.   When 
MTR-1P was incubated in the presence of Flag-MRI1 for 60 minutes, a second peak, m/z 
259.0 → 168.8, was evident confirming the production of MTRu-1P.  Furthermore, the 
peak AUC representing MTR-1P decreased in line with the production of MTRu-1P.  With 
this knowledge, the chemical structures for the fragments arising from both compounds 
were characterised (Figure 44).  There was a difference in retention time between the two 
transitions.  The retention time characteristic for MTR-1P was 14.5 minutes while the 
retention time for MTRu-1P was 11.9 minutes (Figure 43).   
 
 
Figure 41: Mass fragmentograms of MTR
Fragmentation of precursor 
paramaters:  curtain gas, 30 
Source Gas 1, 40 U; Ion Source Gas 2
potential, -10.0 V and collision entrance potential, 
 
(A) Collision energy: -5 V 
(C) Collision energy: -20 V 
(E) Collision energy: -35 V 
(G) Collision energy: -75 V 
-1P generated in negative
ion, m/z 259.0, with increasing collision energy.  MS 
U; IonSpray voltage, -4500 V; source temp., 400°C; Ion 
, 40 U; declustering potential, 
-25.0 V. 
(D) Collision energy: -25 V
(B) Collision energy: -10
(F) Collision energy: -45 V
(H) Collision energy: -130
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Figure 42: Mass fragmentograms of MTR
Fragmentation of precursor ion, m/z 259.0, with
characteristic of MTRu-1P. MS paramaters: curtain gas, 30 
source temp., 400°C; Ion Source Gas 1, 40 
potential, -65.0 V; entrance potential, 
(A) Collision energy: -5 V 
(C) Collision energy: -20 V 
(E) Collision energy: -35 V 
(G) Collision energy: -75 V 
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Figure 43: LC-MS/MS MRM chromatograms for characterisation of MTR
MTRu-1P.  Gradient HPLC method: 0.1 % Formic acid/H
Formic acid/ACN (mobile phase B).  Two MRM t
reaction condition.   Top panel shows transition m/z 259.0 
transition m/z 259.0 → 168.8.  
only T=60 min.  MTR-1P characterised by m/z 25
Flag-MRI1 T=60 min.  Appearance of m/z 259.0 
241.0) as MTRu-1P increased (m/z 168.8)
2O (mobile phase A) and 0.1 % 
ransitions were monitored for each 
→ 241.0.  Bottom panel shows 
(A) Flag-MTAP reaction supernatant in presence of beads 
9.0 → 241.0. (B) MTR
→ 168.8 peak MTR
. 
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Figure 44:  MTR-1P and MTRu-1P fragmentation by MS/MS 
Structure fragmentation was performed using ChemBioDraw Ultra V14.0.0.117. 
Cambridge Soft Corporation. Perkin Elmer Inc. 
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The sensitivity of this HPLC method was a concern as the peak widths of both compounds 
spanned greater than 3 minutes.  Therefore, a second HPLC method was assessed 
(Figure 45).  Isocratic 100 mM ammonium acetate (pH7.4) mobile phase was used.  Using 
the same rationale as before, the transitions m/z 259.0 → 241.0 and m/z 259.0 → 168.8 
were monitored and the retention times for MTR-1P and MTRu-1P were identified as 4.0 
and 3.3 minutes, respectively (Figure 45A and B).  The peak widths for both were less 
than 1 minute and it was evident that the chromatograms had reduced noise and 
increased sensitivity.  Further to this, the transition m/z 259.0 → 96.9 was also monitored 
as the fragment m/z 96.9 corresponds to the phosphate moiety for both compounds (see 
Figure 44).  The shift in the corresponding peak from 4.0 minutes to 3.3 minutes confirmed 
that m/z 259.0 → 96.9 was able to be used to detect the isomerization of MTR-1P to 
MTRu-1P.  Monitoring this transition had the added benefit of increased sensitivity 
compared to m/z 259.0 → 168.8. 
Overall, both MTR-1P and MTRu-1P were identified based on their structural 
fragmentation patterns by MS/MS and the shifts in retention time between the unique 
fragments for each compound (m/z 241.0 or 168.8) by LC-MS/MS.  Additionally, increasing 
sensitivity of detection was accomplished by using an isocratic method of HPLC analyte 
separation and monitoring the m/z for the phosphate group (m/z 96.9).     
Next, Flag-NAT1 was examined to determine if it catalysed the conversion of MTR-1P to 
MTRu-1P.  Flag-MRI1 and Flag-NAT1 beads (and beads only) were incubated in the 
presence of MTR-1P (from Flag-MTAP reaction) for 90 minutes.  The peak AUC for 
transition m/z 259.0 → 96.9 at 3.3 minutes was measured and an increase in AUC above 
the beads-only reaction was interpreted as MTRu-1P production in the presence of the 
Flag-tagged enzyme (MRI1 or NAT1).  MTRu-1P was produced in the presence of Flag-
NAT1 and Flag-MRI1 although there was significantly more conversion of MTR-1P to 
MTRu-1P by Flag-MRI1 (Figure 46).  Conversely, MTR-1P decreased in the presence of 
both Flag-NAT1 and Flag-MRI1 compared to beads only.  Flag-MRI1 converted 79% of 
MTR-1P to MTRu-1P while Flag-NAT1 converted 11% MTR-1P to MTRu-1P.  These 
results indicate that NAT1 has isomerase activity although possibly at a lower rate than 
MRI1 under these reaction conditions.  
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Figure 45: LC-MS/MS MRM chromatograms for characterisation of MTR
ammonium acetate pH 7.4. Three MRM transitions were monitored for each reaction condition.   Top panel shows transition m/z 259.0 
241.0.  Middle panel shows transition m/z 259.0 
containing MTR-1P was incubated at 37°C for 90 min 
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-1P and MTRu-1P.  Isocratic HPLC method: 100mM 
→ 168.8. Bottom panel shows transition m/z 259.0 →
(A) Flag Affinity beads, (B) Flag-MRI1 bound beads or 
300 
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Figure 46: Production of MTRu-1P in the presence of Flag-MRI1 and Flag-NAT1.  
Flag-MRI1 and Flag-NAT1 bound to flag affinity beads or beads only were incubated with 
the product of Flag-MTAP reaction (MTR-1P) for 90 mins.  (A) Results reported as AUC of 
peak m/z 259.0 → 96.9 at 3.3 minutes corresponding to MTRu-1P less background AUC 
from beads-only indicates enzymatic production of MTRu-1P.  (B) AUC of peak m/z 259.0 
→ 168.9 at 4 minutes corresponding to MTR-1P indicates substrate turnover.  One-way 
ANOVA* = p<0.05 compared to beads only. Means ±SEM; n=3. 
 
These results, however, proved difficult to reproduce.  In an additional experiment, NAT1 
produced MTRu-1P (again with minimal efficiency compared with MRI1) but twice no 
product formation was detected.  Furthermore, the conversion of MTR-1P to MTRu-1P 
was not detected in the presence of recombinant Flag-NAT1 expressed in bacteria.  
Whether this related to a lack of post-translational modification in bacteria requires 
experiments beyond the scope of the current study.  Consequently, the role of NAT1 as an 
MTR-1P isomerase was not demonstrated convincingly. 
 
MRI1 expression in human cancer cells lines 
Both MRI1 and NAT1 needed to be knocked down in the HeLa cells to achieve the growth 
phenotype in - methionine + MTA medium observed in HT-29 NAT1 KD cells.  This 
suggests that there was a difference in MRI1 between the cell lines and that MRI1 is either 
absent or inactive in the HT-29 cell line.  Consequently, MRI1 expression was further 
investigated in these cells.   
HeLa and HT-29 mRNA was extracted, cDNA synthesised and MRI1 message amplified 
by PCR.  A single band corresponding to the expected size for MRI1 (approximately 1280 
bp) was detected for both cell lines.  The PCR products were then sequenced and 
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compared to the MRI1 coding region (GeneBank® Accession: NM_001031727.2).  There 
were no base changes in the sequence for HT-29.  By contrast, HeLa cells had a point 
mutation, G1022C, which resulted in an amino acid change from Gly319 to Ala319.  Both 
glycine and alanine are non-polar amino acids and have small side chains (H for glycine 
and CH3 for alanine).   
Next, MRI1 protein expression in HeLa and HT-29 cell lines was investigated by Western 
blot.  HeLa cells expressed significantly more MRI1 (Figure 37A).  Taking this further, the 
levels of MRI1 protein in a wide range of human cancer cell lines was investigated (Figure 
37B) to determine if the low MRI1 protein expression observed for the HT-29 cell line was 
anomalous.  MRI1 protein expression was variable in the cancer cell lines assessed.  
When normalised to tubulin, HeLa, SW620, T-24, MDA-MB-436, T-47D, MCF-7, PC-3, 
22Rv1 and IMR32 cell lines have high MRI1 protein expression (relative density ≥ 1), 
CaCo-2, PANC-1, HepG2, MDA-MB-231 and BT-549 have moderate MRI1 protein 
expression (relative density 0.5-1), and HT-29, SK-OV-3, SK-N-MC and SH-SY-5Y have 
low MRI1 protein expression relative to tubulin (relative density ≤ 0.2).  Interestingly, two 
cell lines, MCF-7 and MDA-MB-231, that do not have a functioning methionine salvage 
pathway (due to the MTAP gene deletion) [167] still express MRI1. 
The low levels of MRI1 protein detected for HT-29 complements the previous results in 
which ectopically expressed MRI1 rescues growth in HT-29 NAT1 KD cells.  Together this 
suggests that the limited expression of MRI1 in HT-29 cells is insufficient to support the 
methionine salvage pathway.   
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Figure 47: MRI1 protein expression in cancer cell lines by Western blotting.  Cell 
lysates prepared for a range of human cell lines were analysed by Western blotting.  MRI1 
was detected using anti-MRI1 antibody and tubulin was probed with anti-tubulin (DM1A) 
antibody as the loading control. (A) HeLa and HT-29 lysate (10 µg protein).  (B) HeLa cell 
lysate (10 µg protein) was loaded on each blot as a positive control (lane 2).  The top 
panel – human cancer cell lines from the digestive system.  Middle panel – human breast 
cancer cell lines. Bottom panel – Lane 2-5 human cancer cell lines from reproductive 
system and Lane 6-8 human cancer cell lines from the brain. 
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Transient NAT1 KD in cell lines with minimal MRI1 protein expression did not 
recapitulate the phenotype observed in HT-29 NAT1 KD stable cell lines 
Transient knock-down of NAT1 in cells that express little MRI1 protein should replicate the 
phenotype observed in the stable HT-29 NAT1 KD.  Similar to HT-29, SK-OV-3 cell line 
has low MRI1 protein levels (Figure 47).  Consequently, this cell line was investigated 
along with transient NAT1 knock-down in HT-29 cells was also performed.  siRNA (20 nM) 
for NAT1 gene silencing or scrambled siRNA for the control was used for each transfection 
and cells were cultured in - methionine + MTA medium over 7 days.  It was confirmed that 
NAT1 remained knocked down (93% NAT1 knock-down in HT-29 and 90% NAT1 knock-
down in SK-OV-3) throughout the study.  Unexpectedly, there was no difference (two-way 
ANOVA) in growth for either HT-29 or SK-OV-3 when NAT1 was silenced (Figure 48).  
 
Figure 48: The effect of transient NAT1 KD in low MRI1 expressing SK-OV-3 and HT-
29 cells on the methionine salvage pathway. SK-OV-3 and HT-29 cells transfected with 
20 nM NAT1 () or 20 nM scrambled siRNA () were cultured (10000 cells seeded on a 
96 well plate) in – methionine + MTA medium 48-72 hrs after transfection.  Means ±SEM; 
n=4. 
 
MRI1 protein expression differs between HT-29 stable control and NAT1 KD cells 
Because transient knock-down of NAT1 in either HT-29 or SK-OV-3 cells did not affect the 
methionine salvage pathway, a closer investigation of MRI1 in the HT-29 cell lines was 
undertaken.  Western blots for MRI1 were performed on cell lysates from HT-29, HT-29 
control and NAT1 KD stable cell lines. All three NAT1 KD clones were deficient in MRI1 
while the parent cell line and both control clones contained detectable amounts of the 
protein (Figure 49).   
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Figure 49: MRI1 protein expression in HT-29 stable shRNA clones by Western 
blotting.  Cell lysates for HT-29 stable cell lines were prepared in modified RIPA buffer 
and protein concentrations were determined.  40 µg protein was loaded for HT-29 samples 
while 3 µg protein was loaded for HeLa as a positive control. MRI1 protein levels were 
detected by Western blot.  Immunoblotting was performed with anti-MRI1 antibody and 
tubulin was probed with anti-tubulin (DM1A) antibody as the loading control.  NOTE: the 
low tubulin in the HeLa cells was due to the reduced protein loading in that lane. 
 
The methionine salvage pathway in HT-29 cells when MRI1 was knocked down 
In order to confirm whether the phenotype observed in the HT-29 stable control and NAT1 
KD cells was a result of the differential expression of MRI1 in these cell lines, MRI1 was 
transiently knocked-down by siRNA in HT-29 cells.  Further to this, NAT1 and MRI1 were 
knocked down simultaneously in a double knock-down to determine if NAT1 contributed to 
the methionine salvage pathway in the absence of MRI1.   
siRNA mediated gene silencing of NAT1 and MRI1 (with scrambled siRNA used as the 
control) was performed in HT-29 cells and cultured in - methionine + MTA medium for 7 
days.  NAT1 activity remained knocked down for the duration of the time course in both 
single and double knock-down treated cells (Figure 50B).  As observed previously, 
transient NAT1 knock-down in the HT-29 cells did not alter growth in - methionine + MTA 
medium, while MRI1 knock-down completely inhibited growth (Figure 50A).  These results 
indicated that when NAT1 was knocked down, growth was supported by the presence of 
MRI1.  By contrast, when MRI1 was knocked down, the presence of NAT1 did not 
compensate.  Consequently, it was concluded from these experiments that the original 
growth phenotype (in - methionine + MTA medium) arose due to the differential expression 
of MRI1 between the stable control and NAT1 KD cell lines.   
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Figure 50: Growth via the methionine salvage pathway for HT-29 NAT1 and MRI1 
double KD.  HT-29 cells transfected with 20 nM NAT1, 20 nM MRI1, 20 nM NAT1 + 20 nM 
MRI1 siRNA or 40 nM scrambled siRNA were cultured in differing medium conditions 72 
hrs after transfection.  Cells (10000) seeded on a 96 well plate were grown (A) Growth 
curves for each transfection.  + Methionine, - Methionine, - Methionine + MTA. 
Means ±SEM; n=4. (B) NAT1 activity was determined using saturating concentrations of 
pABA as substrate (440 µM) and acetyl Co-A (1.1 mM) as cofactor.   scrambled siRNA, 
 MRI1 KD,  NAT1 KD,  NAT1/MRI1 KD. Mean ± SD; n=2. 
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Ectopic expression of NAT1 in HT-29 control cells supported the methionine 
salvage pathway when MRI1 was knocked down 
Earlier results (Figure 35) indicated that NAT1 supported the methionine salvage pathway 
in HeLa cells when MRI1 was knocked down.  NAT1 expression is significantly reduced in 
HT-29 cells due to the presence of only one NAT1 allele [169].  Therefore, it is possible 
that the amount of NAT1 present in HT-29s is not sufficient to compensate for the loss of 
MRI1.  To investigate this possibility, NAT1 was overexpressed in control HT-29 cells and 
growth with and without MRI1 knock-down was determined.  
NAT1 expression was 40.2 and 73.3 nmol/min/mg protein for two stable cell lines, 
compared to 6.5 nmol/min/mg protein in the control line containing empty vector.   
Using the NAT1 knock-in cell line with an NAT1 activity of 73.3 nmol/min/mg protein, 
growth in - methionine + MTA medium was examined (Figure 51A).  Cells grew similarly to 
HT-29 cells (Figure 50).  However, unlike HT-29 cells with stable knock-down of NAT1, the 
over-expressing line showed significant growth following MRI1 inhibition (Figure 51A).  The 
loss of MRI1 is demonstrated in Figure 51C.  These results support previous data that 
NAT1 and MRI1 are redundant enzymes.  Moreover, they are in agreement with the LC-
MS/MS assay, which suggests NAT1 is very inefficient in catalysing the isomerization of 
MTR-1P. 
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Figure 51: Ectopically expressed NAT1 in HT-29 control cells supported the 
methionine salvage pathway in the absence of MRI1.  HT-29 control (cnt) cells stably 
transfected with NAT1 (untagged) were transiently transfected with 20 nM MRI1 or 20 nM 
scrambled siRNA were cultured in – methionine + MTA medium 72 hrs after transfection.  
Cells (10000) seeded on a 96 well plate were grown in differing medium conditions. (A) 
Growth curves for each transfection.  + Methionine, - Methionine, - Methionine + 
MTA. Means ±SEM; n=4. Two-way ANOVA* = p<0.05.  (B) NAT1 activity was determined 
using saturating concentrations of pABA as substrate (440 µM) and acetyl Co-A (1.1 mM) 
as cofactor.  Mean ±SEM; n=3. One-way ANOVA* = p<0.05.  (C) 40 µg protein was loaded 
for HT-29 samples while 3 µg protein was loaded for HeLa as a positive control. MRI1 
protein levels were detected by Western blot.  Immunoblotting was performed with anti-
MRI1 antibody and tubulin was probed with anti-tubulin (DM1A) antibody as the loading 
control.  NOTE: low Tubulin in HeLa cells was due to the reduced protein loading in lane 1.  
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Discussion 
Metabolomic analysis in the previous chapter identified the methionine salvage pathway as 
a biochemical process in which human NAT1 may play a novel role.  By measuring cell 
proliferation in response to medium deficient in methionine but containing MTA, growth 
supported by this pathway could be investigated.  The effect of NAT1 in human cancer cell 
lines was explored and changes in the methionine savage pathway were assessed.  
Overall, it was determined that human NAT1 has an endogenous role in the methionine 
salvage pathway in line with the reaction performed by MRI1.  Two strong arguments for 
this were described.  Firstly, knocking down NAT1 and MRI1 simultaneously in HeLa cells 
resulted in a loss of growth in - methionine + MTA medium.  This was not seen when either 
enzyme was silenced alone and shows that each can support the methionine salvage 
pathway.  Secondly, HT-29 cells have a very low endogenous NAT1 activity compared to 
most other cells and this level was not sufficient to support the methionine salvage 
pathway in the absence of MRI1.  However, ectopic expression of human NAT1 at levels 
that were equivalent to or higher than other cells allowed HT-29 cells to grow in - 
methionine + MTA when MRI1 was silenced.  Taken together, these results show that 
human NAT1 has a novel role in the methionine salvage pathway.    
There were a number of observations in this chapter that require further investigation. 
Surprisingly, when human NAT1 was transiently knocked down in HT-29 cells by siRNA, 
the phenotype where the cells were unable to grow in - methionine + MTA was not 
reproduced.  Western blotting confirmed that MRI1 was present, albeit at low levels, in 
both the HT-29 parent and control shRNA cell lines. However, the enzyme was not 
detectable in the stable human NAT1 shRNA knock-down cell lines.  The loss of MRI in 
these cells was not due to an off-target effect caused by the specific sequence of the 
shRNA.  This was confirmed firstly by demonstrating the phenotype in other knocked down 
clones generated with independent shRNA sequences and, secondly, by showing the 
phenotype in different clones generated from the same shRNA sequence.  Experiments to 
re-introduce human NAT1 into the stably knocked down cells were unsuccessful, although 
it was easily re-introduced into cells expressing the scrambled sequence.  These results 
show that the shRNA was sufficient to suppress ectopic expression of NAT1.  Previously, 
a study investigating the methionine salvage pathway in the DLD-1 human colon 
carcinoma cell lines showed heterogeneity for MRI1 expression [170].  This cell line 
originated from a Duke’s type C colorectal carcinoma and two sub-populations were 
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identified and characterised  [171]. Ghoda et al. showed that one population expressed 
MRI1 while the second did not.  HT-29 cells are also heterogeneous for markers such as 
CD133 [172], carcinoembryonic antigen [14], growth adaptation to methotrexate [15] and 
response to differentiating agents [173].  Consequently, it is possible that the HT-29 cell 
line is also heterogeneous for MRI1 expression and MRI1 expression could have been 
selected for/against during the generation of the stable HT-29 clones.  If this were the 
case, then MRI1 was selected against in the NAT1 KD cell lines suggesting that the lack of 
MRI1 provided a growth advantage only when NAT1 was deficient.  Why this would occur 
remains unclear. Alternatively, long term knock-down of human NAT1 may lead to the 
down regulation of MRI1 expression.  Further studies are required to interrogate this 
observation.   
While the altered growth in - methionine + MTA medium in HT-29 cells stemmed from the 
lack of MRI1 expression in the stable NAT1 KD cell lines, the effect of ectopic expression 
of NAT1 in HT-29 cells supported growth in - methionine + MTA medium demonstrating 
that NAT1 was able to support the methionine salvage pathway in place of MRI1.  MRI1 is 
the second enzyme in the methionine salvage pathway.  It is the methylthioribose 1-
phosphate isomerase responsible for the conversion of MTR-1P to MTRu-1P.  NAT1 was 
capable of catalysing the isomerase reaction, albeit at a much lower rate than MRI1.  
Because MTR-1P and MTRu-1P are not commercially available, both compounds were 
synthesised enzymatically.  MTAP produces adenine and MTR-1P in a 1:1 stoichiometric 
ratio and adenine was readily detected by UV/Vis HPLC as a control for the isomerase 
reaction.   
On two separate occasions, Flag-NAT1 isomerase activity was detected. On two other 
occasions MTRu-1P was undetected.  NAT1 activity was used to confirm that Flag-NAT1 
was bound to the beads used to isolate the enzyme from cell cytosol.  However, it was not 
determined if the beads bound the same amount of protein.  The reaction conditions for 
MRI1 activity were adapted from previous work [174], while optimal reaction conditions for 
the NAT1 isomerase reaction remain unknown.  In fact, the reaction matrix used in this 
investigation reduced NAT1 pABA acetylation activity by 70% (results not shown).  
Therefore, it is possible that the isomerase reaction may have been similarly limited.  
Additionally, the presence of tags on proteins may interfere with their structure, stability or 
function [175].  Therefore, it is possible that the Flag hindered the NAT1 isomerase 
reaction.  Using untagged NAT1 in the isomerase reaction would be useful to exclude this 
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possibility.  Determining MTR-1P isomerase activity in vivo would be ideal as it would 
remove the limitations associated with the in vitro method used here.  
In addition to experimental data, there are similarities between the catalytic mechanism of 
NAT1 acetyltransferase activity and MRI1 isomerase activity.  The crystal structures for 
MRI1 have been determined for the Saccharomyces cerevisiae [176], Bacillus subtilis 
[177] and human [178] form of the enzyme.  MRI1 is dimeric in solution.  Each monomer 
contains a deep cleft between two distinct domains, the N- and C-terminals, which form 
the active site.  A highly conserved catalytic dyad (Cys168 and Asp248) present in the active 
site of MRI1 is essential for isomerase activity.  NAT1 contains a conserved catalytic triad 
essential for activity which includes a cysteine and aspartate residue (Cys68-His106-Asp122 
in humans).  MRI1 active site volume is 110 Å3 while NAT1s active site is 162 Å3, which is 
large enough to accommodate the phosphorylated ribose substrate.  Structural homologs 
for both the N- and C-terminal domains of MRI1 have been identified.  Interestingly, the C-
terminal domain closely resembles glutaconate CoA-transferase from Acidaminococcus 
fermentans [176].  This enzyme transfers the CoA moiety from a donor (acetyl-CoA) to an 
acceptor substrate by a ping-pong mechanism [179].  Taken together, these observations 
suggest that NAT1 may possess the necessary structural features for the isomerase 
reaction.  Structural homology studies may be helpful to determine if the location of NAT1 
Cys68 and Asp122 residues are similarly located within the active site as those in MRI1.  
Docking MTR-1P into the NAT1 active site would also provide valuable information.  These 
studied could provide the first clues to determining the reaction mechanism for the 
possible NAT1 isomerase function. 
In summary, the initial growth phenotype that suggested human NAT1 supported the 
methionine salvage pathway, resulted from the selection of the HT-29 stable cell lines 
used in the study.  Nevertheless, over-expression of human NAT1 in HT-29 cells did 
confirm that NAT1 supported the methionine salvage pathway by compensating for the 
lack of MRI1.  Furthermore, this was verified in HeLa cells.    Overall, the results in this 
chapter provide evidence for a novel endogenous role for human NAT1 in the methionine 
salvage pathway. 
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CHAPTER 5: OVERALL DISCUSSION 
The Phase II drug metabolising enzyme, NAT1, is ubiquitously expressed and 
evolutionarily conserved.  This suggests that NAT1 may play an important role in cell 
biology.  Until recently, the only clue to an endogenous role for NAT1 was through its 
metabolism of the folate catabolite, pABG.  However, it has now become evident that 
NAT1 may have an intimate role in cancer biology.  Therefore, this study sought to identify 
the effects of NAT1 at a biochemical level to discern its role in cancer cells. 
Folate is important for cell growth and proliferation.  The folate pathway is involved in 
many cellular processes including DNA, RNA and protein synthesis as well as methylation 
reactions and epigenetic regulation of genes.  It was supposed that folate was linked to an 
endogenous role for NAT1, initially because NAT1 acetylates pABG (presumably for 
excretion) and also because NAT1 expression coincides with key folate requiring events 
during development as reviewed in Chapter 2.  Moreover, there were reported incidences 
of ocular and neural tube defects, phenotypes attributable to folate deficiency, in Nat2 
knock-out mice [90, 124].  More recently, folic acid has been found to interact with NAT1 
and act as a co-factor for the NAT1-catalysed hydrolysis of acetyl-CoA [104].  In silico 
docking studies show folic acid, interacts with the NAT1 active site.  The original finding by 
Ward et al. showed that folic acid (and methotrexate) inhibits NAT1 acetylation activity 
[28].  Taken together, this suggests that folic acid most likely competes with substrates in 
the active site. 
This study began by investigating the effect of mouse Nat2 on 5-mTHF, the predominant 
folate, and folate catabolites, pABG and N-acetyl pABG in mice (Chapter 2).  N-acetyl 
pABG was only detected in the wild-type mice confirming that Nat2 was absent in the 
knock-out mice.  It was surprising to discover that there were very few differences between 
5-mTHF and pABG in the Nat2-/- and wild-type mice tissues investigated.  While there was 
a significant increase in 5-mTHF in the liver of Nat2-/- mice compared to wild-type, this 
was only evident in males and no differences were observed between pABG levels in the 
liver or kidney.  This indicated that Nat2 is not essential for regulating the levels of pABG 
or 5-mTHF in mice under normal conditions.  
It is reasonable to consider that mouse Nat2/human NAT1 regulation of folate might be 
important under stress, for example during proliferation, when folate utilization is high.  
Consequently, the effect of human NAT1 on 5-mTHF and its catabolites, pABG and N-
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acetyl pABG was investigated in a cancer cell model, the HT-29 human colon 
adenocarcinoma cell line (Chapter 3).  The enzyme was successfully knocked down by 
more than 80% in the stable NAT1 KD cell line using RNAi.  Based on the metabolomic 
results presented in this chapter, the intracellular concentration of pABG (approximately 20 
pmol/mg protein) equates to 1-5 µM [180, 181].  Since the Km reported by both Minchin 
[27] and Ward et al. [28] for N-acetylation of pABG (approximately 300 µM for endogenous 
NAT1) is approximately 100-fold greater than the intracellular concentration of this 
substrate, this reaction is physiologically inefficient.  As in the Nat2-/- mouse investigation, 
there was no difference in intracellular pABG between control and RNAi mediated NAT1 
knock-down HT-29 cells.  Interestingly, both pABG and N-acetyl pABG were elevated in 
the culture medium compared to medium only (no cells), with no difference observed when 
human NAT1 was knocked down indicating that both metabolites were excreted by the 
HT-29 cells independent of NAT1.    
Similar to the in vivo metabolomics, there was no difference in the intracellular folate 
measured between the control and NAT1 KD HT-29 cells.  Both investigations focused on 
5-mTHF as it is the predominant circulating and intracellular folate.  However, other folates 
should also be considered (e.g. DHF, THF, 10-formyl-THF, etc.).  Moreover, intracellular 
folates are polyglutamated to support cellular sequestration and promote high affinity 
binding with folate-dependent enzymes and binding proteins [87].  Therefore, in addition to 
the experiments performed here, it would be useful to investigate the effect of human 
NAT1/mouse Nat2 on polyglutamated folate forms.   
Overall, this study presents no evidence to suggest that NAT1 is involved in the regulation 
of 5-mTHF or pABG in the mouse or cancer cell model.  Additionally, these results indicate 
that NAT1 is not required for the removal of pABG via acetylation and suggests that pABG 
is not the major endogenous substrate for NAT1.  These results are interesting because 
the major reported folate catabolite in urine of pregnant women is N-acetyl pABG [89].  It 
has been proposed that another enzyme might be responsible for the acetylation of pABG 
[27].  However, N-acetyl pABG is absent in the urine of Nat2-/- mice [90] and indeed 
Chapter 2 showed that N-acetyl pABG was undetectable in the Nat2-/- tissues suggesting 
that human NAT1/mouse Nat2 is responsible for this metabolite.  It is possible that the 
increase in folate requirements during pregnancy results in increased intracellular 
catabolites and consequently, an elevated substrate concentration for more efficient NAT1 
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production of N-acetyl pABG.  The importance of this inefficient reaction remains unclear 
and may be physiologically irrelevant.   
One avenue not considered so far is the effect of NAT1 under folate deficient conditions.  It 
would be interesting to examine the Nat2-/- phenotype of offspring from mice fed a folate 
deficient diet as well as the effect of folate deficiency in adult mice.  Additionally, the effect 
of NAT1 on the growth of human cancer cells could be investigated in medium deficient in 
folic acid.  Finally, the remaining (known) link between NAT1 and folate lies in the 
hydrolysis of acetyl-CoA in the presence of folic acid.  It would be valuable to determine if 
this reaction is physiologically relevant and whether it is regulated by other folates as 
acetyl-CoA is an important metabolite and has been shown to promote cell growth and 
proliferation [182].   
Epigenetic regulation has been implicated in the role of human NAT1 in cancer biology.  
The SAM cycle is important for DNA methylation, a form of epigenetic regulation.  
Therefore, the effect of mouse Nat2 in mice (Chapter 2) and human NAT1 in HT-29 cancer 
cells (Chapter 3), on the components of the SAM cycle, were examined in conjunction with 
the investigations discussed above.  As with pABG, there was no difference in Hcy or 
methionine levels between Nat2-/- and wild-type mice in any of the tissues examined.  
There was a significant increase in blood SAM levels and lung SAH levels in male Nat2-/- 
mice.  In the HT-29 NAT1 KD and control cells, there was no difference in intracellular 
concentration for any of the SAM cycle compounds.  Overall, there was little evidence to 
suggest that human NAT1 regulates the SAM cycle to alter methylation reactions and 
consequently, the observed elevation in E-cadherin in HT-29 NAT1 KD cells [115] is 
unlikely due to changes in DNA methylation.  Furthermore, a role for human NAT1 in other 
forms of gene regulation (e.g. histone modification) now warrants consideration.  
Metabolomic analysis of amino acids in the extracellular medium from NAT1 knock-down 
and control HT-29 cells was performed in an attempt to identify altered metabolic 
processes in the absence of human NAT1 (Chapter 3).  Of the 17 amino acids analysed, 
two displayed significant differences between NAT1 KD and control cells.  Glutamate 
increased in the medium over time with the NAT1 KD culture medium containing 
significantly, albeit slightly, elevated concentrations throughout the time course.  More 
pronounced was the difference in alanine present in the culture medium of the two cell 
lines.  HT-29 NAT1 KD cells maintained significantly higher concentration of alanine in the 
medium from day 2 to the end of the time course (day 4).  Interestingly the differences 
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were only observed for amino acids released into the medium.  Hence, there was no 
indication that human NAT1 altered uptake of any of the amino acids measured.  
Metabolomic analysis of the SAM cycle compounds was also performed in the medium 
from HT-29 NAT1 KD and control cells.  While SAM and SAH were below levels of 
detection, methionine and Hcy were measured up to 5 days.  Methionine was depleted 
from the medium by both cell lines at day 3 whereas Hcy was released into the medium up 
to this time point.  Once methionine was depleted, control cells continued to release Hcy 
while the NAT1 KD cells took up Hcy to support intracellular methionine production and the 
maintenance of SAM cycle homeostasis.  This study highlights the power of metabolomic 
screening for identifying target biochemical processes in response to altered biological 
stimuli, i.e. altered NAT1 gene expression.  In particular, two major phenotypic changes 
were observed in response to human NAT1 knock-down; altered alanine levels in the 
medium and the uptake of Hcy when extracellular methionine was depleted.     
As discussed in Chapter 3, alanine has the potential to be involved in glycolysis, 
gluconeogenesis and the citric acid cycle.  Alanine may be produced by the metabolism of 
pyruvate, a product of glycolysis, or reversibly, catabolised to produce pyruvate, by alanine 
aminotransaminase.  Interestingly, the decarboxylation of pyruvate results in acetyl-CoA 
synthesis.  NAT1 interaction with acetyl-CoA could provide a mechanism for regulating 
these pathways.  For example, the consumption of acetyl-CoA by NAT1 may result in 
reduced substrate necessary for the citric acid cycle and consequently, up-regulation of 
acetyl-CoA synthesis.  This could occur through glycolysis or more specifically pyruvate 
decarboxylase, the enzyme responsible for acetyl-CoA production.  The consequence 
would be less pyruvate catabolism and less alanine production, when NAT1 is present.  
The Warburg Effect is a characteristic of proliferating cells where glycolysis is increased 
even in the presence of oxygen. This is thought to support the production of the building 
blocks necessary for cell growth and proliferation.  The Warburg Effect is characterised by 
an increase in glucose consumption and increased acidification due to lactate excretion 
[158, 183].  The increased presence of alanine in the medium may be an indication that 
the conversion of pyruvate to lactate in the NAT1 KD cells is reduced compared to the 
controls cells.  Cell lysates and medium could be investigated in order to determine if 
either pyruvate and/or lactate is influenced by the presence of human NAT1.   
The changes in medium Hcy levels were attributable to changes in the methionine salvage 
pathway in response to human NAT1 deficiency.  Consequently, an extensive investigation 
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of the role of NAT1 in the methionine salvage pathway was pursued (Chapter 4).  By 
growing cells in medium deficient in methionine, it was possible to show that human NAT1 
may have a role in the methionine salvage pathway.    
Initially, it seemed that human NAT1 compensated for the lack of MRI1 present in the HT-
29 cells until it was determined that the small amount of MRI1 present in this cell line was 
sufficient to support growth, in the absence of methionine, when NAT1 was transiently 
knocked down.  Subsequently, it was discovered that, when human NAT1 was stably 
knocked down, so too was MRI1.  This was not a result of off-target gene silencing as 
multiple clones and different shRNA sequences gave the same double knock-down 
phenotype.  Consequently, altered dependence on the methionine salvage pathway in 
these cell lines cannot be attributed directly to human NAT1.  Moreover, the differences in 
Hcy levels observed in medium and Hcy uptake when NAT1 was knocked down also 
cannot be attributed to NAT1 directly.  However, these phenotypes may be the result of an 
indirect effect of NAT1 knock-down resulting in MRI1 down regulation.  This is worth 
further investigation.   
Ectopic expression of human NAT1 supported the salvage pathway when MRI1 was 
silenced in HT-29 cells.  Moreover, when both NAT1 and MRI1 were silenced in HeLa 
cells, the methionine salvage pathway was no longer functional.  Therefore, human NAT1 
does have a novel role in the methionine salvage pathway and suggests a redundancy 
between NAT1 and MRI1. 
Methionine dependency is a key characteristic of many cancers [184].  The methionine 
salvage pathway is important in these cells for obtaining methionine required for cancer 
cell survival.  Is NAT1 role in the methionine salvage pathway physiologically relevant?  
Western blot analysis in a range of human cancer cell lines indicated that MRI1 expression 
is widely variable.  Nevertheless, the limited amount of MRI1 detected in HT-29 cell lines 
was sufficient to support the methionine salvage pathway.  Furthermore, NAT1 supported 
the methionine salvage pathway in the absence of MRI1 in HT-29 cells, when NAT1 
protein expression was high.  Therefore, this function may only be relevant when NAT1 is 
up-regulated or in tissues with high NAT1 protein expression.  It is plausible that the role of 
human NAT1 in the methionine salvage pathway is important when MRI1 is non-functional, 
NAT1 expression is high and there is a methionine deficiency.   
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In this study, it was hypothesised that NAT1 might catalyse the isomerisation of MTR-1P. 
When NAT1 was incubated in the presence of the MRI1 substrate, MTRu-1P was 
produced in two independent experiments.  However, MTRu-1P was undetected on two 
other occasions.  Therefore, further work is required to definitively determine NAT1 
isomerase activity and how efficient this reaction is compared to MRI1.  The amino acids 
essential to the MRI1-cataylsed isomerase reaction (Cys and Asp residues), [177, 178] are 
similar to those present in the NAT1 catalytic triad.  In Bacillus subtilis, RuBisCO (ribulose-
1,5-bisphosphosphate carboxylase/oxygenase of the Calvin cycle) can substitute for the 
enolase enzyme downstream in the salvage pathway, but at a much slower rate [185, 
186].   Therefore, it is plausible that NAT1 may perform the isomerase reaction 
physiologically, albeit less efficiently.  Docking of the ribose substrate into the NAT1 active 
sight would be useful in characterising the possible catalytic mechanism. 
Since the isomerase activity of NAT1 remains unclear, the involvement of human NAT1 in 
the methionine salvage pathway in some other capacity deserves further consideration.  
NAT1 may regulate MRI1 expression or stabilise the MRI1 protein.  However, transient 
NAT1 knock-down in both HeLa and HT-29 cells did not result in a change in MRI1 protein 
level. Nor did it affect MTA-dependent growth.  Thus, it seems unlikely that NAT1 
regulates MRI1 protein expression.  NAT1 may post-translationally modify MRI1 to alter its 
isomerase activity.  Ectopic untagged NAT1 expression in HT-29 cells, in the absence of 
MRI1, supported MTA-dependent growth, which suggests that NAT1 did not affect MRI1 
activity.  In eukaryotes, the enolase/phosphatase reactions are catalysed by the same 
protein (ENOPH1).  However, in Bacillus subtilis, two enzymes perform these reactions 
independently [187], which highlights that different steps in the salvage pathway can be 
achieved through multiple routes.  Therefore, NAT1 may catalyse the conversion of MTR-
1P to an alternative product that can also be metabolised through the salvage pathway 
resulting in methionine production.  Finally, it is possible that NAT1 alters the translocation 
of MRI1 in the cell.  Kabuyama et al. showed that MRI1 is present in the nucleus, 
cytoplasm and cellular projections [157].  MRI1 was primarily located in the nucleus in 
normal cells whereas it was located in the cytosol of tumour cells.  The effect of NAT1 on 
the different cellular MRI1 pools is worth investigating.   
Along with its role as an isomerase, MRI1 also has a role in the RhoA signalling pathway 
[157].  RhoA signalling is involved in formation and organisation of actin filaments, 
regulation of microtubule dynamics and altered gene transcription [188].  Consequently, 
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RhoA is of interest in cancer biology as it influences the cell cycle, cell morphology and cell 
migration.  Proteomic screening identified MRI1 as a target protein of RhoA [157].  MRI1 
expression was induced upon RhoA activation and conversely, silencing RhoA resulted in 
the reduction of MRI1 protein expression.  RNAi mediated knock-down of MRI1 resulted in 
decreased cell invasion by metastatic cell lines, as did RhoA knock-down.  Moreover, 
MRI1 was required for the RhoA-dependent tyrosine phosphorylation of Focal Adhesion 
Kinase (FAK-Tyr(P)397).  FAK-Tyr(P)397 promotes a range of signalling cascades, actin 
stress fibre turnover and focal adhesion complex disassembly necessary for increased 
motility, migration and invasion [189].  Additionally, increased actin stress fibres were 
observed when MRI1 was knocked down.  Taken together, the authors proposed that 
MRI1 facilitated RhoA induced cell invasion by promoting FAK tyrosine phosphorylation 
and subsequent stress fibre turnover [157].   
Interesting parallels can be made between the previously reported effects of human NAT1 
inhibition and those observed in melanoma cell lines following MRI1 silencing.  Changes in 
cell morphology were observed in both invasive and non-invasive cell lines when human 
NAT1 was knocked down [115, 190] including changes in the actin cytoskeleton and 
filopodia, both of which can be regulated by the RhoA signalling pathway.  Similarly, MRI1 
silencing resulted in changes in the actin stress fibre turnover.  Furthermore, NAT1 knock-
down in breast cancer cell lines reduced cell invasion [190], as did MRI1 knock-down in 
melanoma lines [189].  Both human NAT1 and MRI1 have been detected in cellular 
protrusions (filopodia) of cancer cells and co-localisation of these proteins could be 
possible.  It would be important to determine whether the redundancy observed between 
human NAT1 and MRI1 in the methionine salvage pathway correlated to a redundancy in 
the RhoA pathway. 
In the non-invasive HT-29 cell line, E-cadherin expression was upregulated, β-catenin was 
redistributed to the plasma membrane (from the nucleus) and anchorage independent 
growth was reduced when NAT1 was silenced [191] suggesting changes in adherens 
junctions in the presence of NAT1.  Adherens junctions are important for cell-cell contact 
and involve the assembly of E-cadherins, recruitment of intracellular proteins (e.g. α- and 
β-catenin) and stabilization with the actin cytoskeleton [192].  RhoA has been shown to 
regulate adherens junctions’ formation and integrity through its effector protein ROCK and 
actin filament (F-actin) formation [188, 193].  Moreover, the recruitment of β-catenin to the 
cell membrane alters the amount present in the cytosol and nucleus effecting canonical 
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Wnt signalling and expression of genes involved in proliferation and cancer progression 
[194, 195].  HT-29 cells exhibited changed cell morphology when NAT1 was knocked 
down.  At high density, actin stress fibres were associated with sub-cortical cytoskeleton at 
sites of cell-cell contact in HT-29 NAT1 KD cells whereas actin stress fibres were present 
intracellularly in control cells [115].  Again, RhoA is linked to cell morphology by regulating 
actin filaments.     
In the invasive breast cell line, MDA-MB-231, a reduction in N-cadherin and nuclear β-
catenin was observed as was the reduction in growth and invasiveness when human 
NAT1 was knocked down [190].  RhoA is important in the regulation of N-cadherin [196].  
Inhibition of NAT1 blocked the cell cycle as cells accumulated in the G2/M phase [114].  
RhoA also influences the cell cycle at the beginning of the nuclear/cell division phase (M) 
[188].  Breast cancer cell lines displayed smaller and reduced number of filopodia as well 
as changed F-actin localisation when NAT1 was knocked down [190].  Moreover, human 
NAT1 was detected in the filopodia extensions [190].  Again, RhoA is involved in filopodia 
formation and cell migration as it promotes polymerization of F-actin orientated to the 
membrane that extends the leading edge forming filopodia [197, 198].   
MRI1 has been described as a moonlighting enzyme.  The isomerase activity is 
independent of the role in RhoA signalling and distinct structural elements are required for 
each function [157, 178].  As well as MRI1, other enzymes in the methionine salvage 
pathway are moonlighting proteins (MRI1 [157, 178], APIP [163, 164], ADI1 [166, 199]).  
Therefore, NAT1 could also be a moonlighting protein.  It is evolutionarily conserved, 
expressed ubiquitously, shown to have the potential to catalyse multiple and differing 
reactions (N-acetylation, hydrolysis of acetyl-CoA, possibly the isomerization of MTR-1P).  
In summary, the research presented here aimed to identify an endogenous role for human 
NAT1 that could shed light on the effects NAT1 has in cancer biology.  Overall, human 
NAT1/mouse Nat2 acetylation of the only known endogenous substrate pABG does not 
appear to be physiologically important under normal physiological conditions.  Human 
NAT1 does not regulate the intracellular SAM cycle although it altered efflux of the amino 
acids, glutamate and alanine.  This warrants further investigation as alanine could be 
important in the Warburg Effect.  A novel endogenous role for human NAT1 in the 
methionine salvage pathway was presented when MRI1 is absent.  NAT1 isomerization of 
methylthioribose 1-phosphate has been considered.  However, further characterisation of 
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this reaction is important, particularly, as the physiological relevance of the human 
NAT1/MRI1 redundancy remains unclear.   
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